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AB STRACT
This thesis is divided into three chapters. These are all self-contained,
including relevant references and experimental details, as well as results
and discussion. The numbering of compounds, however, is continuous
throughout the text.
Chapter one introduces the role of metabolism in gathering energy for
biological processes from the environment. Phototrophic mechanisms are
briefly mentioned, with primary chemotrophic metabolism being
described in more detail. The methodology of biosynthetic investigations
is introduced, with respect to the elucidation of the stereochemical course
of fatty acid biogenesis. Nmr spectroscopic methods are described, prior to
the discussion of early studies regarding polyketide biosynthesis, a
secondary metabolic process.
The antibiotic pseudomonic acid is introduced in chapter 2. Work
leading to the discovery of this natural product, and subsequent
investigations into the biological action and clinical applicability of the
metabolite is detailed. Early studies regarding the biogenesis of this entity
are discussed. Investigations into the biosynthetic origins of a C 3 moiety
within the molecule are presented. An hypothesis invoking the
intermediacy of two distinct entities in the biogenesis of pseudomonic acid
is proposed, and studies directed towards verification of this are described
in both whole cell and cell free systems.
The polyketide biosynthetic pathway is further discussed in chapter
three, with reference to monic acid (a constituent of pseudomonic acid)
Experiments directed towards verifying a processive biosynthetic origin for
this moiety are detailed, including the development of syntheses towards
labelled compounds with respect to such experiments. Studies directed
towards the elucidation of the differing origins of the branching methyl
units within monic acid are detailed.
DECLARATION
I declare that, unless where acknowledged within the text, the work
described throughout this thesis is that carried out solely by myself at the
University of Bristol and SmithKline Beecham Pharmaceuticals





I am indebted to Professor Tom Simpson for the creation of this
project, and his subsequent help and encouragement. Thanks must also
go to Dr. Keith Baggeley for similar support during my industrial
placement. Funding from both the SERC and SmithKline Beecham was
gratefully received.
Advice from Mr Adrian Maloney, regarding the microbiological
aspects of this work, and from Dr. Stefan Woroniecki, with respect to the
cell free work, was gratefully received. I must also thank Mr. John
Warrack for the electron microscopy photographs.
As always, the emotional support for this work is the most
appreciated. For the odd 'swift half' and associated nights of light relief I
must thank past and present members of the Simpson group, and the Lee-
Sweeney-Willis possee.
My parents, who have supported me throughout the last six years,
both in Bristol and Leicester, are whole-heartedly thanked for this, and for
the entire 24 years of my existence.
Finally, to Helen. Without you this would not be. We had too much
too soon. Those 16 months were the most memorable of my life. That
time was not on our side, that we could not see it through together; this is
the source of immense sorrow. You will always be special.
"What would the world be, once bereft
Of wet and of wildness? Let them be left,
O let them be left, wildness and wet;
Long live the weeds and the wildness yet."
'Inversnaid'
Gerald Manley Hopkins.
"Life must be lived forwards,










1.1.2: The energy for life 	 3
1.1.3: Natural oxidants and reductants 	 5
1.1.4: Primary chemotrophic metabolism 	 7
1.1.5: Energy storage	 10
1.2: BIOSYNTHETIC METHODOLOGY	 12
1.2.1: Isotopic labelling	 12
1.2.2: The elucidation of fatty acid biosynthesis using radio-labels. 13
1.2.3: The use of stable isotopic labels 	 18
1.3: SECONDARY METABOLISM	 19
1.3.1: Introduction	 19
1.3.2: The polyketide biosynthetic pathway	 20
References	 24
CHAPTER TWO: PSEUDOMONIC ACID	 26
2.1: THE ANTBIOTIC PSEUDOMONIC ACID	 27
2.1.1: Discovery of the antibiotic 	 27
2.1.2: The mode of operation of pseudomonic acid 	 28
2.1.3: Other pseudomonic acid metabolites 	 30
2.2: PSEUDOMONIC ACID BIOSYNTHESIS 31
2.2.1: Pseudomonic acid production by Pseudomonas fluorescens 31
2.2.2: Previous studies on the biosynthetic origin of
pseudomonic acid 	 33
2.2.3: Pseudomonic acid biosynthesis involving three sub-units	 38
2.3: STUDIES ON THE ORIGIN OF 9-HYDROXYNONANOIC ACID 42
2.3.1: The C-7' anomaly 	 42
2.3.2: 3-hydroxypropionate as a chain starter 	 45
2.3.3: Pseudomonic acid biosynthesis involving two entities 	 50
2.3.4: Synthesis of labelled 9-hydroxynonanoic acid 	 52
2.3.5: Feeding studies using radio-labelled 9-hydroxynonanoic acid 52
2.3.6: Feeding studies using [1- 13C]-9-hydroxynonanoic acid	 54
2.4: PSEUDOMONIC ACID BIOSYNTHESIS USING A CELL
FREE SYSTEM	 56
Page
2.4.1: The use of cell free systems	 56
2.4.2: Lysis of cell membranes	 59
2.4.3: Determination of cell lysis 	 60
2.4.4: Lysis of Ps. fluorescens 	 60
2.4.5: Cell free studies	 61
2.5: SEQUENTIAL PSEUDOMONIC ACID BIOSYNTHESIS	 64
2.5.1: Precursors to monic acid 	 64
2.5.2: The use of oxidase inhibitors and mutant strains 	 65




CHAPTER THREE: MONIC ACID	 97
3.1: POLYKETIDE CHAIN ELONGATION IN PSEtJDOMONIC ACID
BIOSYNTHESIS	 98
3.1.1: Introduction 	 98
3.1.2: The classical polyketide hypothesis	 98
3.1.3: Processive polyketide biosynthesis	 100
3.1.4: Stereochemistry of polyketide biosynthesis 	 107
3.1.5: The enzymolgy and genetics of polyketide biosynthesis 	 110
3.1.6: Application of the processive hypothesis to monic acid 112
3.1.7: Synthesis of the N-acetylcysteamine thioester of acetoacetate 114
3.1.8: Synthesis of the N-acetylcysteamine thioester
of (2S, 3S)-3-hydroxy-2-methylbutanoate 	 119
3.1.9: Synthesis of the N-acetylcysteamine thioester
of (2E, 4S, 5S)-5-hydroxy-4-methylhex-2-enoate	 125
3.1.10: Adminstration of putative biosynthetic precursors
to Ps. fluorescens	 126
3.2: THE ORIGIN OF C-15 OF MONIC ACID	 128
3.2.1: The cleavage of acetate 	 128
3.2.2: The synthesis of serine 	 133
3.2.3: The adminstration of serine to Ps. fluorescens	 133
3.3: THE ORIGINS OF C-16 AND C-17	 134
3.3.1: Biosynthetic methylation 	 134
3.3.2: Synthesis of labelled methylmalonate	 136
3.3.3: Administration of methyl malonate -to Ps. fluorescens	 136



























































Flavin adenine dinucleotide (oxidised form)

































Nicotinamide adenine dinucleotide (oxidised
form)
Nicotinamide adenine dinucleotide (reduced
form)
Ni cotinamide adenine dinucleotide phosphate
(oxidised form)
























Since time immemorial the origin, function and modus operandii of
life has been the source of both enchantment and perplexion for the
human mind. Throughout the known world explanations for the
existence of consciousness have been forwarded in terms of omniscient
supra-universal Deities upon •whose placation rests our continued
existence.
In the 'Western world' the Judaeo-Christian philosophy of the
Genesis has been the dominant creed of thought and inspiration. Indeed,
the deep belief in the absoluteness of such ideas led one Irish Bishop to
decree the Universe to have been created at 6am on Sunday, October 23rd,
4004 B.C.1
Mankind is an inately curious creature, however, and the need to
inspect such philosophical pontification has led to the refinement and
creation of new theories concerning the existence of life. As a result of this,
the Greek teachings of Pythagoras were resurrected in the 15th century by
Copernicus, 2 whose heliocentric heresies can be said to mark the
conception of modern scientific thought.
Since then the development of the scientific method by Galileo and
contemporaries has led to discoveries that have sought to demystify much
of the physical world, and replace the pious monopoly of the clergy in
explaining the enigmas of existence. Thus Newton's apple, Foucault's
pendulum and Schrodinger's cat have passed into folk-lore as Physics vied
with Theology for the paramount position. However, despite these and
other successes, theological thought is still the dominant force in many
parts of the world.
Practitioners of the chemical sciences were somewhat belated in
relinquishing the influence of supra-natural forces, however. It was not
until 1828, when Wöhler demonstrated that the pyrolysis of ammonium
acetate (1) led to formation of urea (2), as shown in scheme 1.1.1, that the
vitalist doctrine of organic chemistry was laid to rest. 3 As a result of this,
new avenues of scientific thought were opened up including the study of
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Scheme 1.1.1: Wöhler's synthesis of urea (2)
The chemical processes which underpin the propagation of life have
been the subject of much scrutiny. The introduction of evolutionary
theories of natural selection by Darwin4 added impetus to such studies
leading ultimately to the solution of the genetic code and the structure of
DNA.
1.1.2: The energy for life.5
As with all physical processes the continuation of life requires a
readily available source of energy. Biological processes utilise energy in
chemo-electric form and two basic mechanisms for the extraction of useful
energy from the environment have evolved.
As the powerhouse of the Solar System the energy of the Sun is the
spark of life for phototrophic species. These trap insolation via chlorophyll
(3), causing an electron potential gradient which ultimately leads to the
reduction of carbon dioxide by water to form carbohydrate and oxygen.
This process is called photosynthesis.'
Chlorophyll (3)
The second mechanism, chemotrophy, involves the oxidation of
available foodstuffs to carbon dioxide. These foodstuffs are frequently the
end product of photosynthetic processes, thiis demonstrating how life
itself is a further expression of the first law of thermodynamics.
3
The chemistry of life that leads to the generation, storeage and
utilisation of appropriate energy forms is called metabolism. Two broad
classes of have been identified:
a) Primary Metabolism: That which is essential for the appearance and
propagation of life, and varies little across the
species.
b) Secondary Metabolism: That which is not necessary for the
continuance of life, and is frequently restricted
to one species, or even a strain of a species.
Regardless of the mechanism of energy entrapment, all life forms
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Phototrophic species synthesise ATP (4) by the use of two finely
balanced systems involving light of wavelength <700nm (photosystem I)












As shown in scheme 1.1.2 photosystem I produces a strong reductant
and weak oxidant, whereas the converse case arises from photosystem II.
The interaction of the weak oxidant with the weak reductant ultimately
leads to ATP (4) synthesis. This process is termed photophosphorylation.7
In chemotrophic species ATP (4) is produced as a result of a series of
degadative processes which can be classified into three stages:
a) breakdown of macro-molecules into smaller compounds,
b) degradation of these small compounds into the basic units of life,
c) complete combustion of these units to carbon dioxide.
Nearly all of the ATP (4) produced by this series of processes occurs in
the final stage.
Since the studies to be detailed in this work involve a chemotrophic
bacterium, Pseudomonas flu orescens, a brief overview of the degradation
of foodstuffs follows.
1.1.3: Natural oxidants and reductants
Although many different reactions appear in the living world the
scope of operations is limited in number. Of these reductions, oxidations,
esterifications and hydrolyses account for a large fraction.
The reduction of ketones to hydroxyl functions is frequently mediated
by nicotinamide adenine dinucleotide hydride (NADH, 5). This becomes
nicotinamide adenine dinucleotide (NAD, 6) as a result, and this species
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Stheme 1.1.3: NADH (5)/NAD (6) as reductant/oxidant.
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For the dehydogenation of saturated carbon-carbon bonds, flavin
adenine dinucleotide (FAD, 7) is frequently used. Again the end product,














Scheme 1.1.4: FAD (7)/FADH2
 (8) as oxidant/reductant
The utilization of NAD (5) leads to the formation of 3 molecules of
ATP (4), and that of FAD (6) to the production of 2 molecules of ATP (4),
as a result of an electron cycling system that ultimately induces a transfer
of electrons to oxygen. This process is termed oxidative phosphorylation.12
Often, particularly in biosynthetic processes, FAD (7) or NADH (5) (and
their counterparts) are phosphorylated. The abbreviations
NADPH/NADP and FADP/FADPH2 are used in those cases.
As will be shown, acetate is a key entity for biological processes.
Activation of this for biological purposes arises via the use of coen.zyme A
to produce acetyl CoA (9).
N1-
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1.1.4: Primary chemotrophic metabolism
Throughout nature, primary metabolism has a dual role: the
utilisation of foodstuffs as source of energy and simple building blocks of
life, and the using this energy to build the components of life from these
precursors.
As previously mentioned one of the major sources of energy is
carbohydrate, and in particular glucose (10). The glycolytic pathway is the
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ADP ATP	 b) fructose-6-phosphate
c) fructose -1,6-bisphosphate
OH	 d) dihydroxyacetone phosphate
e) glyceraldehyde-3-phosphate
f) 1 ,3-bisphosphglycerate





Although a little All' (4) is generated overall by this process, it is by
use of the Krebs' (or tri-carboxylic acid) cycle 9
 that energy is most efficiently
extracted via the complete combustion of acetate.1°
Pyruvate is converted to acetyl CoA (9) as shown in scheme 1.1.6, with



























Scheme 1.1.6: Conversion of pyruvate (11) to acetyl CoA (9)
Acetyl CoA (9) then enters the Krebs' cycle via condensation with
oxaloacetate (14) to produce citrate (15) as shown in scheme 1.1.7. A series
of reactions is then under taken resulting in complete combustion of
acetyl CoA (9) and regeneration of oxaloacetate (14).The potential net gain
of ATP (4) from this series of reactions, and through other electron cycling
systems, is 38 molecules per molecule of glucose (10).
Simple organisms have a secondary part to this cycle, termed the
glyoxylate pathway. The regulatory step occurs at isocitrate (16) (scheme
1.1.8), which can be alternat.vely lysed to yield lyoxy1ate (17) and succinate
8
(18). The succinate (18) is available for biosynthetic purposes, whereas





































Scheme 1.1.7: The Krebs' cycle
In using two molecules of acetate and producing fewer molecules of
ATP (4), this cycle has a reduced energy producing efficiency. However in
times of high food-stuff availability the succinate produced can now be
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Scheme 1.1.8: The glyoxylate cycle
1.1.5: Energy storage
For cellular processes ATP (4) is a transitory form of energy, used up
rapidly after production. For long term energy storage glycogen, a polymer
of D-glucose (10), and fatty acids are synthesised. These can then be readily
degraded (catabolised) in order to retrieve the energy contained within.
Glycogen, after degradation to glucose (10) which undergoes gylcolysis to
yield ATP (4). However fatty acids are degraded by a different process,

















Krebs' cycle	 Scheme 1.1.9: Fatty acid catabolism.
Acyl CoA fatty acid derivatives (20) undergo degradation via a series of
steps that formally resemble the last few stages of the Krebs' cycle leading
10
to oxaloacetate regeneration (14). Thus dehydrogenation to yield the a,13
unsaturated thioester (21) is followed by hydration to produce a 3-
hydroxythioester (22). Oxidation to the -keto derivative (23), prior to
thiolysis with coenzyme A forms one molecule of acetyl CoA (9) and a
new acyl CoA (24). This acyl CoA (24) can under go the same cycle of
reactions whereas the acetyl CoA (9) is now available either for
biosynthetic procedures or combustion within the Krebs' cycle.
As a result of this process palmitic acid (25), for example, can be
completely combusted, producing 129 molecules of ATP (4) as a result.
OH
Palmitic acid (25)
Fatty acids are biosynthesised for later retrieval by the process shown
in scheme 1.1.10. Acetyl CoA (9) is carboxylated to malonyl CoA (26),
which is then transferred to an acyl carrier protein (ACP). Condensation of
this with acetyl ACP yields acetoacetate ACP (27) with concomitant release
of carbon dioxide. Reduction by NADPH produces (3R)-3-hydroxybutanoyl
ACP (28), which then under goes loss of water to produce (2E)-but-3-
eneoyl ACP (29). A final hydrogenation step yields the fully saturated
butanoyl ACP (30) which can then under go further homologation until
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Scheme 1.1.10: The biogenesis of fatty adds.
11
Fatty acid metabolism is essentially identical in all living systems.
However the enzymes involved show a range of structural differences."
Although they all possess the required catalytic domains, namely 3-
ketoacyl synthase, acetyl transferase, 13-hydroxyacyl dehydratase, malonyl
transacylase, enoyl reductase, -ketoacyl reductase, thioesterase and an acyl
carrier protein, the arrangement of these can vary.
Two classes of fatty acid synthase have been identified:
Typel: Of mammalian origin, these exist as single multi-functional
peptides with a globular arrangement of catalytic domains and a
molecular weight of appproximately 5 x 106.. A further sub-
division of this type of fatty acid synthase are found in yeasts
and some fungii, whereby two sub-units co-operate. The a-
subunit includes the -ketoacyl reductase, 3-ketoacyl synthase
and the acyl carrier protein. The n-subunit contains the
remaining activities. In active form the enzyme is ;16 complex
of molecular weight 2.4 x 106.
Type II: Found in plants and most bacteria, these exist as eight
structurally independant mono-functional enzymes.
Fatty acid biosynthesis has been intensely studied, 12
 and the
elucidation of the stereochemical aspects of the process serves as an
excellent example of the use of isotopic labelling studies. This will be
described in the next section, which discusses the methodology used in the
investigation of biogenetic processes.
1.2: BIOSYNTHETIC METHODOLOGY.
1.2.1: Isotopic labelling.
The biologically common elements all exist predominantly in one
isotopic form, but small amounts of other isotopes are available. Thus if a
compound containing an 'unnatural' isotope is used instead of the more
common form it may be possible to determine whether the isotope, and
therefore the compound, is incorporated into the required metabolite.
Two types of isotope may be used, stable or radioactive. For classical






detection. The introduction of readily available powerful spectroscopic
methods within the last twenty years, however, has facilitated the use of
stable labels such that those studies have become the more common type.
1.2.2: The elucidation of fatty acid biosynthesis using radio-labels.
That acetate was a precursor to the fatty acids was initially
demonstrated in 1945 with the use of stable labels. 13
 The fatty acids isolated
from rats after administration of [1- 13C, 2-2H31-acetate were completely
combusted. The water resulting from this process was isolated and
comparison of the refractive index to that of 1H20 showed the label to have
been incorporated. Mass spectral analysis of the CO 2 produced showed that
the 13C label had also been incorporated.
Later work using H14CO3 showed that CO2 was required for the fatty
acid biogenetic process, but was not contained within the final product.14
This was explained by showing that malonate, as opposed to acetate, was
the effective chain extension unit with the carbon dioxide being used to
carboxylate acetyl CoA (9) and then being released upon subsequent
condensation with a second molecule of acetyl CoA (9). The carbon dioxide


















Scheme 1.2.1: The fixing of carbon dioxide mediated by biotin
A purified fatty acid synthase (FAS) enzyme derived from baker's yeast
was later incubated with [1- 4C] acetyl CoA (9), and the process terminated
via protein precipitation. Base hydrolysis led to the release of an enzyme
13
bound intermediate which was shown to be acetoacetate (32).
Decarboxylation of this and isolation of the acetone produced showed the
label to have been incorporated into C-3 of acetoacetate (32), scheme 1.2.2.
0	 FAS	 base	 heat	 0






Scheme 1.2.2: Incorporation of label from acetate (9) into acetoacetate (32)
When acetoacetyl CoA (27) was incubated with the enzyme in the
presence of NADPH (5), production of (3R)-3-hydroxybutanoyl CoA (28)
was observed. Incubation of this with the enzyme led to production of
trans-but-2-enoyl CoA (29). The (3S) isomer did not give rise to any UV
active products, showing it not to be accepted as a substrate.15"6
Only the trans-but-2-enoyl CoA (29) was accepted by the enzyme to
form the fully saturated butanoyl CoA (30), the cis- isomer being found not
to be a substrate.
It is note-worthy that these experiments were also carried out using
the substrates in the form of their N-acetylcysteamine thioesters (33). This
thiol contains the same structure as the terminus of the pantotheinic acid
side chain of coenzyme A (see acetyl CoA (9)). It was hoped that such
substrates would be accepted by the enzyme in a manner analagous to the
CoA forms. This was indeed found to be so.
0
RS N ( A general N-acetylcysteamine
thioester (33)
In monothioester-monoacid form, malonate is prochiral. The stereo
specific introduction of a 3H label into malonate meant that the 2R and 2S
forms could be incubated with the enzyme to determine any
stereospecificity in the biogenesis of fatty acids. The utilisation of all three
isotopes of hydrogen meant that chiral acetates could be similarly
employed.
Such experiments, as shown in scheme 1.2.3, indicated that the
conversion of acetyl CoA into malonyl CoA proceeded retentively with
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Scheme 1.2.3: The use of chiral acetate and malonate in
the elucidation of fatty acid biosynthesis
The use of (2R)- and (2S)-[2-2H1,3H1]-malonates gave rise to preferential
uptake of the 3H label from the (2S)-enantiomer. 18 The condensation step
leading to acetoacetate (32) could proceed with either retention or
inversion of configuration at C-2 of malonate. As previously described, the
reduction of acetoacetate leads to specifically the (3R)-isomer (28), with
further dehydration leading to the trans isomer (29). Therefore an
experiment was required to determine the stereochemical course of the
dehydration, as this would also yield information regarding the
condensation step.
(2R, 3R)-[2-3H]-3-hydroxybutanoic acid (34) was synthesised, converted
to the N-acetylcysteamine thioester and then incubated with the enzyme.
Upon isolation of the trans-but-2-eneoate (35), 93.5% of the label was
found to be retained. A control experiment with non-stereospecifically
labelled [2-3H 111-3-hydoxybutanoate led to the loss of approximately 50% of
the label. This demonstrated that the (pro-2S) hydrogen was removed,
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Scheme 1.2.4: The loss of the pro-2S hydrogen during the dehydration
step in fatty acid biosynthesis
Since it was known that the label from the 2S enantiomer of malonate
was incorporated into the final metabolite, but that the pro-2S hydrogen
had now been shown to be specifically eliminated during dehydration, the
deduction that the condensation of acetyl ACP with malonyl ACP occurs
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Scheme 1.2.5: inversion of configuration at C-2 of malonylACP during
the condensation with acetyl ACP.
This only left the saturation step to be investigated.Previous work had
shown that the hydride introduced to C-3 was NADPH (5) derived,19
whereas the proton at C-2 came from the aqueous medium, 2° as shown in
scheme 1.2.6.
Further work involved incubating the N-acetylcysteamine thioester














Scheme 1.2.6: The origin of the hydrogens during the final reductive
step of fatty biosynthesis
Dehydrogenation of the resultant fatty acid with pig liver
dehydrogenase (PLD), an enzyme which was known to specifically remove
the pro-2R,pro-3R hydrogens, was carried out.
NADP3H
	








Scheme 1.2.7: The anti delivery of hydrogen to the si faces in the final
reductive step of fatty acid biosynthesis.
It was found that label from NADP 3H (5) was retained after this
operation, as was that from 3H20. Thus it had been demonstrated that the
final reductive step proceeds with anti delivery of hydrogen to the si faces
of the prochiral alkene, scheme 1.2.7.
Subsequent studies have shown that this final enoyl reduction step
varies across species.21'
These investigations demonstrated how the use of isotopic labelling,
biomimetic compounds, purified enzymes and outstanding ingenuity
could lead to the unravelling of the stereochemical course of biosynthetic
processes.
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The use of radio labels has a major disadvantage, however.
Determination of the position of label incorporation within a metabolite
requires careful and tedious degradative work, resulting in loss of often
valuable material. Prolonged exposure to radio-activity is also undesirable.
For studies of these kind, the introduction of high power nmr techniques
has led to an increased use of stable labels for biosynthetic investigations.
1.2.3: The use of stable isotopic labels.
The use of nuclear magnetic resonance spectroscopy has greatly
enhanced progress in many areas of chemical research. In particular
structural determinations of unknown compounds, especially natural
products, can now be achieved without the need to degrade material.
Additionally, very little compound is required for such experiments.
For many years was the only experimentally useful isotope. The
introduction of readily accessible Fourier Transform nmr, however, has
led to a proliferation in the isotopes which can be observed, such that the
availability of an isotope is often the limiting factor in the design of
experiments.
For biosynthetic investigations specific incorporation of labels can be
determined with relative ease providing the complete spectral properties
of the natural product are known. Indeed it is the full assignment of
resonances in the nmr spectrum which often proves to be the trickiest part
of such studies.
The isotopes commonly used in conjunction with such investigations
are 1 H, 2H and 13C. Of these 3C is often the most productive. The isotope
accounts for only 1.1% of all naturally occurring carbon, with the major
isotope being nmr inactive. Chemical synthesis can be used to introduce
high enrichment of this isotope within a putative biosynthetic precursor.
This is important, as administered compounds will frequently be directed
along more than one metabolic pathway, leading to large dilutions of the
applied label.
The chemo-magnetic environments of carbon atoms lead to large
variations in the relaxation time of the nucleus after initial excitation.
This results in variations in the intensity of spectral signals, that are
unrelated to the relative amounts of carbon present. Thus, to ensure that
any observed enhancement is 'real,' a high 13C content in the administered
compound is desirable. 	 -
18
In itself the use of a single C label does not lead to any increase in the
amount of information to be gained with respect to the use of radio-label.
Any advantages arise from the analysis being less tedious and material
needing not to be destroyed.
Further information may be gained through spectroscopic methods,
however, by the utilisation of multiple labelling techniques, either homo-
or heteronuclear. Thus if two adjacent carbons in a molecule are labelled
with 13C it is effectively the bond that is labelled. Any incorporation of
these atoms as a unit (ie bond incorporation) will be observed via '3C-13C
couplings in the nmr spectrum. The low natural abundance of 13C means
that such couplings are not observed under normal conditions.
A heteronuclear bond, for example C-0, can be labelled by the use of
13C and 180. Although 180 is nmr inactive the different nudear properties
of this with respect to 160 mean the carbon resonance has a slightly
different value. This shift is usually visible with only a little extra
analytical work being required. Similar possibilities exist for the use of '3C-
2H and 13C-15N labelling.
Such techniques have been readily applied to the investigations of
secondary metabolic processes, as will be demonstrated in the next section.
1.3: SECONDARY METABOLISM.24
1.3.1: Introduction
Secondary metabolism was previously described as being non-essential
to life and consisting of metabolic processes restricted to a few species.
Whilst this is true in terms of the metabolites expressed by such pathways,
the types of processes themselves are readily classified and exist in many
species.
Thus metabolites derived from shikimic acid (36), mevalonic acid (37)
and amino acids are found throughout nature. However, the resultant






Perhaps the most striking examples of this are found in metabolites
resulting from the polyketide pathway.
1.3.2: The polyketide biosynthetic pathway.
At the dawn of the present century a series of biosynthetic hypotheses
were forwarded by Collie, one of which described the biogenesis of





Scheme 1.3.1: The biosynthesis of orsellinic acid (38) as proposed by Collie.
Such ideas were largely ignored until after the Second World War and
discovery of the involvement of acetyl CoA (9) in fatty acid biogenesis.
Resurrection of Collie's ideas by Birch arose from a hypothesis invoking
the retention of 3-keto functions in the linear chains resulting from
sequential acetate-malonate condensations, as shown in scheme 1.3.2.26
Subsequent modifications of the the polyketide chains, by Claisen ester











Scheme 1.3.2: Acetate-malonate condensations leading
to fatty acids or polyketides
20
The first natural product recognised as being derived from such a
process was campnospermonol (39)•27
(cH2)7CH =CH(cH2)7CH3OHy
(39)
Experimental evidence was first obtained from the utilisation of [1-'4C]
acetate, which was administered to the fungus Penicillium griseofulvum.
Amongst a range of metabolites produced by this species is 6-
methylsalicylic acid (6-MSA, 40). Degradation of this after isolation led to
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Schemel.3.3: The biosynthesis of 6-methylsalicylic acid (40)
Further experiments showed that other metabolites were of polyketide
origin, including griseofulvin (41)29 and curvularin (42).° The original
natural product chosen by Collie, orsellinic acid (38), was also shown to be
the result of this pathway. Confirmation that the oxygen atoms in this





That polyketide biosynthesis was analgous to fatty acid biosynthesis
with respect to an acetyl starter unit condensing with a malonyl chain
extender unit was also demonstrated.32
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The introduction of high field FT nmr capabilities led to the possibility
of gaining further insights into this biosynthetic process, particularly with
respect to the poly-13-keto chain configuration that leads to the final
metabolite. This was demonstrated by studies regarding the biosynthetic
origin of ravenelin (43)33
Thus the administration of [1,2- 13C 2]-acetate to cultures of
Helminthosporium ravenelii resulted in 13C- 13C coupling in the 13C nmr
spectrum, as shown in scheme 1.3.4. It was shown, therefore, that a
symmetrical precursor was an intermediate on the biosynthetic pathway,




Scheme 1.3.4: The biosynthesis of ravenelin (43)
Such techniques have been used on a variety of metabolites and have
proven to be highly productive.23
The pioneering work of Birch has therefore been expanded to show
that polyketide biosynthesis is a widely occurring metabolic phenomenon,
analgous to fatty acid biogenesis but lacking in the reduction, dehydration,
and reduction steps. This pathway has been adopted in many different
species, including bacteria, fungi and some plants, to produce metabolites
of astonishing multifariousness.
Extensive research into the biosynthesis of polyketide metabolites has
been undertaken since the pioneering work of Birch. As a result of this
work the 'classical' polyketide hypothesis having been supplanted over
the last decade. New hypotheses regarding the biogenetic origins of
22
polyketide natural products are discussed in depth within chapter three,
with relevance to the biogenetic origin of pseudomonic acid (44).
OH
OH	 (44)
Aspects regarding the discovery and utility of this natural product, and
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2.1 : THE ANTIBIOTIC PSEUDOMONIC ACID
2.1.1 :Discovery of the antibiotic
The growth inhibitory effects of Pseudomonas flu orescens, a Gram
negative bacterium 1 of the Pseudomonadace family2, upon various
fungi, bacteria and yeasts were first noted in 1887. Further reports on the
biological activity of cultures and culture extracts were made over the
ensuing decades4. No chemical entity was identified to account for this
behaviour, however, until 1971 when a purified acidic extract was
demonstrated to exhibit nearly all the observed activity.5
This compound was termed pseudomonic acid (44) and structural
elucidation studies showed it to possess a unique carbon framework,6
including a 1,2-dihydroxy substituted tetrahydropyran ring, an epoxide
functionality, an c unsaturated ester, with the condensed alcohol being
the unprecedented 9-hydroxynonanoic acid (45). Further work showed the





Figure 2.1.1: The absolute configuration of pseudomonic acid (44)
The biological activity of this agent was found to be restricted to the pH
range 4 to 9,5 but within these limits it showed high levels of activity
against Gram positive bacteria, especially Staphylococci and Streptococci
species,8
 although only a limited number of Gram negative species were
affected. Interestingly, it exhibited no cross-resistance with other clinically
available antibiotics. Binding to human serum was found to be high (95%)
but toxicity levels were low. Subcutaneous administration to mammals
resulted in rapid excretion, via hydrolysis, of mainly monic acid 1 3
-glucoronide (46), as shown in scheme 2.1.1.
As a result clinical applications of the metabolite are restricted to the
topical treatment of skin infections. 10 Currently it is marketed by
SmithKline Beecham under the generic name Mupirocin as the active











Scheme 2.1.1: Excretion of monic acid j3-glucoronide (46)
after pseudomonic acid (44) adminstration
2.1.2: The mode of operation of pseudomonic acid.
Early studies on the modus operandii of the antibiotic showed it to
inhibit protein biosynthesis 11 which was later found to be the result of
competitive inhibition of isoleucyl t-RNA synthetase. 12 It has been
suggested that the epoxy side-chain is the moiety responsible for such
activity, as shown in figure 2.1.2. This side chain has the same carbon back-






Figure 2.1.2: The structural similarity between pseudomonic acid (44) and
isoleucine (47), with respect to isoleucyl t-RNA synthase
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Resistance to the antibiotic by the producing organism was shown to
be through a modified isoleucyl t-RNA synthetase. This was found to
have an affinity for isoleucine (47) over pseudomonic acid (44) of 6 orders
of magnitude greater than other prokaryotic isoleucyl t-RNA synthetases.'3
Only one other natural product, furanomycin (48),14 has been shown to
exhibit comparable behaviour, 15 but this has found no clinical utility. In
conjunction with the unique structure of pseudomonic acid (44), this




As mentioned above, the biological activity is only observed within
pH limits of 4 to 9•5 This results from the instability of pseudomonic acid
(44) to strong base or acid. 16
 At low pH, rapid rearrangement (30 minutes)
occurs, leading to a 1.6:1 mixture of the isomeric compounds (49) and (50),
scheme 2.1.2. Under strongly alkaline conditions, a slower rearrangement
(18 hours) takes place, yielding the same products but in a ratio of 3.7:1.
The fact that it is the epoxy function which is disrupted as a result of this
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H	 (50)
Scheme 2.1.2: Rearrangement of pseudomonic acid in acid or base.
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2.1.3: Other pseudomonic acid metabolites
Further isolation work on extracts from Pseudomonas fluorescens
cultures gave rise to the discovery of 3 further members of the
pseudomonic acid family. These are named pseudomonic acid B (5j),17 C
(52),18 and D (53),19 with the parent now termed pseudomonic acid A (44).
Recent work at SmithKline Beecham has resulted in the extraction of a



















Figure 2.1.3: Co-metabolites of pseudomonic acid (44)
These minor metabolites have biological activities similar to or less
than that of pseudomonic acid A. Within this work, the term
pseudomonic acid will refer to the major metabolite. (44).
The discovery of two pseudomonic acid derivatives (55) and (56),
isolated from an unidentified pink bacterium, itself isolated from the
marine sponge Darwinella rosacea. 21 has been recently reported. In both
these metabolites the 9-hydroxynonanoic acid chain has been replaced by
an 8-hydoxyoctanamide side chain with what ap 'pears to be an amino 6-
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lactam moiety derived from ornithine (57). The derivative (56) also
possesses a 4-3-hydroxy function.
The biological activity of these metabolites is unknown, but their








2.2: PSEUDOMONIC ACID BIOSYNTHESIS
2.2.1 : Pseudomonic acid production by Pseudomonas flu orescens.
The strain of Ps. fluorescens originally selected for isolation studies
was a soil isolate. 1 ' 9 From this was developed a higher producing strain,
NCIB 10586. This strain has been used for the majority of the studies
reported herein.
The media used for growing Ps. fluorescens were based on those
developed by workers at SmithKline Beecham. Lyophilised samples of
the bacterium were reconstituted prior to storage on nutrient deficient
agar slopes. In this form the bacteria are viable for 4 months.
For use, a slope was flooded with nutrient broth in which the bacteria
were resuspended. An aliquot of this was used to inoculate a primary
medium, designed to promote efficient cell growth and replication. After
24 hours, a portion was transferred to a secondary medium in which
metabolite production occurred.
The production was found to be complete within 48 hours of
inoculation. Acidification of the culture broth preceeded extraction with
ethyl acetate. The concentrated extracts were then treated with an excess of
diazomethane, and pseudomonic acid (44) was purified as its methyl ester
(58) by preparative TLC. Throughout the period of this work, the titre of
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Figure 2.2.1: Growth production curve for pseudomonic acid (44)
produced by Ps. fluorescens.
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For biosynthetic studies it is necessary to have knowledge of the
production phase of the metabolite (the idiophase). Since pseudomonic
acid (44) has a chromophore at 230nm, the culture broth was monitored
for metabolite production by HPLC. The resultant growth-production
curve is shown in figure 2.2.1, along with the pH variation of the medium
during this time. This shows that metabolite production commences
about 16 hours after inoculation of the secondary medium, with
maximum production commencing soon after..
2.2.2: Previous studies on the bios ynthetic origin of pseudomonic acid
Despite the structural uniqueness of the pseudomonic acids, the
oxidation pattern along the carbon back-bone appears to be consistent with
a polyketide/fatty acid biogenesis.
To enable verification of this hypothesis by the utilisation of labelled
compounds for nmr studies, the rigorous assignment of all resonances in
the nmr spectra was required. The 1 H and 3C nmr spectra of pseudomonic
acid have been fully assigned,24'25
 and are shown in figures 2.2.2 and 2.2.3.
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Feeding studies using variously labelled acetates propionates and
methionine were carried out. These results are shown in scheme 2.2.1.
Radiolabelled mevalonate (12) was also fed, but no incorporation was
observed. This was not surprising, as bacteria have not been shown to
utilise this precursor. Radiolabelled formate was also tested as an
alternative 'C1-pool,' but the levels of incorporation were found to be very
low.
The incorporation of acetate units in a 'head to tail' manner along
much of the carbon framework was found to be consistent with a fatty
acid/poyketide biogenesis. There were, however, inconsistencies.
Whilst carbons 16 and 17 were found to be labelled from methionine,
indicating branching methylation via S-adenosylmethionine (59), the




(59) Me	 jHO OH
At the time, such a pathway was unique to pseudomonic acid (44)
biosynthesis. Subsequent studies have shown a similar pathway to
apparently be operating in the biogenesis of virginamycin M1 (60),26













A further anomaly was discovered at C-7' in the aliphatic chain. This
was found to be labelled by C-i of a cleaved acetate unit, but the efficiency






The origin of the aliphatic chain as a whole was also unusual. Intact
acetate units appeared to be incorporated in a 'head to tail' manner at C-
l'/C-2', C-3'/C-4', and C-5'/C-6' such that C-i' is derived from C-i of
acetate. C-8'/C-9' also appeared to be derived from an intact acetate unit,
but the derivation of C-8' from C-2 of acetate indicated that the direction of
acetate incorporation was the opposite to the rest of the aliphatic unit,
with C-7' appearing to be the pivot for this reversal.
Studies using labelled propionate only served to exacerbate the
confusion. [1- 3C1-propionate was found to specifically label the C-7'
position. In contrast, the use of [3-13C]-propionate gave rise to a metabolite
showing a labelling pattern identical to that of [2-13C]-acetate, indicating
incorporation through acetate via a-oxidation to pyruvate (11), scheme










Scheme 2.2.2: Conversion of propionate to acetate via pyruvate (11)
From these early biosynthetic studies it was clear that although the
metabolite (44) seemed to be of mainly polyketide origin, unusual
pathways were being expressed.
2.2.3: Pseudomonic acid biosynthesis involving three sub-units.
The fact that both C-I and C-9' were derived from the carbonyl carbon
of acetate implied that the ester functionality was not the result of a
Baeyer-Villiger type oxidation upon a pre-formed carbon chain. To
confirm that the bonding oxygen of the ester moiety was acetate in origin,
[1- 13C,O2]-acetate was fed to Ps. fluorescens?2 The results of this are shown
in scheme 2.2.3, and confirm that the C-9' to oxygen bond is indeed from







Scheme 2.2.3: Results of a feeding study with [1- 13C, 1802]-acetate
That the oxygen at C-5 was retained from acetate implied that the C-5/
C-6 bond was not dehydrated and led to the postulation of a mechanism
for the formation of the tetrahydropyran ring. This invoked a Michael
type ring closure, as shown in scheme 2.2.4.30
Scheme 2.2.4: Mechanism of tetrahydopyran ring formation
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To test this proposal, [1- 13C, 2-2H3]-acetate was fed to Ps fluorescens, the
results22'3° of which are shown in scheme 2.2.5. The lack of a n-shift in the
nmr spectrum at C-7 indicated that deuterium from acetate was not
retained at C-8. This was consistent with the proposed mechanism of ring
formation.
The fact that the ester moiety appeared to be formed from two acetate
units and not via a Baeyer-Villiger type mechanism indicated that at least
two units were involved in pseudomonic acid (44) biogenesis. The
labelling pattern previously described along the 9-hydroxynonanoic acid






Scheme 2.2.5: Results of feeding study with [1- 13C, 21-1311-acetate
These anomalies were accounted for by proposing a triadic cascade
biosynthetic pathway, invoking 3-hydroxy-3-methy1glutarate (64) as
shown in scheme 2.2.6. Such a theory also gave a ready explanation for the
origin of C-15 from the methyl carbon of acetate.
Thus, a polyketide derived C12 unit (65) was postulated to undergo
allylic nucleophilic attack from a C5 unit (66) derived from 3-hydroxy-3-
methyiglutarate (64). The resultant a4-unsaturated thioester (67) was
postulated to undergo a further nucleophilic attack from a C9 entity (68),
again derived from -hydroxy-f3-methy1g1utarate (64) in conjunction with
a fatty acid type chain elongation. Hydrolysis of the final thioester (69) gave
release of pseudomonic acid (44).
To explain the labelling pattern at C-7', competition between 3-
hydroxy- 3-methylglutarate (64) and -hydroxy- -ethylglutarate (70) was
postulated, as shown in scheme 2.2.7. The incorporation of
homomevalonate (71) (presumed to be derived from -hydroxy-3-ethyl









































Scheme 2.2.6: Triadic cascade hypothesis
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Scheme 2.2.7: -hydroxy-3-ethylglutarate (70) as a precursor to
the C9
 entity, originating from propionate.
These workers reported no data to verify the theory, however and it
was not until some time later that the question was again addressed, when
a report was made of the high incorporation of radiolabelled f3—hydroxy-
f—methy1glutarate (64) into pseudomonic acid (44)•32 This was interpreted
as good evidence for the above hypothesis, although no degradative




Further work using 13C and 13C 2 labelled 3-hydroxy--methy1glutarate
(64) for nmr studies confirmed that efficient label incorporation occurred.
However, in both experiments the 13 C nmr spectra showed label
incorporated throughout the molecule, with no evidence for any specific
incorporation.'3° This implied that the administered compound had been
degraded to acetate by catabolic enzymes prior to utilisation by the usual
metabolic pathways. Further work confirmed this finding.33
In order to determine any involvement of malonate in the
biosynthesis of pseudomonic acid (44), an initial experiment involving the
adminstration of 250 mg of [2-13C]-malonate to 250ml of inoculated
medium was carried out. Incorporation into those sites already shown to
be enriched by [2- 13C]-acetate was observed, with no evidence for any
preferential incorporation at any site to indicate a starter effect. A second
experiment involving 1.07g of [2- 13C]-malonate being fed to 125 ml of
innoculated secondary medium was carried out. The results this time
indicated some preferential incorporation of label into the 9-hydroxy
nonanoic acid moiety, thus indicating a possible role for malonate in the
biosynthesis of the aliphatic side chain.
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2.3 : STUDIES ON THE ORIGIN OF 9-HYDROXYNONANOIC ACID.
2.3.1 : The C-7' anomaly.
As has been previously discussed, the origin of C-?' is biosynthetically
unique. Although studies utilising both terminal and carboxyl carbon
labelled propionates were carried out, the use of [2-13C] propionate was not
investigated. To see if this could yield any further information, 250mg of
sodium [2-13C] propionate were administered to Ps. fluorescens. leading to
the isolation of 17mg of metabolite (44).
The 13C nmr spectrum obtained from this experiment is shown in
figure 2.3.1. Enhanced signals are evident throughout the spectrum,
corresponding to those carbons derived from the carboxyl of acetate. This
is consistent with the [3-13C]propionate result,tm ie a-oxidation to pyruvate
(11) prior to incorporation via acetate.
In an attempt to gain further information regarding the origins of the
C-7'/C-8' bond, and thus C-?', [1,2- 13C 2] malonate (73) was synthesised.
Owing to the inherent symmetrical nature of malonate, this is effectively a
triply labelled moiety, with relative 13C enrichments of 0.5:1:0.5. Should
the bond under investigation originate from malonate, then associated
3C- 13C couplings would be observed in the 13C nmr spectrum.
For synthetic purposes, the label source chosen was sodium [1,2-13C2]
acetate. As shown in scheme 2.3.1 this was converted to ethyl [1,2-13C2]
acetate in 83% yield via reflux with triethyl phosphate (74) and distillation
into a liquid nitrogen trap.34 The lithium enolate (75) was formed and
reacted with ethyl chioroformate (76) to produce diethyl [1,2-13C2] malonate
(73) in 73% yield. Saponification of this for feeding studies 21 was achieved
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Scheme 2.3.1: Synthesis of diethyl [1,2-13C2}-malonate
Thus 250mg of the di-sodium salt was fed to Ps. fluorescens, leading to
isolation of 13mg of methyl pseudomonate (58). The ' 3C nmr spectrum is




































contrast to the C-8' signal, which is a triplet showing coupling uniquely to
C-9'.
This demonstrates that the C-7'/C-8'/C-9' unit does not originate from
an intact malonate starting group. Such a result was perhaps not
unexpected, as for an intact malonate to be incorporated in this manner
the bond labelled from [1,2- 13C2] acetate would be expected to be C-7'/C-8',
as shown in scheme 2.3.2.
) SEnz HO
0 0 0 0
HO	 HOSEnz
Scheme 2.3.2: Expected labelling pattern from acetate
if malonate was the chain starter.
Further inspection of the aliphatic moiety led to speculation that 3-
hydroxypropionic acid (77) may be a chain starting unit. Although not
directly explaining the origin of C-7', such a possibility was further
investigated.
2.3.2: 3-Hydroxypropionate as a chain starter.
For these studies a synthesis of labelled 3-hydroxypropionic acid (77)
was required. Potassium [13C]-cyanide is a readily available source of label,








Scheme 2.3.3: Proposed synthesis of 3-hydroxypropionic acid (77)
However, perusal of the literature showed that although the first step
proceeded well under temperature controlled conditions, the hydrolysis
of the nitrile was low yielding and a large fraction (5%) of the product (77)
was water. Clearly this was undesirable.
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A more protracted route was briefly investigated, as outlined in
scheme 2.3.4. Again the label source was to be potassium [ 13C1 cyanide,
introduced via reaction with either bromoacetic acid (78) or its ethyl ester
(79)37 The possibility of subsequent specific reduction of the nitrile to the
aldehyde (80) by the Stephen reaction, and further reduction of this with
sodium borohydride to yield the required alcohol was studied.
Br"( R KCN	 R Stephen	 RNC	 p- OHC	 NBHHO•..._._y R
0	 0	 0	 0
R=OH, (78)	 (81)	 (80)	 (77)
R=OEt, (79)
Scheme 2.3.4: Proposed synthesis of (77) via selective reduction
The Stephen reaction involves the addition of the nitrile to an
anhydrous hydrogen chloride saturated ethereal solution of tin (II)
chloride. An aldiminium hydrochloride salt (82) which precipitates out of
the reaction mixture can be hydrolysed to the aldehyde (80) after isolation.
The process is shown in scheme 2.3.5.
RCN + HC1	 - RCC1=NH
(81)
RCC1=NH + SnCl 2 + 2HC1	 - RCH=NH.NC1 (s) + SnCl4
(82)
RCH=NH.HC1 + H3O	 - RCHO	 R=HO2CCH, (from (78))
(80)	 EtO2CCFJ2 (from (79))
Scheme 2.3.5: The course of the Stephen reduction
The initial report on the reaction states the use of 1.5 moles of SnCl2
per mole of nitrile, but under these conditions neither of the cyanoacetates
(81) reacted as required. Increments in the amount of reductant were
investigated,39 however as much as 6 equivalents led to no discernible
variance in the outcome of the reaction.
At this juncture re-investigation of the original nitrile hydrolysis was
proposed, with the premise that for feeding studies the sodium salt would
be required.22 Thus 3-hydroxypropionitrile (83) was synthesised in 92%
yield and subsequently hydrolysed with 1.05 çquivalents of sodium


































concentrated in vacuo prior to lyophilisation. This yielded a quantitative
yield of the required sodium 3-hydroxypropionate (77), scheme 2.3.6.
For feeding studies the sequence was repeated with potassium [l-13C1
cyanide thus producing the labelled form of sodium [i-'3C]-3-hydroxy
propionate. Administration of 250mg of this to the bacteria produced,
upon work-up, 29mg of methyl pseudomonate (58).
KCN	 NaOH
HO- C	 HO—	 HO%.- CO2Na
(83)	 (77)
Scheme 2.3.6: Synthesis of sodium [i-13C,2-2H2]-3-hydroxypropionate
Analysis of the ' 3C nmr spectrum (figure 2.3.3) obtained from this
showed enhancement of the resonance at 25.94, that due to C-?1 . This, in
turn, was the predicted site of incorporation of label from 3-
hydroxypropionate (77), thus implying a possible role for this moiety in
pseudomonic acid (44) biosynthesis.
As [1-13C]-propionate gave comparable results, 25 however, it was
necessary to determine whether C-i of 3-hydroxypropionate (77) was
incorporated via the same mechanism as that of propionate, or as an intact
unit. For this, a bond labelled form of 3-hydroxypropionate (77) was
required, with introduction of deuterium onto the carbon a to the labelled
carbonyl being the chosen target.
Initially introduction of deuterium was attempted via proton-
deuteron exchange in NaOD/D 20. However neither the use of catalytic nor
stoichiometric amounts of base led to significant exchange, even under
refluxing conditions left overnight.
An alternative was sought via modification of the nitrile hydrolysis
reaction. Thus the use of 1.05 equivalents of NaOD in D20 led to hydrolysis
with concomitant label introduction, scheme 2.3.7. Nmr analysis of the
freeze-dried product showed complete exchange to have taken place, with
the loss of signal at ö2.0 (C-2) and the triplet at ö3.55 (C-3) collapsing to a
broadened singlet, figure 2.3.4.
KCN	 NaOD
HO-	 HO.-	 HO7ç CO2Na
(83)	 (77)DD


























To Ps. fluorescens was administered 250mg of the doubly labelled
material and after work up the 13mg of recovered methyl pseudomonate
(58) was analysed by 13C nmr spectroscopy, figure 2.3.5. No evidence for any
incorporation of label was observed, either by enhancement of the C-7'
resonance or by a 2H () shift. Repetition of this experiment confirmed the
result.
Although perhaps unlikely, a plausible explanation for this may be an
isotope effect. If label incorporation was the result of decarboxylative
cleavage and subsequent incorporation into a different (unknown) moiety
prior to involvement in pseudomonic acid biosynthesis, then the 2H label
may have been deleterious to the action of enzymes upon the applied
compound.
Duplication of the original singly labelled experiment was carried out
in order to verify that result. However, 13C nmr analysis of the resultant
metabolite showed no evidence for label incorporation in contrast to the
original experiment.
2.3.3: Pseudomonic acid biosynthesis involving two entities
Studies thus far have shown that neither a Baeyer-Villiger type
oxidation, nor a triadic cascade biogenesis account for the labelling patterns
observed in pseudomonic acid (44) biosynthesis. A simpler hypothesis
invokes two distinct precursors to pseudomonic acid (44), monic acid (84)








Scheme 2.3.8: Postulated biosynthesis of pseudomonic acid (44) from






























In order to verify such a hypothesis, two basic approaches can be taken
viz-a-viz administration of either labelled monic acid (84) or labelled 9-
hydroxynonanoic acid (45) to the Ps. fluorescens in order to determine
specific label incorporation.
The first of these approaches was undertaken by Mantle and
MacGeorge. 4° They obtained [16,17-14C2]-monic acid (84) via administration
of radiolabelled methionine to bacterial cultures and subsequent
saponification of the isolated labelled methyl pseudomonate (58). Upon
feeding this to fresh cultures of the bacterium they found that essentially
all the radioactivity remained in the medium, with the accumulated
pseudomonic acid (44) being unlabelled.
Although this inability to traverse cell walls explains, at least partially,
the low biological activity of monic acid (84),13 it is uninformative
regarding pseudomonic acid (44) biosynthesis. Indeed, it suggests that
probing later stages on the biogenetic pathway of this metabolite may be
fraught with similar difficulties.
The second of the above processes, namely the feeding of of labelled 9-
hydroxynonanoic acid (45), is detailed below.
2.3.4: Synthesis of labelled 9-hydroxynonanoic acid (45)
As with the previously discussed synthesis of 3-hydroxypropionate
(75), cyanide was chosen as the source for introduction of label. Thus
carboxyl labelled 9-hydroxynonanoic acid (45) was synthesised by the route
shown in scheme 2.3.9. Readily available 8-bromooctan-1-ol (85) was
mixed with potassium cyanide under refluxing conditions overnight.
Hydrolysis of the resultant 9-hydroxynonanitrile (86) produced the
required product, in an overall yield of 78%.
KCN	 a)NaOH
HO(CH2) 8Br	 HO(CH2)8CN b) H	 HO(CH2)8CO2H
(85)	 (86)	 (45)
Scheme 2.3.9: Synthesis of 9-hydroxynonanoic acid (45)
2.3.5: Feeding studies using radiolabelled 9-hydroxynonanoic acid (4)
The use of radiolabels to study specific biosynthetic processes requires
the precise position of any incorporation of label into a metabolite to be
determined. This is usually achieved via degradative chemistry. The
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hydrolysis of pseudomonic acid (44) to monic acid (84) has been described,41
but this entails loss of the 9-hydroxynonanoic acid (45) by-product. Since,
for these studies, this moiety would need to be recovered, a modification
of the procedure was developed, as shown in scheme 2.3.10.
The methyl pseudomonate (58) isolated from the bacterial cultures
was initially protected at the hydroxyl positions with trimethyl ortho
formate, in order to prevent the rearrangements previously described
(scheme 2.1.2). Saponification of this methyl ester, followed by hydrolysis
of the monate ester, deprotection, treatment with dia.zomethane and then
subsequent purification afforded the required methyl monate (87) and
methyl 9-hydroxynonanoate (88). Unfortunately, this process was low














OH	 (87)	 +	 (88)
Scheme 2.3.10: Degradation of methyl pseudomonate (58).
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To cultures of the Ps. fluorescens were administered 10.41pCi of [1-14C]
9-hydroxynonanoic acid (45). From these was isolated 34mg of methyl
pseudomonate (58) exhibiting 82nCi of radioactivity, corresponding to an
efficiency of label incorporation of 0.82%. Degradation of the metabolite
was carried out as described to yield 3mg of methyl monate (87) and 1mg of
methyl 9-hydroxynonanoate (88). Scintillation counting of these methyl
esters showed both to contain significant amounts of radioactivity. The
poor yields of the degradation process, and the low weights of the
recovered products, meant that large errors were present such that
accurate figures for the incorporation of activity into these moieties could
not be calculated.
From these results it became obvious that some degradation of the
administered 9-hydroxynonanoic acid (45) was taking place. In view of the
inherent fatty acid nature of this moiety, this was not surprising. To probe
the extent of this degradation it was decided to utiise stable labels and nmr
analytical techniques.
2.3.6: Feeding studies usingIi 13C]-9-hydroxvnonanic acid (41
The required compound was synthesised as described using potassium
[ 13C1-cyanide as the label source, and 250mg were fed to Ps. fluorescens,
which produced 29mg of methyl pseudomonate (58). Inspection of the 13C
nmr spectrum (figure 2.3.6) of this showed that although label had been
efficiently incorporated into the metabolite, such incorporation was
entirely non-specific via degradation to acetate through the action of 3-
oxidation enzymes.
Owing to the ubiquity of such enzymes, these competing biological
processes are an inherent problem in studies of this nature. A number of
inhibitors to fatty acid catabolic enzymes have been developed, of which
one of the most effective is tetradecyithiopropionic acid (89). It was hoped
that concomitant administration of this inhibitor with labelled 9-
hydroxypropionic acid (45) would reduce the in vivo degradation of this
and therefore lead to information regarding the involvement of (45) in



























Prior to such an experiment it was necessary to ensure that the I-
oxidase inhibitor did not also inhibit pseudomonic acid (44) biosynthetic
processes. Thus 30mg of tetradecylthiopropionic acid (89) were added to
250m1 of secondary media 20 hours after inoculation. Work-up as usual
led to the isolation of 21mg of methyl pseudomonate (58). A control
sample of Ps. fluorescens produced 23mg of metabolite, indicating that no
inhibition had occurred.
For the main study, tetradecyithiopropionic acid (89) was fed in
tandem with [1- 3C]-9-hydroxynonanoic acid (45). The usual work-up
procedure led to the isolation of 17mg of methyl pseudomonate (58).
Analysis of the 13C nmr spectrum of this (figure 2.3.7) indicated that
although incorporation of label had occurred, it was again via degradation
of acetate with no evidence for any specificity.
Although these studies may be taken as evidence against the direct
involvement of 9-hydroxynonanoic acid (45) in pseudomonic acid (44)
biosynthesis, no firm conclusions can be drawn as a result of competitive
catabolic processes. At this juncture it was clear that simple feeding studies
were not going to yield definite information. It was therefore decided that
the use of a 'cell-free' system should be investigated.
2.4: PSEUDOMONIC ACID BIOSYNTHESIS USING A CELL FREE
SYSTEM
2.4.1: The use of cell free systems
The vast majority of intracellular chemical reactions are mediated by
enzymes acting as highly efficient, commonly substrate specific, catalysts.
As has been demonstrated, however, the in viva study of one enzyme
system can be thwarted by the presence of less selective enzymes.
Resolution of such problems may be possible by the isolation of
enzyme activity for in vitro studies. Many examples of this approach exist
in the literature, and two recent examples demonstrate the value of such
experiments.
The biosynthesis of erythromycin (90) in Streptomyces erythrea (now
re-named Saccharopolyspora erythreus ) had been postulated to proceed
via 6-deoxyerythronolide B (91) from the use of mutant strains. 43 Earlier


























biosynthetic pathway." The hydroxyl group on C-6 of (92) was known not
to be derived from acetate/propionate/ malonate precursors.
Scheme 2.4.1: Production of erythronlide B (92), a precursor to
erythromycin B (90), from 6-deoxyerythronolide B
(91) ,as shown in a cell-free system.
The demonstration that 6-deoxyerythronolide B (91) was the direct
precursor to erythronolide B (92) was accomplished through use of a cell
free system to which 6-deoxyerythronolide B (91) was administered
leading to the production of erythronolide B (92), as shown in scheme
2.4.1.
One of the most studied of all secondary metabolic processes has been
that which leads to the penicillins and cephalosporins, the 13-lactam
antibiotics. 46 Although it was known that the biogenetic pathway began
with the coupling of L-a-aminoadipic acid (93), L-cysteine (94) and L-
valine (95) to form a tri-peptide starter unit, -(L-a-aminoadipyl)-L-
cysteinyl-D-valine (96), the process of the coupling itself was little studied
until 1987. Cell free systems developed from Cephalosporium
acremonium 47 and Streptomyces clavuligerus 48 showed that a single
enzyme was responsible for the coupling process and that valine
epimerisation occurs during formation of the tri-peptide, as shown in
scheme 2.4.2.
It was hoped that verification of the hypothesis invoking two distinct
precursors to pseudomonic acid (44) may be possible by the development











Scheme 2.4.2: The formation of the tri-peptide starter unit for the
3-lactam biosynthetic pathways.
2.4.2: Lysis of cell membranes.
To produce a cell free system at least partial destruction of the cell
walls to enable release of enzyme is required. A variety of methods have
been developed for this.49
a) Enzymatic
The use of enzymes to digest cell walls is usually achieved by the use
of lysozyme, which is extracted from egg-whites. This enzyme hydrolyses
the f-1,4-glycosidic bonds of the mucopeptide of bacterial cell walls. In
general, Gram positive bacteria are most susceptible to such treatment.
Other enzymes less frequently used are microbial gluconases and
lysostaphin.
b) Chemical
The short exposure (20 minutes) of bacteria to alkaline conditions (pH
12) has been used for cell wall lysis, but the success of such an approach
requires that any released protein be alkali stable.
Detergents, both ionic or non-ionic, have also been used. Ionic
detergents are the most reactive, but are more prone to give rise to enzyme
denaturation as a result. The presence of detergent also leads to an
increased number of steps should enzyme purification be desired.
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c) Physical
The most widely employed technique, especially for small scale work,
is that of sonication. A cellular suspension of cells is subjected to repeated
bursts of high energy sound waves, which leads to the piercing and
ultimately the destruction of the cell walls
Another oft-used method is osmotic shock. This involves washing the
cells free of growth medium prior to suspension of the cells in a buffered
20% sucrose medium. After equilibration the cells are harvested and
rapidly resuspended in water at 4°C. This yields 4-8% of the total bacterial
protein.
Grinding with abrasives, for example glass beads or sand, is a
frequently used method, leading to total destruction of the cell walls.
A different technique is shearing, either in solid or liquid phase. This
involves the extrusion of a sample through a narrow orifice after
subjection to high pressures. For liquid suspensions on a small-scale, a
continuous French press is often used.
With the exception of osmotic shock methodology, physical lysis
techniques cause the generation of large amounts of heat which must be
efficiently and rapidly dissipated so as to avoid enzyme denaturation.
2.4.3: Determination of cell lysis.
For cell free studies extensive rupture of the cellular membrane needs
to have occurred to allow efficient release of protein. A simple qualitative
test for this is a reduction in the viscosity of the cell suspension after
treatment. 5° A more rigorous test is possible through microscopic
observation of changes in the cell structure. Either visible microscopy, for
the study of cell colonies, or electron microscopy, for the study of
individual cells, may be used. Measurement of the amount of protein
release can also be used to quantify any cell membrane disrupture.
2.4.4: Lysis of Pseudomonas fluorescens.
For these studies a high producing strain of Ps. fluorescens (PF3/N/2),
that had been developed from the usual strain,51 was used with the
assumption that higher titres of enzyme would be present. This was
grown under the same conditions used for the normal producing strain
until metabolite production was shown to have tommenced by HPLC
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assay of the medium. The cells were then harvested by centrifugation, and
washed prior to re-suspension in buffer for cell fissure experiments.
The nature of the enzyme system under investigation was unknown
and so it was decided that mild lysis techniques would be investigated to
reduce the possibility of protein denaturation.
The method initially investigated was sonication. The cells were
suspended in a buffer of pH 7.6 prior to treatment. Sonication led to a
suspension of slightly reduced viscosity. Sonication on cellular
suspensions buffered to pH 7.2 and 6.9 was also carried out.
Lysozyme was also utilised for cell lysis. Initially the direct addition of
the enzyme to a buffered suspension at pH 7.6 was tested. However as
Ps.fluorescens is a Gram negative bacterium it was unlikely that this
would lead to useful cell rupture. In order to aid the enzyme the cellular
suspension was pre-treated with EDTA. 52
 It was hoped that such a
chelating agent would remove metal cations from the outer membrane
leading to a weakening of the cell wall thus rendering it more susceptible
to enzymatic lysis.
Finally, liquid shear by passage though a French press was also
investigated.
Optical microscopy was used to analyse the effect of such treatments
on the cells. In all cases it was observed that with respect to an untreated
sample, cellular coagulation occurred. Staining of dried sample slides gave
no further information. Thus, although it appeared that a change had
occurred it was not possible to quantify the nature or extent of this. The
samples were submitted for electron microscopy, but the time needed for
such analysis meant that studies proceeded without definite confirmation
of cell rupture. The results of the electron microscopy studies are discussed
in appendix 2A.
2.4.5: Cell free studies
In order to test the working hypothesis two reactions were chosen for
investigation. The first of these was that between monic acid (84) and 9-
hydroxynonanoic acid (45) based on the premise that this was the formal
reaction being postulated within the hypothesis.
In biological systems, however, reactants are frequently utilised in an
activated form, a common example of this being the activation of acetate
as acetyl CoA (9). Such thioesters are frequenfly found as a source of
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activation in biological systems. The studies into the stereospecificity of
fatty acid biosynthetic processes discussed in chapter 1 showed that N-
acetylcysteamine thioesters (33) acted as mimics for this type of activation.
The second reaction chosen for observation, therefore, was that between
the N-acetylcysteamine thioester of monic acid (97) and 9-
hydroxynonanoic acid (45).
This was synthesised by the use of DCC/IDMAP coupling,53 N-acetyl-
cysteamine (98) being easily synthesised from readily available materials,54
as shown in scheme 2.4.3. The solubility of monic acid (84) in organic
solvents was found to be poor, with the exception of simple alcohols (the
use of which would lead to oxy-esters as the main product). Solvation of
monic acid (84) in tetrahydrofuran led to a turbid solution and so this was
employed as the reaction medium. However under these conditions the
yield of the required thioester (97) was only 18%. As monic acid (84) was
readily available, the poor yield was deemed to be sufficient for these
studies.
















Scheme 2.4.3: Synthesis of N-acetylcysteamine (98) and the N-acetyl
cysteamine thioester of monic acid (97).
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For each set of experiments, fresh cell preparations were used for lysis
and the resultant suspensions used immediately after treatment. Further
experiments were carried out using the supernatant after centrifugation of
lysed samples in order to determine the extent of any membrane
association requirement.
The initial ratio of monic acid (84) or thioester (97) to 9-hydroxy
nonanoic acid (45) was 1:3, with the acid/thioester at 5mmol
concentration. In later experiments the ratio was increased to 1:5 with an
acid/thioester concentration of 2mmol. Reaction times ranging from 2 to
20 hours were tested, under static and mixing conditions.
Under these conditions, and using all the possible permutations of
available cell free 'enzyme,' no production of pseudomonic acid was
observed by HPLC assay.
Within the last decade, Klibanov has pioneered the use of 'anhydrous'
organic solvents as media for the use of enzymes. Following the lack of
success of the previous experiments it was decided that the use of freeze-
dried enzyme preparations should be investigated to see if this would
yield any information. One advantage of such an approach was the use of
a further reaction, namely the hydrolysis of pseudomonic acid (44) to
monic acid (84) and 9-hydroxynonanoic acid (45). This was postulated on
the basis that esterases are known to catalyse both the formation and
hydrolysis of esters.
For such studies three anhydrous solvents were chosen; 1,4-dioxan,
tetrahydrofuran and acetonitrile. A small amount of water is often
required for such reactions, to ensure retention of enzymic structure. Thus
experiments involving the presence of 0.5%, 0.1% and 0% water were
tested. One of the problems with this approach was the parity of substrate
to solvent. Where one of the substrates was not highly soluble in the
solvent of choice, it was added in another of the anhydrous solvents. In all
cases, rapid shaking was used to ensure thorough mixing. Again, reaction
times varied from 2 to 20 hours for all possible permutations.
No evidence for pseudomonic acid (44) production or degradation (ie
monic acid (84) production) in any of the experiments was observed by
HPLC assay.
There exists a number of plausible explanations for these results. One
possibility is simply due to poor release of protein. Another reason may
arise from denaturation of enzyme owing to either inherent extra-cellular
instability or oxidation under atmospheric conditions. Experiments under
63
reducing conditions were not carried out. The enzyme may require a
number of co-factors for efficient catalytic activity which would have been
unavailable under the conditions investigated.
Further explanations may lie in the actual timing of the esterification
(and thus the species involved) with respect to other steps on the
biosynthetic pathway to pseudomonic acid (44).
2.5: SEQUENTIAL PSEUDOMONIC ACID (44) BIOSYNTHESIS.
2.5.1: Precursors to monic acid (45)
The esterification hypothesis postulated the reaction partners to be
monic acid (84) and 9-hydroxynonanoic acid (45). However, it is possible
that precursors to either of these species are the actual substrates, with
further modifications subsequent to this giving rise to the final metabolite.
The timing of the ring closure step with respect to any esterification
process is also unknown.
A co-metabolite of pseudomonic acid (44) is pseudomonic acid C (52).
This has an identical carbon back-bone to (44) but lacks the epoxide
functionality, possessing a trans-double bond instead. It is more likely that
epoxidation of the double bond leads to pseudomonic acid (44) as opposed
the de-oxygenation of pseudomonic acid (44) leading to pseudomonic acid
C (52). However such an epoxidation step may occur prior or subsequent to
any esterification, as shown in scheme 2.5.1. The existence of pseudomonic
acid C (52) does not discriminate against either possibility.
The events leading to the origin of C-15 from C-2 of acetate are to be
discussed in chapter three. However, such a process could occur in a
relevant precursor to either monic acid (84) or pseudomonic acid (44). The
timing of this step with respect to ester formation is again unknown.
In order to ascertain information regarding the sequence of steps on
the pathway to pseudomonic acid (44), some preliminary experiments






















Scheme 2.5.1: Relative timing of epoxidation and esterification steps
on the biogenetic pathway to pseudomonic acid (44).
2.5.2: The use of oxidase inhibitors and mutant strains
The ordering of biosynthetic events can determined by two methods,
namely the use of blocked mutant strains of the producing organism or
the use of enzyme inhibitors. Potentially the most profitable is the use of
blocked mutants. This involves genetically altering the producing
organism to produce new strains of non-producing organism. If a large
number of altered organisms are screened, then it is possible that some of
these new organisms will produce new metabolites that are intermediates
on the biosynthetic pathway to the natural product under consideration.
In these cases the mutation will have blocked the subsequent step on the
biosynthetic pathway. From structural comparisons it may be possible to
predict the order of events leading to the final metabolite, but this may not
always be obvious.
However if a number of mutants have been produced then co-
synthesis experiments can be used to determine the sequence. If one non-
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producing mutant accepts the intermediate excreted by another mutant
such that the first mutant now produces the original metabolite, then it
can be deduced that the pathway in the acceptor mutant has been blocked
earlier than in the second (excreting) mutant. Investigation of all the
possible permutations from such mutants leads to a precise knowledge of
the ordering of events along a biosynthetic pathway.
Studies into the genetics of pseudomonic acid (44) biosynthesis in Ps.
fluorescens have produced a number of non-producing mutant strains of
the bacterium. 57 As part of this work it was of interest to determine
whether any of these expressed any new metabolites that may be of
biosynthetic interest. The mutant strains were cultured under the usual
conditions and then assayed by HPLC for pseudomonic acid (44), monic
acid (84) and then any new peaks under a variety of solvent systems.
However, no peaks were seen.
The genetic work is continuing and more mutant strains are being
produced. Further assay of these may give useful results. A further
experiment worth investigating as part of such studies is the 'spiking' of
the culture broth with a trace of radiolabelled methionine. Any uptake of
this will be detectable and, in conjunction with preparative HPLC
techniques, new metabolites may be discovered.
The second method used for gaining information regarding the
sequence of events on a biogenetic pathway is by the use of enzyme
inhibitors. In many cases these are only useful for probing late biosynthetic
events, as early inhibition is unlikely to yield interesting structures of
biosynthetic use.
Pseudomonic acid (44) has two oxygen atoms known not to be derived
from acetate,22'° the epoxide oxygen and the hydroxyl on C-6. These are
assumed to be of atmospheric origin, although experiments designed to
confirm this did not produce enough metabolite for the relevant analysis
to be performed. If such an assumption is correct, the oxidase involved is
likely to be a cytochrome-P450
 type enzyme.58 A known inhibitor of this
species of enzyme is ancymidol (99)59 In possessing both lipophilic and
heteroatomic moieties, this can reversibly bind to the lipophilic domain
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This inhibitor blocks the conversion of kaurene (100) to kaurenol (101)
on the gibberellin (eg gibberellic acid, 102) biosynthetic pathway, 61 scheme
2.5.2
Scheme 2.5.2: The oxidation of kaurene (100) to kaurenol (101) on the
biogenetic pathway to gibberellic acid (102), a step
inhibited by ancymidol (99).
This inhibitor has been applied to the study of plant metabolism, 62 but
was also employed in the study of betaenone B (103) biogenesis, a
polyketide metabolite produced by the fungus Phome beta. The
biosynthesis of betaenone B (104) had already been shown to be the result
of the sequential condensation of acetate with eight malonate units, with
branching methylation resulting from methionine. 63 The use of [1-13C,
180 2]acetate indicated that the keto oxygen on C-i was not acetate derived.
From this a biogenetic hypothesis invoking an intra-moleculer Diels-












Scheme 2.5.3: The biosynthesis of betaenone B (103)
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Experiments using ancymidol (99) as a mono-oxygenase inhibitor led to
the suppression of the production betaenone B (103), the reduction in titre
being directly proportional to the amount of ancymidol (99) administered.
A new metabolite was found to accumulate, which was shown to be the
intermediate (104) proposed as the Diels-Alder product."
A similar experiment was conducted to measure the effect of
ancymidol (99) on pseudomonic acid (44) biosynthesis. Thus to one of five
flasks of secondary medium inoculated with the high producing strain of
Pseudomonas fluorescens was added 0mg, 5mg, 10mg, 20mg, 40mg of
ancymidol (99) at the commencement of metabolite production. The
cultures were left to grow as usual before HPLC analysis. No significant
difference in metabolite titre was found across the range of flasks, and no
new peaks were observed by HPLC.
2.6: Conclusions and further work.
These results imply that 3-hydroxypropanoic acid (75) is not intimately
involved in the biosynthesis of pseudomonic acid (44). However, the
incorporation of label from the singly labelled form needs to be clarified.
The original hypothesis regarding the involvement of 13-hydroxy-13-
methyl glutarate (64) in pseudomonic acid (44) biosynthesis invoked 5-
hydroxypentanoic acid as an intermediate (scheme 2.2.5). The possibility of
this being a chain starter may be worth investigating.
The multiply labelled malonate (73) experiment showed the C-7'/C-8'
bond is not constructed as a result of fatty acid'/polyketide type processes.
A further experiment employing D-[U- 13C]-glucose (10) may lead to further
information regarding the biosynthetic origin of this bond. A recent
example of the value of such an approach is in the elucidation of the
biosynthesis of obafluorin (105), a 3-lactone metabolite from Ps.
fluorescens (ATCC 39502).
In order to define the separate units involved in obafluorin biogenesis
D-[U- 13C]-glucose (10) was fed to Ps. fluorescens and the isolated metabolite
analysed by 13C nmr spectroscopy. The resultant 13C-13C couplings (scheme
2.6.1) showed the intact bond incorporations, and demonstrated that the
aromatic rings were of shikimate (36) origin. Two intact C2 units were also













Scheme 2.6.1: Result form feeding D-[U-.13C]-glucose in obafluorin
(105) biosynthesis
Another possibility is from label being introduced as a result of the
decarboxylation of 'acids' and subsequent metamorphosis to a reduced
state before (or during) incorporation into C-7'. The carboxyl groups of
acetate, propionate and (possibly) 3-hydroxypropionate all label this
position. It would be interesting to discover whether any other simple
acids exhibit similar behaviour.
No positive information has been gained regarding the proposed
biosynthesis of pseudomonic acid (44) from monic acid (84) and 9-
hydroxynonanoic acid (45). Further information may be forthcoming from
the genetic/mutant strain work. Repetition of the ancymidol (99)
inhibition experiment with the normal producing strain of Ps. fluorescens
may be worthwhile, as it is possible that the high producing strain
effectively swamped any inhibition.
The experiments described earlier in the chapter regarding the use of
labelled 9-hydroxynonanoic acid (45) gave results consistent with complete
catabolism. However, one problem with these experiments may be due to
a lack of sensitivity in using a singly labelled compound. This may be
overcome by the use of a doubly (bond) labelled precursor, in the form of
the N-acetylcysteamine thioester (106). Some work towards this has been
undertaken.
Studies to produce the N-acetylcysteamine thioester of 9-hydroxy
nonanoic acid (106) directly from the acid and the thiol using the
DCC/DMAP 53 or PhOP(0)C1 2 /Py 67coupling methods (to be further
discussed in chapter three) were low yielding. As a doubly 13C labelled
compound was required, however, a different approach was considered.
As catabolism has been shown to be the dominant pathway the labels
needed to be present in a manner such that any intact incorporation could











formed by an acetate/malonate condensation, as opposed to one that is
present within the condensing moiety. The target molecule therefore
chosen was the N-acetylcysteamine thioester of [2,3-13C2]-9-hydroxy
nonanoate (106). The primary sources of labels from this scheme are [2-
13C]-bromoacetic acid (78) and potassium [ 13C]-cyanide, and these are
proposed to be coupled by a Wittig reaction.
For this, the synthesis of the required ylid (107) was achieved by the
coupling of bromoacetic acid (78) with N-acetylcysteamine (96) using
DCC/DMAP,53 followed by reaction of the resultant thioester (108) with
triphenylphosphine to produce the N-acetylcysteamine thioester of
[(triphenylphosphoniumacetate) bromide] (109). Titration of this against
sodium hydroxide, with phenolphthalein indicator, produced the required












Scheme 2.6.2: Synthesis of the ylid (107)
For the second half of the coupling reaction, the aldehyde (110) was
required. Thus, 7-hydroxypropionitrile (111) was synthesised in 92% yield
by the action of cyanide on 6-bromohexan-1-ol (112).
KCNJ	 a) ProtectHO(CH2)6C1	 HO(CH2)6cN	 XO(cH2)6cHOb) DIBAL(112)	 (111)	 (110)
(X=protecting group)
Scheme 2.6.3: Synthesis of the aldehyde (110)
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Ethoxyethoxy ether protection of this in quantitative yield proceeded
reduction of the nitrile moiety to the required aldehyde (110) by DlBAL in
76% yield, scheme 2.6.3
Preliminary investigations into the Wittig coupling, scheme 2.6.4,
indicate that the reaction proceeds under refluxing chloroform conditions.
However, separation from the triphenylphosphine oxide by-product has
not yet been achieved. Further work towards optimisation of this
synthesis is required, particularly with respect to the choice of protection
group, the DIBAL reduction, the coupling reaction, and also the final











Scheme 2.6.4: Wittig coupling of aldehyde (107) with ylid (104), prior




Electron microscopy studies on Ps. fluorescens after cell lysis experiments
These studies were undertaken after completion of the cell free
investigations into the biogenesis of pseudomonic acid (44), but the
samples examined were taken from those used in the experiments.
The accompanying photographs clearly show that sonication
treatment had the most dramatic effect upon the cells (figure 2.A.1), when
compared to an untreated cell colony. The attempt at liquid shear cell
rupture by passage through a French press appears to have had some
effect, as shown by the resultant debris. However, large numbers of intact
cells are still present.
Figure 2.A.1: Electron microscopy studies on lysis of Ps.fluorescens by means
of sonication and French press shear.
72
The use of lysozyme by itself led to no discernable change in the cell
colony (figure 2.A.2). Treatment with EDTA prior to lysozyme treatment
led to apparent shrinkage of the cells, but there is no evidence for cell lysis.
Therefore, it seems that sonication is the method of choice for further
studies of this kind.
Figure 2.A.2: Electron microscopy studies on lysis of Ps. fluorescens by means




All 1 H and 13C nmr spectra were recorded on a Jeol GX270 and PMX6O
instruments in C2HC13 solution and were referenced to tetramethyl silane,
except those stated to have been run in 2H20 which were referenced to
sodium 2,2-dimethyl-2-silapentane-5-sulphonate.
Melting points were determined on a Kofler hot-stage apparatus, and
were uncorrected.
Mass spectra were obtained from a Kratos M59 spectrometer with VG
ZAB ion source and electronics.
Scintillation counting was performed on a LKB 1215 Rackbeta
scintillation counter, with unisolve E as the scintillant.
Infra-red spectra were recorded on a Perkin-Elmer 881 spectrometer.
Gas chromatography was carried out using a Perkin-Elmer 8320
capillary gas chromatograph. High performance liquid chromatography
was performed on a Gilson 303 system. The HPLC column was 250mm in
length, with internal diameter 4.1mm and Ailtech versapack C-18 lOU
packing.
Preparative thin layer chromatography was carried out on 200 x
200mm glass plates coated with silica gel (0.25, 0.5 or 1.0 cm, Fluka 60765
Kieselgel Gf245). Bands were visualised by the use of ultra-violet light
(245nm) or via staining with ammonium molybdate (10% w/v in 2M
sulphuric acid). Flash column chromatography was carried out using
silica gel (40-63gm, Kieselgel 60, Merck, and 220-440 mesh, Kieselgel 60,
Fluka).
Microbiological work was performed under sterile conditions, in a
Biomat Class II microbiological cabinet. Sterilisation of all materials prior
and subsequent to use was carried out in an autoclave under the described
conditions.
Sonication was carried out on an MSE Soniprep 150 machine with a
9.5mm probe. The French press was an SLM Aminco FA079 press with an
20K manual fill FA073 cell. Lysozyme was purchased from BDH chemicals
Ltd. and had 25,000 units mg1.
Buffer solutions were made using tris-HC1.
All solvents were dried and distilled prior to use according to
published procedures. 7° Nitrogen was dried by passage through a silica
gel/calcium chloride column.
Rehydration of Ps. flu orescens
A freshly opened lyophile of Ps. fluorescens was rehydrated by
suspension in 0.5m1 of sterile nutrient broth. The suspension was
deposited in 4.5m1 of sterile nutrient broth with stirring to ensure
homogeneity. 10l Loopfuls of this suspension were streaked onto 1/10
6sp agar slopes, the constitution of which is shown in table 2.E.1. These
were left to grow at 25°C for 48 hours prior to storage at 4°C, under which
conditions they were viable for four months.
Culturing of Ps. flu orescens.
A slope was flooded with 5m1 of sterile nutrient broth and the bacteria
suspended in this. A Imi aliquot of this suspension was transferred to a
sterile 250m1 conical flask containing 25m1 of primary medium, the
constitution of which is shown in table 2.E.2. The inoculated flask was
then shaken at 240 rpm for 24 hours at 22-24°C.
After this time ten 250m1 conical flasks each containing 25m1 of
secondary medium (the constituents of which are shown in table 2.E.3)
were each inoculated with a Imi aliquot of the primary medium. These
flasks were then shaken at 240 rpm for 28 hours at 22-24°C.
These procedures were used for the culturing of both the NCIB 10586
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Antifoam L-81	 3 drops
Non-essential additives were : MnC1 2 .4H20 (imi of a 2% solution 11)
CoC12.6H20 (lml of a 0.03% solution 11).
Medium adjusted to pH 7.0 prior to sterilisation (1 15°C, lopsi)
Table 2.E.3: Constituents of secondary (production) medium.
Isolation of methyl pseudomonate (58)
The combined secondary media were centrifuged (lO,000g, 4°C, 10
minutes) and the supernatant was acidified to pH 4.5, saturated with
sodium chloride and extracted with ethyl acetate (5 x 150m1). The
combined organic layers were dried over anhydrous magnesium sulphate,
filtered and concentrated in vacuo. The orange residue was taken up in
5m1 of methanol and treated with an excess of ethereal diazomethane, in a
vessel devoid of ground glass joints. After two hours the diazomethane
was blown off with nitrogen and the mixture concentrated in vacuo.
Purification by prep. TLC (2.5% methanol in ethyl acetate) yielded methyl
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pseudomonate (58) as a colourless oil which solidified upon refrigeration.
Dmax 3309, 1742, 1717, 1651cm 1 ; oH 0.94 (3H, d, J=7.4Hz, H-17), 1.22 (3H, d,
J=6.51-Iz, H-14), 1.31-1.38 (9H, br s, H-4', H-5', H-6', H-12), 1.44-1.98 (6H, m,
H-3', H-8', H-9), 2.03 (1H, m, H-8), 2.22 (4H, s, H-4ax, H-iS), 2.31 (2H, t,
J=7.6Hz, H-2'), 2.46, 2.64 (1H, m, H-4eq), 2.68-2.73 (1H, m, H-il), 2.81 (IH, m,
H-b), 3.46-3.59 (2H, m, H-l6eq, H-6), 3.67 (3H, s, OMe), 3.94-3.74 (4H, m, H-
7, H-l6ax, H-13, H-5), 4.07 (2H, t, J=6.6Hz, H-9'), 5.76 (1H, s, H-2); O, 12.76 (C-
17), 19.05 (C-15), 20.8 (C-14), 24.92 (C-3'), 25.97 (C-7'), 28.67 (C-8'), 29.05 and
29.11 (C-4', 5', 6'), 31.56 (C-9), 34.10 (C-2'), 39.53 (C-8), 42.86 (C-12, 4), 51.53
(OCH3), 55.59 (C-b), 61.37 (C-il), 63.85 (C-9'), 65.34 (C-i6), 69.02 (C-6), 70.42
(C-7), 71.46 (C-i3), 74.88 (C-5), 117.69 (C-2), 156.66 (C-3), 166.77 (C-i), 174.44
(C-i'); m/z: 515 (M+1, 0.7%), 514 (M, 0.8), 270 (48.6), 227 (87.3), 209 (34.4),
141 (44.6), 111 (92.3), 95.1 (44.6), 83 (51.4), 82 (100), 69 (60.9), 55 (71.2), 43
(65.4).
Growth production study
A lml aliquot was taken from the secondary medium every two
hours, commencing 12 hours after inoculation. These were micro-
centrifuged before analysis by HPLC, with a solvent consisting of
methanol/0.05M ammonium acetate (3:2 at pH 4.5). The flow rate was
1 .5ml min 1
 with peaks being monitored at 230nm.
Preparation of ethereal diazomethane
For this preparation a self-contained distillation apparatus was used
which contained no ground glass joints.
To 0.47g of potassium hydroxide was added l5ml of ethanol and 3Oml
of ether. The mixture was gently warmed imlil the ether began to slowly
distil over into an ice-water cooled receptacle. At this point 1 .79g of dia.zald
was carefully added in l5ml of ether. The mixture was monitored such
that a gentle reflux led to slow distillation of the yellow distillate. Reaction
was complete when the distillate became colourless. The resultant
solution was used immediately.
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Synthesis of 9-hydroxynonanoic acid (45)
a) To 0.993g (4.75mmol) of 8-bromooctan-1-ol (85) in 5m1 of methanol
was added 0.974g (14.76mmol) of potassium cyanide in 5m1 of water. The
mixture was heated under reflux for 7 hours. After cooling the methanol
was removed in vacuo and the residue extracted with ethyl acetate (3 x
lOmi). The organic extracts were combined, dried over anhydrous
magnesium sulphate and concentrated to give 9-hydroxynonanitrile (86)
(0.661g, 3.94mmol, 83%) as a pale yellow oil. u( thin film) 3313, 2247 and;
8H 1-2 (1ZH, br m, 6 x CH 2), 2.3 (2H, t, J=5.3 Hz, CH2CN), 3.6 (2H, t, J=5.3 Hz,
CH2OH).
b) 9-Hydroxynonanitrile (86) (0.609g. 3.93mmol) was dissolved in 5m1
methanol and to the solution was added 6m1 of 2M NaOH solution. The
mixture was heated under reflux overnight. After cooling the solution
was extracted with ethyl acetate (10m1) and the aqueous layer then
adjusted to pH 1.0 before re-extraction with ethyl acetate (5 x lOOmi). The
acidic extracts were combined, dried over anhydrous magnesium sulphate
and concentrated to give 9-hydroxynonanoic acid (45) (0.621g, 3.57mmol,
91%) as a white waxy solid. Omax(flU Ol) 3298, 1732 cm1; H 1-2 (12H, br m, 6 x
CH2), 2.2 (2H, t, J=5.6 Hz, CH2CO2H), 3.6 (2H, t, J=5.6 Hz, CH 2OH), 5.0 (2H, br
s, 2 x OH); E 24.58, 25.57, 28.49, 28.97, 33.98 (C-2,3,4,5,6,7,8), 62.81 (C-9),
174.12 (C-i); m/z 175 (M+1, 1%), 174 (M, 1.1%), 157 (8%), 136 (6%), 69
(41%), 55 (100).
Synthesis of [1- 13C]-9-hydroxynonanoic acid (45)
a) To 0.502g (4.98mmol) of 8-bromooctan-1-ol (85) in 5ml of methanol
was added 0.5g of potassium [13C]-cyanide (7.46mmol) in 5m1 of water. The
mixture was heated under reflux for 7 hours. After cooling the methanol
was removed in vacuo and the residue extracted with ethyl acetate (3 x
lOmi). The organic extracts were combined, dried over anhydrous
magnesium sulphate and concentrated to give [1-13C]-9-hydroxynonanitrile
(86) (0.627g, 4.O3mmol, 81%) as a pale yellow oil. max(thjfl film) 3309, 2245
Cm1; oH 1-2 (12H, br m, 6 x CH 2), 2.3 (2H, dt, Hz JHH...5.3HZ
CH213CO21-I), 3.6 (2H, t, J=5.3Hz, CH2OH).
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b): [1-13C]-9-Hydroxynonanitrile (86) (0.627g 4.O3mmol) was dissolved
in 5ml methanol and to the solution was added 6m1 of 2M NaOH
solution. The mixture was heated under reflux overnight. After cooling
the solution was extracted with ethyl acetate (lOml) and the aqueous layer
then adjusted to pH 1.0 before re-extraction with ethyl acetate (5 x lOOmi).
The acidic extracts were combined, dried over anhydrous magnesium
sulphate and concentrated to give [1-13C]-9-hydroxynonanoic acid (45)
(0.614g. 3.5lmmol, 87%) as a white waxy solid. UmaX (nujol) 3302, 1731 cm1;
1-2 (12H, br m, 6 x CH 2), 2.3 (2H, m, CH 213CO2H), 3.6 (2H, t, J= 5.6 Hz,
CH2OH), 4.8 (2H, br s, 2 x OH); 6, 174.15; m/z 176 (M+1, 0.5%), 175 (M,
1%), 158 (8.6), 139 (6.5), 69 (43), 55 (100).
Saponification of methyl pseudomonate (58)
To methyl pseudomonate in 3m1 of triethyl orthoformate was added a
crystal of PTSA. After 30 minutes the solvent was removed in vacuo and
lOmi of 2ml NaOH added to the residue. This was stirred at 65°C for three
hours, cooled and methanol added. The pH was adjusted to 1.5 for 15
minutes, then to 9.0 at which it was maintained for three hours. The pH
was further adjusted to 3.0, and the mixture extracted with ethyl acetate (5
x 30m1). The combined organics were dried over anhydrous magnesium
sulphate, filtered and concentrated in vacuo. The residue was taken up in
8m1 of methanol and treated with an excess of ethereal diazomethane for 5
hours. The solvents were removed and the mixture purified by
preparative TLC (dichloromethane/acetone, 1:1 with 4% methanol). The
band at RI 0.9 corresponded to methyl 9-hydroxynonanoate (88), Dmax (thin
film) 3367, 1651 cm1; 6H 1-2 (121-1, br m, 6 x CH 2), 2.31 (2H, t, J=5.7Hz,
CH2CO2Me), 3.62 (2H, t, J-5.9Hz, CH2OH), 3.67 (3H, s, OCH3), and that at RI
0.55 was methyl monate (87). D max 11U3) 3297, 1711, 1647 cm1; H 0.92 (3H,
d, J=7.lHz, CH 3), 1.18 (3H, d, J=6.6Hz, CH3), 1.4 (1H, m, H-12), 2.05 (IH, m,
H-8), 2.18 (3H, s, H-15), 2.5-2.75 (3H, m, H-b, H-il, H-4), 3.45-3.75 (6H, m,
H-5, H-6, H-7, H-13, H-16), 3.65 (3H, s, OCH 3), 5.75 (1H, s, 2-H)]
Synthesis of disodium malonate
a) To ig (12.2 mmol) of anhydrous sodium acetate was added 5ml of
triethyl phosphate, and the mixture heated to reflux for 3 hours. After
cooling the condenser was linked to a vacuum pump via two traps. The
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first of these was cooled with ice/salt, whilst the second was cooled with
liquid nitrogen. The system was evacuated and the reaction mixture gently
warmed such that ethyl acetate collected in the second trap, whilst any
triethyl phosphate collected in the first trap. This yielded 0.89g (10.1 mmol,
83%) of ethyl acetate as a colourless liquid. 6H 1.25 (3H, t, J=8Hz, CH 3), 2.05
(3H, s, CH3), 4.18 (2H ,q, J=81-Iz, OCH2)
b) To 20m1 of freshly distilled anhydrous THF at -78°C under an
atmosphere of dry nitrogen was added of hexamethyldisilazide (2.113g.
13.l3mmol). To this was added 5.08m1 of butyl lithium as a 1.6M solution
in hexanes (12.69mmol). After 30 minutes ethyl acetate (0.787g, 8.75mmol)
was added dropwise as a solution in THF. After a further half hour ethyl
chloroformate (1.425g, 13.l3mmol) was added in TI-IF. The mixture was
left for 2.5 hours prior to addition of 10m1 of 1M HC1. The layers were
separated and the aqueous layer extracted with ether (2 x 20m1). The
combined organics were dried over anhydrous magnesium sulphate,
filtered and concentrated in vacuo to yield an orange residue. This was
purified by bulb to bulb distillation (66°C, 6mmHg) to yield 0.994g
(6.2lmmol, 71%) of diethyl malonate C' max(th film) 2996, 1731cm; H
1.25 (6H, t, J=6Hz, CH3) F 3.35(2H, s, CH2), 4.18 (4H, q, J=6Hz, CH2)
c): To the diethyl malonate (73) (0.842g, 5.27mmol) was added 5.22m1 of
2.07M NaOH solution. The mixture was stirred overnight. The water was
removed in vacuo prior to freeze drying. This gave g (0.78g, 5.27mmol,
100%) of disodium malonate as a white S011diJmax(flUJOl) 1562, 1455, 1411
cm 1; H(2H2O) 3.12 (2H, s, CH)
Synthesis of disodium [1 ,2-3C2]-malonate
a): To Ig (11.9 mmol) of anhydrous sodium [1,2- 13C2]-acetate was added
5ml of triethyl phosphate, and the mixture heated to reflux for 3 hours.
After cooling the condenser was linked to a vacuum pump via two traps.
The first of these was cooled with ice/salt, whilst the second was cooled
with liquid nitrogen. The system was evacuated and the reaction mixture
gently warmed such that ethyl acetate collected in the second trap, whilst
any triethyl phosphate collected in the first trap. This yielded 0.833g (9.28
80
mmol, 78%) of ethyl [1,2-13C2]-acetate as a colourless liquid. H 1.25 (3H, t,
J=8Hz, CH 3), 2.05 (3H, dd, Jc H =129Hz, JcH=71' 13CH 3), 4.18 (2H, dq,
J=8Hz, 3J=2Hz, OCH2)
b) To 20m1 of freshly distilled anhydrous THF at -78°C under an
atmosphere of dry nitrogen was added 2.208g (13.69mmol) of
hexamethyldisilazide. To this was added 5.29ml of butyl lithium as a 1.6M
solution (13.23mmol) in hexanes. After 30 minutes ethyl [1,2-13C21-acetate
(0.821g. 9.l2mmol) was added dropwise as a solution in THF. After a
further half hour ethyl chioroformate (1.425g, 13.l3mmol) was added in
THF. The mixture was left for 2.5 hours prior to addition of 6M HCL,
water. The layers were separated and the aqueous layer extracted with
ether (2 x 20m1)). The combined organics were dried over anhydrous
magnesium sulphate, filtered and concentrated in vacua to yield an
orange residue. This was purified by bulb to bulb distillation (66°C,
6mrnflg) to yield (1.043g. 6.29mmol, 69%) of diethyl [1,2-13C21-malonate
(' max ( th film) 3001, 1733 cm1; 6H 1.25 (6H, t, J=6Hz, CH 3), 3.35 (2H, dd,
1Jc = 130Hz, 2Jz6.7Hz, 13CH2), 4.18 (4H, m, CH)
c) To the diethyl [1,2-13C2]-malonate (73) (0.983g, 5.94mmol) was added
5.9n-tl of 2.07M NaOH solution. The mixture was stirred overnight. The
water was removed in vacua prior to freeze drying. This gave 0.889g
(5.93mmol, 100%) of disodium [1,2- 13C 21-malonate as a white solid.
nax (110 1560, 1450, 1410cm; H (2H 20) 3.1 (2H, dd, 1JcH=l3OHz,
JcW64' 13C1-12).
Synthesis of sodium 3-hydroxypropionate (77)
a) To 2-chioroethanol (0.609g. 7.547mmo1) was added potassium
cyanide (1g. 14.93 mmol) in 8ml of water. The mixture was heated at 45-
48°C for six hours. After this time the solvent was removed in vacua and
the solid residue extracted with dichioromethane (3 x l5ml). The
combined extracts were dried over anhydrous magnesium sulphate,
filtered and concentrated in vacua to yield 3-hydroxypropionitrile (83)
(0.4632g, 6.48mmol, 86%) as a colourless oil. D3 (thin film) 3367, 2251 cm1;
81
H 2.6 (2H, t, J=5.5Hz, CH 2CN), 3.4 (1H, br s, OH), 3.85 (2F{, t, fr5.5Hz,
CH2OH); 21.3 (CH2), 54.43 (CH2OH), 118.77 ((N).
b) To 3-hydroxypropionitrile (83) (0.4223g. 5.95mmol) was added
3.02m1 of 2.07M NaOH solution (6.25mmol). The mixture was warmed to
75°C and left at this temperature overnight. After cooling the aqueous
mixture was extracted with 10 ml of ethyl acetate. The water was removed
in vacua and the residue freeze-dried to leave sodium 3-hydroxy
propionate (77) (0.673g. 5.97mmol, 100%) as a white solid. umax(nujol) 3623,
3299, 1523, 1461 crn 1; öH(2H20) 2.38 (2H, t, 5.5Hz, CH 2CO2Na), 3.75 (2H, t,
J=5.5FIz, CH2OH); 40.8l (cl-I2), 59.92 (CH2), 180.71 (CO2Na)
Synthesis of sodium [1-13C]-3-hydroxypropionate
a) To 2-chioroethanol (O.401g, 4.97mmol)) was added potassium [ 13C]-
cyanide (0.5g, 7.46 mmol) in 8m1 of water. The mixture was heated at 45-
48°C for six hours. After this time the solvent was removed in vacuo and
the solid residue extracted with dichloromethane (3 x 15m1). The
combined extracts were dried over anhydrous magnesium sulphate,
filtered and concentrated in vacuo to yield [1-13C]-3-hydroxypropionitrile
(83) (0.274g, 3.83mmol, 77%) as a colourless oil. umax(thin film) 3371, 2250
cm1; H 2.6(2H, dt, J=5.5Hz, J6.5Hz, CH213CN), 2.54 (1H, br s, OH), 3.85
(2H, m, CH2OH)
b): To [1- 13C]-3-hydroxypropionitrile (83) (0.267g, 3.76mmol) was added
1.91m1 of 2.07M NaOH solution (3.95mmol). The mixture was warmed to
75°C and left at this temperature overnight. After cooling the aqueous
mixture was extracted with 10 ml of ethyl acetate. The water was removed
in vacua and the residue freeze-dried to leave sodium [1-13C]-3-
hydroxypropionate (0.426g. 3.78mmol, 100%) as a white solid. o(nujol)
3625, 3299, 1525, 1461 cm 1 ; öH(2H20) 2.38 (2H, m, CH213CO2Na), 3.75 (2H, m,
2H, CH2OH); k 180.75.
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Synthesis of sodium [1- 13C, 2-2k12]-3-hvdroxvpropionate (77)
b): To [1- 13C] -3-hydroxypropionitrile (0.261 3g, 3.2Zmmol) was added
2.05ml of 1.68M NaO2H solution (in 2H20) (3.4lmmol). The mixture was
warmed to 75°C and left at this temperature overnight. After cooling the
aqueous mixture was extracted with 10 ml of ethyl acetate. The water was
removed in vacuo and the residue freeze-dried to leave sodium [1- 13C,2 H2]-
3-hydroxypropionate (77) (0.2879g, 3.l84mmol,99%) as a white solid.
O(flUjOl) 3627, 3301, 1525, 1461 cm 1; H(2H0) 3.74 (1H, br s, HOCH2C2H2).
rnthesis of cyanoacetic acid (82)
To bromoacetic acid (78) (19.158g, 137.8mmol) in lOOmi of water at 50°C
was slowly added 7.73g (72.9mmol) of potassium carbonate. The mixture
was cooled to 0°C and 7.149g (14.59mmol) of potassium cyanide was slowly
added as a solution on lOml of water. This was warmed to room
temperature for 30 minutes, to reflux for 5 minutes then cooled to 0°C for
a further 30 minutes. The mixture was the acidified to pH 2.0 and
concentrated in vacuo to leave a white solid. This was taken up in 50m1 of
ethanol, filtered and the filtrate concentrated to leave cyanoacetic acid (82)
as a white solid (9.297g. 109.4mmol, 80%). Umax 2264 cm1; 3H 3.65 (2H, s,
CH2), 6.05 (IH, br s, OH); m/z: 85 (M, 4.8%), 68 (15), 599 (7.3), 44 (100), 41
(75).
Attempted Stephen reduction of cyanoacetic acid (82)
Anhydrous tin (II) chloride (0.7506g, 3.95mmol) was suspended in 5m1
of freshly distilled anhydrous ether under an inert atmosphere.
Anhydrous hydrogen chloride gas was bubbled through this with stirring
until the tin (II) chloride completely disappeared and two layers formed.
Cyanoacetic acid (0.2239g. 2.63mmol) was added and a precipitate
immediately formed. This was isolated by filtration and treated with warm
water. The resultant mixture was extracted with ethyl acetate (3 x lOml).
The combined organics were dried over anhydrous magnesium sulphate,
filtered and concentrated to give a white solid.
The 1 H nmr spectrum of this showed a multitude of resonances, none
of which corresponded to expected product.
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The identical procedure was carried out on ethyl cyanoacetate, and
again the white solid isolated showed no resemblance to expected product
by 1 H nmr spectroscopy.
Synthesis of N-acetylcysteamine (98)
a): To a three necked flask at 0°C containing 17.04g (149.5mmol) of 2-
aminoethanethiol hydrochloride in 125 ml of water was attached 2
dropping funnels an a pH probe. In one funnel was placed iOOml 11.2 M
NaOH, and in the other 42.42 ml of acetic anhydride. The NaOH and acetic
anhydride were added dropwise to the aqueous solution a rate such that a
pH of 8.0 was maintained in the stirred reaction mixture. After addition of
the acetic anhydride was complete the pH of the mixture was adjusted to
7.0 and the mixture left stirring at room temperature for an hour. After
saturation with sodium chloride the aqueous solution was extracted with
dichioromethane (2 x 20m1). The combined organic layers were dried over
anhydrous magnesium sulphate, filtered and concentrated to give N,S-
diacetylcysteamine as a colourless oil (23.90g, 148.4mmol,99%). This
solidified upon refrigeration. 
"max (CHC13) 1655, 1545 cm-i; H 1.99 (3H, s,
CH 3COS), 2.36 (3H, s, CH 3CON), 3.03 (2H, t, J=6.2Hz, CH 2S), 3.41 (2H, dt
J=6.4, 6.1Hz, CH2N), 6.53 (1H, br s, NH); & 22.9 (CH2N), 28.5 (CH2S), 30.5
(CH3COS), 39.2 (CH3CON), 176.7 (CON), 195.8 (COS); m/z 161 (M, 0.9%),
119 (83%), 118 (21.7).
• b) To 2Oml of water was added 0.927g (5.73mmol) of N,S-diacetyl
cysteamine followed by 0.759g (18.9mmol) of sodium hydroxide. The
mixture was stirred at room temperature for 30 minutes prior to
adjustment of the pH to 7.0. Saturation with sodium chloride was
followed by extraction with dichioromethane (5 x 20m1).. The combined
organic layers were dried over anhydrous magnesium sulphate, filtered
and dried to give 0.5734g (4.8lmmol, 84%) of N-acetylcysteamine (98) as
colourless oil. This was used immediately. Umax (thin film) 1641, 1525 cm1;
H 1.42 (IH, t, J=6.5Hz, SH), 2.02 (3H, s, CH3CON), 2.67 (2H, dt, J=8.4, 6.6Hz,
CH2S), 3.42 (2H, dt, J=6.6Hz, J=6.4Hz, CH 2N), 6.33 (1H, br s, NH); ö, 23.0
(CH2N), 24.4 (CH2S), 42.2 (Cl-I.3), 170.5 (CON); m/z 119 (M, 14.3%), 60 (90.4).
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Preparation of 'cell free' extracts
Ps fluorescens was cultured as previously described until production
of pseudomonic acid (44) was shown to have commenced by HPLC.
At this point the cells were centrifuged (10,000g, 4°C, 10 minutes) and
the supernatant removed. The cells were then washed with pH 7.0 buffer
water and re-centrifuged. A further wash was carried out to leave Ca. 2.lg
of cells (wet weight) per 25 ml of secondary medium. These were
resuspended in 20m1 of pH 7.6 buffer. Further work was carried out with
re-suspension in pH 7.2 and 6.9 buffers.
a) sonication
The cell suspension was cooled to 0°C and subjected to intense sound
energy for two minutes (six x twenty second cycles) with stirring to ensure
efficient heat dissipation between each cycle.
b) lysozyme
To the cell suspension was added lysozyme (10mg m1 1) as a solution
in buffer. This was left stirring for two hours before immediate use.
c) EDTA/lysozyme.
Prior to treatment with lysozyme the cells were treated with 30m1 of a
0.2M solution of disodium EDTA in buffer. Treatment with lysozyme then
proceeded as before.
d) French press
The buffered cell suspension was passed through the press at 0°C with
internal pressure of 3500psi.
For membrane free extracts the treated suspension was micro-
centrifuged and the supernatant retained.
The cell free preparations were used immediately except for




Initial reactions were carried out in aqueous buffer at pH 7.6. Monic
acid (84) (as a 10mg mF 1 solution in buffer) and 9-hydroxy nonanoic acid
(45) (as a 20mg mF 1 solution in 1,4-dioxan) were added to the 'cell free
enzyme' such that the total volume was 500.tl, and the concentrations of
the reactants was 5mmol and l5mmol respectively. The procedure was
repeated with the N-acetylcysteamine thioester of monic acid (97) in place
of monic acid (84).
Further reactions were carried out at pH 7.2 and 6.9. The
concentrations of monic acid (84) (or the thioester (97)) and 9-hydroxy
nonanoic acid (45) were also reduced to 2mmol and lOmmol respectively,
with the total volume maintained at 500.il.
Cell free extracts from all lysis experiments were used, in both the
presence and absence of cellular membrane. Reaction times of two, four
and eighteen hours were investigated.
For reactions in 'anhydrous' organic media, the reactant
concentrations were monic acid (84) (or the thioester (97)) at 2mmol and 9-
hydroxynonanoic acid at lOmmol. Pseudomonic acid was used alone at
2mmol concentration. The total volume of solvent was 500p1, and 30mg of
freshly lyopholised cell free extract was added. The solvents investigated
were 1,4-dioxan, tetrahydrofuran and acetonitrile. The addition of 0.1% or
0.5% of water to the system was also studied.
Reaction times of two, four and eighteen hours were investigated.
For each set of reactions, control systems were also set-up containing
the reactants under equivalent concentrations, but with no addition of cell
free extract
HPLC was used to monitor the reactions as previously described. In
order to assay for the production monic acid the solvent system used was
methanol/0.05M ammonium acetate (5:1 at pH 4.5.). Under no conditions
was any variance from control reactions observed.
Study of mutant strains of Ps. fluorescens.
The mutant strains were grown under previously described culture
conditions. Subsequent to centrifugation (10,000g, 4°C, 10 minutes) the
supernatant was assayed by HPLC, with the solvent being methanol/0.05M
ammonium acetate of ratios from 3:2 to 7:1 at p14 4.5. No production of
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pseudomonic acid (44), monic acid (84) nor any other unusual metabolite
was observed.
Synthesis of the N-acetylcysteamine thioester of monic acid (97)
To 30m1 of freshly distilled anhydrous THF under nitrogen was added
0.917g (2.67mmol) of monic acid (84) to give a turbid solution. To this was
added 0.512g (4.3lmmol) of freshly prepared N-acetylcysteamine (98) in
2m1 of THF followed by DCC (0.577g. 2.8Ommol) and DMAP(0.04g,
0.28mmol) in 5ml THF, and the reaction left stirring overnight. The
mixture was filtered, and the filtrate washed with 25m1 of saturated
ammonium chloride, dried over anhydrous magnesium sulphate,
filtered, concentrated and purified by flash column chromatography to
give 0.2127g (0.48mmol, 18%) of the N-acetylcysteamine thioester of monic
acid as a colourless syrup (97). DmaxHC13) 3671, 3156, 1794, 1664, 1617, 1557,
1543, 1518 cm1; H 0.92 (3H, d, J=7.3Hz, CH3), 1.11 (3H, d, J=6.5Hz, CH3), 1.38
(1H, m, CH), 1.69 (2H, m, CH2), 1.98 (3H, s, CH3CON), 2.02 (1H, m, CH), 2.2
(4H, s, CH3, CH), 2.6-2.84 (3H, m, 3 x CH), 3.04 (2H, m, CH2S), 3,41 (2H, m,
CH2N), 3.5-3.96 (8H, m), 6.17 (IH, s, H-2), 6.27 (IH, br s, NH); 8, 12.68 (C-17),
20.27 (C-15), 20.81 (C-14), 23.19 (CH 2N), 28.39 (CH2S), 31.57 (C-9), 39.68 and
39.89 (C-8, COCH 3), 42.74 (C-12, 4), 55.54 (C-b), 61.27 (C-il), 65.35 (C-16),
68.75 (C-6), 70.33 (C-7), 71.35 (C-13), 74.78 (C-5), 124.11 (C-2), 155.51 (C-3),
170.72 (CON), 189.42 (COS); m/z 327 (M-118, 1.6%), 227 (14.9), 196 (12.3), 179
(6), 199 (12.8), 111 (40), 96 (24), 60 (82.3), 43 (97.6), 30 (100)
Synthesis of 7-(1'-ethoxy)ethoxyheptanal (110)
a) To 0.572g (3.l6mmol) of 6-bromoheptan-1-ol (112) was added 0.2501g
(3.79mmol) of potassium cyanide in lOmi of water. This was heated to
reflux for 3.5 hours. After cooling the mixture was extracted with
dichioromethane and the combined organic layers were dried over
anhydrous magnesium sulphate, filtered and concentrated to give 7-
hydroxyheptanitrile (111) as a colourless oil (0.3259g, 2.57mmol, 82%). Umax
(thin film) 3486, 2245 cm 1 ; 1.3-1.75 (8H, m ,4 x CH2) 2.38 (2H, t, J6.7 Hz,
CH2CN), 3.61 (2H, t, J=6.7Hz, CH2OH)
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b) 7-Hydroxyheptanitrile (111) (0.3259g, 2.457mmo1) was dissolved in
1 Omi of ethoxyethene. To this was added 1 drop of trifluoroacetic acid the
mixture left to stir overnight. The volatiles were removed in vacuo to
yield 0.5117g (2.57mmol, 100%) of 7-(1'-ethoxy)ethoxyheptanitrile as a pale
straw oil. H 1.18 (3H, t, J=6.9Hz, CH3CH2O), 1.24 (3H, d, J=6.8 Hz, CH3CH),
1.27-1.78 (1OH, m), 2.37 (2H, t, 1=6.8Hz, CH2CN), 3.4-3.7 (4H, m, CH2O and
CH2OH), 4.65 (IH, m, OCH(CH3)O)
c) To 0.329g (1.66mmol) of 7-(1'-ethoxy)ethoxyheptanitrile in 5m1 of
anhydrous toluene at room temperature under an inert atmosphere was
added dropwise 1.lOml of a 1.5M solution of DIBAL in toluene
(1.66mmol). The mixture was left stirring overnight, to this was added
lOmi of a 1:1 mixture of methanol/5M HC1 . The layers were separated and
the aqueous portion extracted with ethyl acetate (3 x lOml). The combined
organic layers were dried over anhydrous magnesium sulphate, filtered
and concentrated to leave 7-(1'-ethoxy)ethoxyheptanal (110) as a straw
coloured oil. D (thin film) 1719 cm1; H 1.15 (3H, t, J=6.8Hz, CH3CH2O),
1.3-1.8 (13H, m) 2.44 (2H, t, J= 6.6Hz, CH 2CHO), 3.3-3.7 (4H, m, CH 2O and
CH2OH), 4.67 (IH, q, J= 6.3 Hz, OCH(CH3)O) 9.77 (1H, s, CHO)
Synthesis of the N-acetylcys teamine thioester of triphenylphosphorane
acetate (107)
a) To 2.967g (21.36mmol) of bromoacetic acid (78) in lOmi of
dichioromethane under a nitrogen atmosphere at 0°C was added 3.305g of
freshly prepared N-acetylcysteamine (98) (27.7mmol) in 5m1 of dichioro
methane. To this mixture was added 4.823g (22.4 mmol) of DCC and 0.261g
(2.l36mmol) of DMAP in lOml of dichioromethane. The system was left to
warm to room temperature overnight. The resultant mixture was filtered
and the filtrate washed with saturated ammonium chloride solution,
dried over anhydrous magnesium sulphate, filtered, concentrated in
vacuo and purified by flash column chromatography
(acetone/dichioromethane 2:3) to yield the N-acetylcysteamine thioester of
broxnoacetate (108) as white solid (3.832g. 15.97mmol, 75%). Mpt 98-99.5°C;
J a (1j01) 3306, 1732, 1642, 1548 '' H 1,98 (3H, S, CH3CON), 3.17 (2H, t,
fr6.2Hz, CH2S), 3.49 (2H, m, CH 2N), 4.04 (2H, s, BrCH 2CO), 6.02 (1H, br s,
NH); 23.12 (CH2N), 29.66 (CH2S), 33.28 (CH2Br), 3900 (CH), 170.43 (CON),
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193.01 (COS); m/z (241 M+1, 0.5%), 239 (M-1, 0.4) 160 (8.5), 118 (70.2) 60
(35), 43 (62), 30 (100)
b) The N-acetylcysteamine thioester of bromoacetate (108) (3.82g.
15.97mmol) was suspended in 50m1 of toluene to which was added 4.171g
(15.97mmol) of triphenyl phosphine. This was left for 48 hours with
occasional shaking. The mixture was filtered and the pale peach residue
was dried in vacuo over phosphorus pentaoxide to leave 5.692g
(11.34mmol, 71%) of the N-acetylcysteamine thioester of (triphenyl
phosphonium acetate)] bromide (109). H 2.0 (3H, s, CH3CO), 3.05 (2H, m,
CH 2S), 3.42 (2H, m, CH 2N), 5.8 (2H, d, J=l7Hz, CH 2P), 7.6-7.9 (15H, m, 3x
phenyl), 8.45 (1H, br s, NH);' m/z: (M absent), 278 (12.9), 276 (27.6), 119
(15.8), 72 (13.2), 60 (89.1), 43 (63.8), 30 (100)
c) The N-acetylcysteamine thioester of (triphenyiphosphonium
acetate)] bromide (109) (5.692g, 11.34mmol) was dissolved in water (5Oml)
and titrated against 0.16M NaOH with phenolphthalein indicator. The
resultant mixture was extracted with dichioromethane (5 x 50m1) and the
combined organic layers were dried over anhydrous magnesium sulphate,
filtered, concentrated in vacuo and purified by flash column
chromatography (acetone/dichioromethane, 2:3) to yield the N -
acetylcysteamine thioester of triphenyiphosporane acetate (107) as a
colourless oil (4.535g, 10.77mmol, 95%). Umax(CHC13) 3285, 1732, 1635, 1584,
1551 cm1; H 1.69 (3H, s, CH3CON), 2.99 (2H, m, CH2S), 3.38 (21-1, m, CH2N),
3.83 (IH, br s, CHP), 7.4-7.75 (15H, m, 3 x phenyl); 23.17 (CH 2N), 27.56
(CH2S), 42.98 (CH3), 48.95 (d, J=109.4Hz, HCP), 125.51, 126.85, 129.06,
129.26, 132.26, 132.68, 133.01, 133.14 (all aromatic C), 170.56 (CON), 181.76
(COS); m/z 303 (M-118, 1.3%), 119 (19.5), 118 (13.0), 77 (16.7), 72 (18.0), 60
(79.5), 43 (75.1), 30 (100).
Incorporation studies
a) Sodium [2-13C]-propionate
Primary and secondary media were inoculated as previously described.
A lOmi solution (H20) containing sodium [2-13C]-ropionate (250mg) was
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prepared. 5m1 of this was added to the secondary medium (0.5m1 per flask)
seventeen hours after inoculation. This was repeated after a further three
hours. The cells were harvested as usual, and 11mg of methyl
pseudomonate (58) were isolated. The 1 H nmr spectrum was identical to
that of authentic material.
b) [1-14C]-9-Hydroxynonanoic acid (45)
Primary and secondary media were inoculated as previously described.
A lOmi solution (H20) containing [1- 14C1-9-hydroxynonanoic acid (45)
(250mg, 10.41p.Ci) was prepared. 5m1 of this was added to the secondary
medium (0.5m1 per flask) seventeen hours after inoculation. This was
repeated after a further three hours. The cells were harvested as usual, and
34mg of methyl pseudomonate were isolated, with an activity of 0.82j.tCi.
The 1 H nmr spectrum was identical to that of authentic material.
Hydolysis of this as previously described gave methyl monate (87) and
methyl 9-hydroxynonanoate (88), both of which contained significant
amounts of activity.
c) [1 -13C] -9-Hydroxynonanoic acid (45)
Primary and secondary media were inoculated as previously described.
A lOmi solution (H20) containing [1- 13C]-9-hydroxynonanoic acid (45)
(250mg) was prepared. 5m1 of this was added to the secondary medium
(0.5m1 per flask) seventeen hours after inoculation. This was repeated after
a fUrther three hours. The cells were harvested as usual, and 21mg of
methyl pseudomonate were isolated. The 1H nmr spectrum was identical
to that of authentic material.
d) Tetradecyithiopropionic acid (89)
Primary and secondary media were inoculated as previously described.
A 5ml solution (DMSO) containing tetradecyithiopropionic acid (89)
(30mg) was prepared. 2.5m1 of this was added to the secondary medium
(0.25ml per flask) seventeen hours after inoculation. This was repeated
after a further three hours. The cells were harvested as usual, and 21mg of
methyl pseudomonate were isolated. The 1 H and 13C nmr spectra were
identical to that of authentic material. 	 -
90
e) [1-13C]-9-Hydroxynonanoic acid (45) plus tetradecyithiopropionic acid
(89)
Primary and secondary media were inoculated as previously described.
A lOmi solution (DMSO) containing [1-13C]-9-hydroxynonanoic acid (45)
(250mg) and tetradecyithiopropionic acid (89) (30mg) was prepared. 5ml of
this was added to the secondary medium (0.5ml per flask) seventeen hours
after inoculation. This was repeated after a further three hours. The cells
were harvested as usual, and 15mg of methyl pseudomonate were
isolated. The 1 H nmr spectrum was identical to that of authentic material.
f) Disodium [2,3-13C2]-malonate (73)
Primary and secondary media were inoculated as previously described.
A lOml solution (H20) containing disodium [2,3- 13C 2]-malonate (73)
(250mg) was prepared. 5m1 of this was added to the secondary medium
(0.5m1 per flask) seventeen hours after inoculation. This was repeated after
a further three hours. The cells were harvested as usual, and 10mg of
methyl pseudomonate were isolated. The 1 H nmr spectrum was identical
to that of authentic material.
g) Sodium [1-13C]-3-hydroxypropionate (77)
Primary and secondary media were inoculated as previously described.
A lOml solution (H20) containing sodium [1- 13C]-3-hydroxypropionate (77)
(250mg) was prepared. 5m1 of this was added to the secondary medium
(0.5m1 per flask) seventeen hours after inoculation. This was repeated after
a further three hours. The cells were harvested as usual, and 29mg of
methyl pseudomonate were isolated. The 1 H nmr spectrum was identical
to that of authentic material.
In a repeat experiment, 17mg of methyl pseusomonate were isolated.
The 1H and 3C nmr spectra were identical to that of an authenic sample
h) Sodium [1 - 13C, 2-2H2] -3-hydroxypropionate (77)
Primary and secondary media were inoculated as previously described.
A lOml solution (H2 0) containing sodium [1- 13 C, 2-2 H 2 ]-3-
hydroxypropionate (77) (250mg was prepared. 5mlof this was added to the
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secondary medium (0.5m1 per flask) seventeen hours after inoculation.
This was repeated after a further three hours. The cells were harvested as
usual, and 13mg of methyl pseudomonate were isolated. The 1H and 13C
nmr spectra were identical to that of an authenic sample.
In a repeat experiment, 18mg of methyl pseudomonate were
isolated.The 1 H and 13C nmr spectra were identical to that of an authenic
sample.
i) Ancymidol (99)
Primary and secondary media were inoculated as usual with Ps.
flu orescens PF3/N/2. To one of four flasks of secondary medium was
added either 5, 10, 20 or 40mg of ancymidol (99) seventeen hours after
inoculation. As a control, a fifth flask was inoculated, but no ancymidol
(99) was added. After a further thirty-one hours the media were
centrifuged (10,000g. 4°C, 10 minutes) and the supernatant assayed by HPLC
under previously described conditions. No significant variation in titre
was observed in any of the flasks with repect to the control.
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3.1: POLYKETIDE CHAIN ELONGATION N PSEIJDOMONIC ACID
BiOSYNTHESIS
3.1.1: Introduction
Early work on the biogenetic origins of pseudomonic acid (44)
indicated that the monic acid (84) moiety was polyketide in origin. 1 Methyl
branching was shown to be the result of methylation by S-adenosyl
methionine (59) for carbons 16 and 17. Carbon 15, however, was found to
result from the terminal carbon of a cleaved acetate unit.
The first part of this chapter will discuss the polyketide biosynthetic
pathway postulated to lead to pseudomonic acid (44). Consideration of the
processes leading to the methylations is given in later sections.
3.1.2: The classical polvketide hypothesis
The idea that many aromatic natural products were biosynthesised
from the sequential condensation of acetate and malonate prior to chain
modification operations was introduced in the first chapter. Further work
in this field showed that structural variation could be introduced by the
use of alternative chain starting or extending units. 2 In particular, variants
of the starting unit were more prevalent. For example, cinnamic acid (112)









Scheme 3.1.1: Cinnamic acid (112) as a starter in polyketide biosynthesis
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As information accumulated it was realised that the biosynthesis of
many non-aromatic natural products could also be accounted for by a
polyketide pathway. Many metabolites containing 1,3 oxidation patterns
were known, although the actual oxidation levels varied. Despite the
species restricted distribution of such metabolites, a common biogenetic
















The macrolide lactones, eg erythromycin B (90) and methymycin (115),
were shown to be the result of the sequential condensation of
methylmalonate (derived from the a-carboxylation of propionate) onto
simple propionate or butanoate starting units,4
 as shown in scheme 4.1.2.
CO2





Scheme 3.1.2: Propionate as a starter and chain extender
unit (as methylmalonyl CoA)
The use of these precursors introduced concomitant branching off the
growing chain, thus eliminating any requirement for S-adenosyl
methionine (59). An exception to this general rule is exhibited by
aplasmomycin (116). This unusual boron containing macrolide produced
by Streptomyces griseus was shown to be the result of sequential malonate
condensations onto a glycerol derived C 3 starter,5 scheme 3.1.3.
Unusual starting units were also discovered in non-macrolide
polyketide derived metabolites. Coronatine (117), from Pseudomonas
syring pv. atropurpur and Pseudomonas syring pv glycin, was
99
shown to be derived from the condensation of five malonate units onto a
pyruvate starter,6 scheme 3.1.4.
OH OH
yCO2H
Scheme 3.1.3: the biosynthesis
of alpasmomycin (116;
(116)
The classical ideas of polyketide aromatic biosynthesis seemed to apply
to more complex metabolites. Experimental evidence began to emerge in
the 1980's, however, that suggested the basic premise may be incorrect,





Scheme 3.1.4: The biosynthesis of coronatine (117)
3.1.3: Processive polyketide biosynthesis
Rifamycin S (118) is a natural product produced by the organism
Norcardia mediterranei. 7 Studies upon mutant strains of N. mediterranei,
led to the isolation of metabolites that resembled part of the rifamycin
structure. 8 The major isolate of these was shown to be 2,6-dimethyl-3,5,7-
trihydroxy-7-(3'-amino-5'-hydroxyphenyl)-hepta-2,4-dienoic acid (119). As
a result, it was deduced that these metabolites were biosynthetic precursors
to rifamycin (118), scheme 3.1.5, and were the fi.rst compounds related to










Scheme 3.1.5: A precusor to rifamycin (118) isolated from mutant
strains of Norcardia med iterra nei.
The polyether antibiotics, 9 for example monensin (120) and lysocellin
(121), are a large class of natural products known to be of polyketide
origin. 10
 In 1985 Cane, Westley and Celmer postulated a unified stereo
chemical and biogenetic model for this metabolic family, 11 following on
from the unified stereochemical theory for the macrolide lactones
formulated by Celmer in 1965.12 Structural considerations of the polyether
antibiotics, and in particular the basic biogenetic origins of these natural
products, led to the deduction that two basic families existed:
a) Those derived from initial acetate, propionate, propionate, acetate
(APPA) condensation reactions, postulated to arise via a triepoxide
precursor, eg monensin (120), scheme 3.1.6.
(120)
Scheme 3.1.6: Monensin (120) biosynthesis from a triepoxide
initiated via an APPA condensation sequence.
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b) Those derived from intial propionate (or butanoate), acetate,
propionate (or butanoate), acetate (PAPA) condensation reactions,




Scheme 3.1.7: Lysocellin (121) biosynthesis from a diepoxide
initiated by a PAPA condensation sequence.
Further structural considerations of the macrolides and the polyether
antibiotics, in particular the putative precursors to both, have shown a
great deal of stereochemical homology between these two classes of
metabolite. This has led to the suggestion that such natural products have
a common evolutionary ancestor. Structural variation is postulated to
have arisen as a result of specific environmental pressures upon the
producing organisms.13
The epoxy precursors were the initial result of modifications after the
polyketide chain elongation operations. The classical polyketide
hypothesis for such epoxy precursors involves the formation of a poly-3-
keto chain of the required length, followed by reductive modifications
leading to the relevant intermediate. However, it was plausible that
modifications could also occur contemporaneously with chain extension.
In effect, such a processive pathway is directly analagous to fatty acid
biosynthesis but with the proviso that stereochemical variation is possible,



















Scheme 3.1.8: Alternative polyketide biosynthetic hypotheses.
These new ideas were first postulated by Hutchinson for the study of
the biogenetic origin of the macrolide tylactone (122).14 Scheme 3.1.9.
shows the alternative biosynthetic pathways to this metabolite. Path (a) is
that which would result were a processive mechanism in operation
whereas path (b) is that predicted by classical polyketide ideas.
Discrimination between the two pathways was reasoned to be
experimentally possible via the specific incorporation of proposed
intermediates along either pathway.
To this end the adminstration of [6- 3CJ-(2R, 3R)-2-methyl-3-hydroxy
pentanoate (123) to cultures of Streptomyces fradi was investigated.14
Initial studies utilising the free acid or the sodium salt of this moiety led to
the random incorporation of label, consistent with the operation of
catabolic processes. The use of N-acetylcysteamine thioesters for the in
vitro study of fatty acid biosynthesis was discussed in chapter one, and it
was postulated that the use of such compounds would promote the in
vivo study of polyketide biosynthesis. Thus the N-acetylcysteamine
thioester (123) was administered to cultures and the isolated tylactone (122)
analysed by 13C nmr spectroscopy. This showed the specific incorporation
of label into C-18, as predicted by the processive hypothesis, although
concomitant catabolism had also taken place. Further evidence for this
pathway operating in the biosynthesis of tylactone (122) was gained from
the intact incorporation of [9-13C]-(2E, 4R, 5R)-2,4-dimethyl-5-hydroxyhept-
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Investigations by Cane into the biosynthesis of erythromycin B (90)
produced analagous results, thus presenting further evidence for the
processive hypothesis. It was shown that [2,3- 13C2]-(3S, 2R)-2-methyl-3-
hydroxpentanaote (125) was incorporated intact into isolated erythromycin
B (90) after adminstration to cultures of Streptomyces erythreus, 15 scheme
3.1.11. The use of the doubly labelled compound meant that intact
incorporation was demonstrated by the presence of 13C- 13C couplings in the
nmr spectrum. Had catabolism taken place, such couplings would not
have been observed.
Scheme 3.1.11: Incorporation of a chain elongation intermediate
into erythromycin B (90)
Evidence regarding the processive hypothesis of polyketide
metabolism was further produced by the incorporation of putative
triketide precursors into nonactin (126)16 and nargenicin (127).
(127)
However, the use of the N-acetylcysteamine thioester of [2,3-13C2]-(3S)-
3-hydroxybutanoate (128) to investigate the biogenesis of
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dehydrocurvularin (129) (a metabolite from the fungus Alternaria
cinerari) led to complete catabolism upon administration. 18This seemed
initially anomalous with respect to the other reports, but further work
involving the use of U.V. mutants unable to utilise fatty acids as a food
source, the use of pent-4-ynoic acid (130) as a n-oxidation inhibitor and a
high glucose replacement medium finally led to intact incorporation of
(128) into dehydrocurvularin (129).18 Under such conditions the intact
incorporation of racemic [1,2-' 3C21-(2E)-7-hydroxyoct-2-enoate (131) was also
observed, albeit with concomitant catabolism, 18 scheme 3.1.12. This was the














Scheme 3.1.12: Incorporation of chain elongation intermediates
into dehydrocurvularin (129),
The competition between catabolism and metabolism of administered
compounds has already been described for the case of 9-hydroxyrionanoic
acid (45) in chapter two of this work. Other reports have similarly been
made with respect to studies into the biosynthesis of monensin (120)19 and
monocerin (132).20
Further work on the biogenesis of dehydrocurvularin (129)
demonstrated that a variety of 3-oxidation inhibitors promoted the
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increased incorporation of the N-acetylcysteamine thioester of [2,3-13C2]-(2E,
7S)-7-hydroxyoct-2-enoate (131) into the metabolite.21 Amongst the most
efficient were hypoglycin (133), ethyl-3-hydroxypent-4-ynoate (134) and











3.1.4: Stereochemistry of polyketide biosynthesis.
That variations in the stereochemical course of polyketide biogenetic
processes between species are allowed can be inferred from the range of
metabolites produced by this pathway.
Early studies on the stereochemistry of polyketide biosynthetic
processes involved feeding mono- and tri-deuterated acetates to cultures
of Pen icillium patulum, a producer of 6-methylsalicylic acid (40). It was
found that the relative retention of labels at both C-3 and C-5 was the same
in either case (scheme 3.1.13), thus indicating that the abstraction of
hydrogen at these positions proceeded with no primary kinetic isotope
effect. It was deduced, therefore, that the aromatisation step was under
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Scheme 3.1.13: Incorporation of deuterated acetates
into 6-methylsalicylic aid
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Further investigations on the stereochemical pathway to 6-
methylsalicylic acid (40) were possible using purified polyketide synthases
from Pen icilliurn species. The incubation of chiral malonic acids with
this, in the presence of acetyl CoA (9) and succinyl CoA transferase (to
catalyse the formation of malonyl CoA), was reported by Jordan. 24 The
comparison of the experimentally derived mass spectrum of the isolated 6-
methylsalicylic acid was compared to those predicted statistically. This
showed C-3 and C-5 of 6-methylsalicylic acid (40) were derived from




















Scheme 3.1.14: Stereochemical pathway to 6-methylsalicylic acid (40)
Experimental determination of the origin of C-3 (and thus by
implication C-5) was made by the substitution of acetoacetyl CoA (27) for
acetyl CoA (9) as the starter unit, as under such conditions only C-3 would
be labelled. Mass spectral analysis showed that C-3 of the isolated
metabolite originated from Hre of malonate, and therefore C-5 was from
H. A stereochemical pathway to 6-methylsalicylic acid (40) was postulated,
as shown in scheme 3.1.14.
Experimental evidence regarding the control of stereochemistry in the
chain elongation process was achieved by Vederas et al, by comparative
studies of polyketide and fatty acid processes in the species Alt ernia
cinerari,25Penicillirn turba turn25 and Cladosopriurn cladosporioides. 26 In
particular the enoyl reductase step in both pathways was investigated.
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Scheme 3.1.15: Incorporation of deuterium from labelled acetate into
the pro-R positions during fatty acid biosynthesis
In all three species it was found that after adminstration of [2-13C,2H3]
acetate the deuterium label occupied the pro-R positions along the carbon
chain of oleic acid (136),26 scheme 3.1.15.
Similar experiments were carried out on the polyketides isolated from
these fungii. Both C-7 of dehydrocurvularin (129, from A. cinerari) and
C-8 of A26771B (137, from P. turba turn) were shown to have deuterium in
the pro-S position. 25
 For cladosporin (138, from C. cladosporioides), the
deuterium was found to occupy the pro-S position at C-Il, but the pro-R













Scheme 3.1.16 : Differential incorporation of deuterium
in the course of polyketide biosynthesis.
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These studies demonstrated not only the variation of the
stereochemical course of polyketide metabolism between species, but that
within one species fatty acid and polyketide biosynthetic modes may
follow different stereochemical pathways. It was also demonstrated that
the polyketide pathway towards one metabolite within a species exhibited
varying stereochemical operations.
3.1.5: The enzymology and genetics of polyketide biosynthesis.
There is growing evidence that the polyketide and fatty acid
biosynthetic pathways are, at least partially, controlled by the acyl carrier
proteins (ACP). 27 The three-dimensional structure of an Escherischia coli
AC? has been elucidated by nmr methods, 28 and has been shown to
include a hydrophobic cleft suggested to be a possible site for the binding of
acyl chains. A heat stable factor known to be a pre-requisite for the
biosynthesis of fatty acids in Saccharopolyspora erythrea has been isolated
and shown to be a discrete AC?.29 This suggests that the FAS of S. erythrea
is a dissociable complex, similar to that of E. coli.
By analogy to fatty acid biosynthesis, the enzymes that catalyse
polyketide biosynthetic processes are termed polyketide synthases (PKS).
To date only two have been isolated, namely 6-methylsalicylic acid (40)
synthase from Pen icillium species and orsellinic acid (38) synthase from









Studies on the genetics underlying the polyketide biosynthetic process
leading to actinorhodin (139), produced by Streptomyces coelicolor,
indicated the presence of discrete genes coding for the different
biosynthetic operations. This implies that individual non-covalently
linked enzymes catalyse the biosynthesis of this metabolite.31
The study of the genetics of S. erythrea, the erythromycin B (90)
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enzymatic processes involved.32 From this work it is clear that the
biosynthesis of erythromycin B (90) is an elaborately controlled process
]OH 0	 CO2H 2
(139)
Study of the DNA around the resistance gene led to the ultimate
discovery of three PKS genes, each of which code for large multi-
functional proteins capable of carrying out two chain extension cycles.
Scheme 3.1.17: The extension of the polyketide chain in erythromycin
biosynthesis, from the expression of three genes, and
the enzymes which carry out these processes.
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The implication from these studies is that for each individual step on
the biosynthetic pathway to erythromycin B (80) there exists an individual
catalytic domain. These domains appear to be linked into six groups, and
further grouped into 'cassettes' that lead to the production of 6-
deoxyerythronolide B (91) as the first 'enzyme free' intermediate, as
shown in scheme 3.1.17.
Thus there appears to be 2 classes of polyketide synthase enzyme:
a)Type I polyketide synthases exist as single multifunctional proteins
eg 6-methylsalicylic acid (40) synthase,
b)Type II: polyketide synthases consist of a series of individual
enzymes eg actinorhodin (139) synthase
The 'cassette compilation' of discrete enzymes, as in the case for
erythromycin, appears to bye intermediate between these two.
3.1.6: Application of the processive hypothesis to monic acid (84)
Using this hypothesis a step-wise biosynthetic pathway can be
postulated for the biosynthesis of monic acid (84) as shown in scheme
3.1.18. The initial acetate/malonate condensation produces enzyme bound
acetoacetate (140), which undergoes cc-methylation and then reduction of
the 13-keto function to give a (2S, 3S)-3-hydroxy-2-methylbutanoyl enzyme
bound moiety (141). A further condensation of malonate onto this causes
chain extension to an enzyme bound hexanoyl moiety. n-reduction and
subsequent dehydration leads to the (2E, 4S, 5S)-5-hydroxy-4-methylhex-2-
enoate enzyme bound intermediate (142). Further chain extension via
malonate condensation reactions and appropriate reductive modifications
between each condensation step ultimately leads to the putative
heptaketide precursor (143) to monic acid (84)
In order to determine the validity of this scheme, the first three
intermediates on the pathway, acetoacetate (140), (2S, 3S)-3-hydroxy-2-
methylbutanaoate (141) and (2E, 4S, 5S)-5-hydroxy-4-methylhex-2-enoate
(142) were chosen for incorportion studies.
For this to be possible efficient syntheses of isotopically labelled forms







The choice of position of label was important, to ensure experiments could















Scheme 3.1.18: Processive biosynthesis of monic acid (84)
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3.1.7: Synthesis of the N-acetylcysteamine thioester of acetoacetate (144
It was decided that double isotopic labelling of this moiety would
produce the desired experimental sensitivity. As was discussed in the case
for the N-acetylcysteamine thioester of 9-hydroxynonanoic acid (106),
labelling of a bond equivalent to that formed by an acetate/malonate
condensation process leads to the highest sensitivity. This meant that the
required target molecule was the N-acetylcysteamine thioester of [2,3- 13C2]-
acetoacetate (144).
o 0
)% 1 _JL. S_..%%)L1(
• =13C (144)
Introduction of labels was possible by the use of ethyl [2- 13C1-acetate and
[1-13C]-acetyl chloride, as shown in scheme 3.1.19, to produce ethyl [2,3- 13C2]-
acetoacetate (145) in 71% yield. This left conversion of the ethyl ester into









Scheme 3.1.19: Synthesis of ethyl [2,3-13C21-acetoacetate (145).
Previous work by Martin had led to the development of the synthesis
outlined in scheme 3.1.20. This involved initial protection of the ketone
function as its ethylene ketal derivative (146) prior to saponification to the
sodium salt (147). Activation of the carbonyl group via mixed anhydride
(148) formation preceeded introduction of the N-acetylcysteamine (98)
entity. Deprotection led to the final product (144).
This scheme was reinvestigated. It was found that under the described
conditions (2 equivalents ethyl chioroformate, catalytic triethylamine) the
formation of the mixed anhydride (148) gave erratic yields. Replacement of
triethylamine by DMAP led to reliable yields of 61%. Although the
introduction of N-acetylcysteamine (98) by way of the mixed anhydride
(148) proceeded well in high yield (80%), the deprotection reaction
involved the use of catalytic PTSA, and the thioester function was























Scheme 3.1.20: Martin's synthesis of the N-acetylcysteamine
thioester of acetoacetate (142)
Overall, although this scheme led to production of the required
product it is rather lengthy for such an intrinsically simple conversion,
and led to a high waste of material. This is an important factor when
expensive labels are to be used. It was therefore decided to investigate
alternative strategies.
For the study of monensin (120) biosynthesis Cane and Block
synthesised the N-acetylcysteamine thioester of 2-methylacetoacetate (149)
from the di-lithium enolate of N-acetyl-S-propylcysteamine (150) and
acetyl chloride, scheme 3.1.21. Although the recovery of product was low










Scheme 3.1.21: The Cane synthesis of N-acetylcysteamine thioesters.
It was hoped that by use of the di-lithium enolate of N,S-
diacetylcysteamine (151), the N-acetylcysteamine thioester of acetoacetate
(144) could be synthesised in a similar fashion. However, neither the use
of LDA nor LHMDS for generation of the dienolate led to formation of the
required compound, with the N,S-diacetylcysteamine (151) being returned.
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(151)	 0
The synthesis of the ethyl thioester of 4-bromoacetoacetate (152) from
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Scheme 3.1.22: Ley's synthesis of ethyl thioesters.
It was reasoned that the use of acetyl chloride to form the acetyl
Meldrum's acid derivative (154), followed by reaction with N-acetyl
cysteamine (98) would lead to formation of the desired product (144).36
Being as Meidrum's acid (153) is itself made from malonate,37 the use of [2-
13C] malonate and [1-13C1-acetyl chloride would lead to introduction of the
required labels, scheme 3.1.23.
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Scheme 3.1.23: Proposed synthesis of the N-acetylcysteamine thioester
of acetoacetate (144) from Meldrum's acid (153)
However, although the required acyl Meidrum's acid derivative (154)
was easily synthesised the reaction with N-acetylcysteamine (98) led only
to return of the reactants, even with the use of five equivalents of thiol in
refluxing chloroform. Since thiols are 'soft' nucleophiles and the
carboxylates of the Meidrum's acid is a 'hard' nucleophilic site, the use of a
'hard' sulphur was investigated, the thallium(I) thiolate of N-





It is worth noting that since the investigation of this scheme was
completed a report of the synthesis of the N-acetylcysteamine thioester of
acetoacetate (144) by way of Meidrum's acid (153) has been made.39
However no experimental details or yields were supplied.
At this point it was decided that re-investigation of the conversion of
the ethyl ester (145) to the N-acetylcysteamine thioester (144) might be
beneficial. A number of methods exist in the literature for the conversion
of acids to thiols. 4° However this would require the use of a 3-ketoacid for
the formation of the N-acetylcysteamine thioester of acetoacetate (144),
entities which are known to be labile owing to facile de-carboxylation with
the ketone acting as an electron sink,41 scheme 3.1.24. Only two syntheses
of acetoacetic acid (156) could be found in the literature. One of these was
of a concentrated ethereal solution, 42 whilst the other was of a crystalline





Scheme 3.1.24: The decarboxylation of -keto acids
It was found that the careful hydrolysis of distilled ethyl acetoacetate
(145) using sodium hydroxide at 5°C followed by slow acidification at 0°C
and multiple extractions with cold ethyl acetate produced acetoacetic acid
(156) in 93% yield. At room temperature this was a colourless liquid that
soon decomposed. However upon placement in a freezer the acid
solidified and was stable long periods. H nmr spectral analysis of this
revealed it to be 85-95% pure with the enol tautomer accounting for ca
15% of this.
Initial investigations into the direct conversion of this acid (156) into
the N-acetylcysteamine thioester of acetoacetate (144) were made by the use
of the phenyl dichiorophosphate (157) method. 44 In conjunction with
pyridine, this leads to the in situ activation of the acid function via
phosphoanhydride formation such that attack ty the thiol is enhanced,
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scheme 3.1.25. However under the conditions described the desired
product was not formed. Reduction of the reaction temperature to -50°C,
with overnight warming to room temperature, led to no product
formation.
0	 0
II	 pY	 0	 0	 R'SH	 0R AOH + PhO'	 R"*./4'Q	 R SROPh(157)
Scheme 3.1.25: Course of the thioesteriuication of acids mediated
by phenyl dichlorophosphate (157)
The synthesis of thioesters for the study of aspyrone (158) and
nonactin (127) biosynthesis was achieved by the use of DCC coupling
reactions. This reagent is often used for the synthesis of both oxy- and
thioesters in conjunction with DMAP as a catalyst. 46 '47 The postulated
mechanism for this reaction 47'48
 is shown in scheme 3.1.26.
(158)
The use of this method to synthesise the N-acetylcysteamine thioester
of acetoacetate (144) was found to be unproductive. Replacement of DMAP
with pyridine,49 however, and the use of a -25°C starting temperature gave
the required product in 71% yield.
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Scheme 3.1.26: Course of DCC/DMAP medrated esterifications
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The complete synthesis of the N-acetylcysteamine thioester (144) is
displayed in scheme 3.1.27, and the 1H nmr spectra of the labelled and
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Scheme 3.1.27: Synthesis of N-acetylcysteamine
thioester of acetoacetate (144)
It was found that purification of the N-acetylcysteamine thioester of
acetoacetate (144) on silica led to substantial hydrolysis of the thioester
bond. This was reduced by pre-treating the silica with tri-ethylamine, and
the use of preparative TLC as opposed to flash column chromatography
also reduced the problem.
31.8: Synthesis of the N-acetylcysteamine thioester of (2S,3S)-3-
hydroxy-2-methylbutanoate (i59)
The branching methyl group of (159) is postulated to correspond to C-
17 of monic acid (84) by the processive hypothesis (scheme 3.1.18). This
carbon is known to be derived but from methionine. Therefore should
any isotopically labelled compound undergo n-oxidation after
administration to Pseudomonas fluorescens, the label would not be
expected to appear at C-17 of the isolated metabolite as such processes lead
only to acetate production. Hence if label is introduced into the branching
group of (2S, 3S)-3-hydroxy-2-methylbutanoate (159), detection of any label
at C-17 would imply intact incorporation of this compound into the
metabolite. By this reasoning the desired target molecule therefore became
the N-acetylcysteamine thioester of [5-2H3]-(2S, 3S)-3-hydroxy-2-

















































Again, earlier work by Martin had led to the development of a
synthesis of this compound, as shown in scheme 3.1.28. The required
stereochemistry was introduced by means of a baker's yeast reduction of
ethyl acetoacetate (145) to produce ethyl (3R)-3-hydroxybutanoate5° (160) in




Scheme 3.1.28: Martin's synthesis of the N-acetylcysteamine thioester
of (2S, 3S)-3-hydroxy-2-methylbutanoate (159)
As shown in scheme 3.1.29, the presence of the methyl group causes






Scheme 3.1.29: Asymmetric induction in the methylation of
(3R)-3-hydroxybutanoate (158).
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At this point Martin protected the hydroxy function prior to taking a
series of operations directed to introduction of the N-acetylcysteamine (98)
moiety. From the work already undertaken on the synthesis of the N-
acetylcysteamine thioester of acetoacetate (144) it was decided to investigate
a more direct route, scheme 3.1.30. Thus ethyl (2S,3S)-3-hydroxy-2-methyl
butanaote (161) was saponified to the free acid in 86% yield which was
then thioesterified via the DCC/DMAP method to give the required
thioester (159) in 78% yield. The hII and 2H nmr spectra of labelled and
unlabelled material are shown in figure 3.1.2
	
OH 0	 OH 0	 OH 0OEt a) NaOH	 DC/DMAP
___ - _____
b) H	 01-! N-acetylcyteamine _	 s JL 5_._'1_
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Scheme 3.1.30: Synthesis of the N-acetylcysteamine thioester of
(2S, 3S)-3-hydroxy-2-methylbutanoateb (159)
The enantiomeric purity of the synthesis was verified by GLC of the














It was found that the baker's yeast reduction gave an ee of 89-93%, and
that methylation yielded (161) in 82-85% de. The saponification process
was found to induce no epimerisation. These results are in good
agreement with the literature values. 50 '51 The 1 H nmr spectra of these
(figure 3.1.3) show the presence of predominantly one stereoisomer. The
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Figure 3.1.2: 1H and 2H nmr spectra of unlabelled and labelled N-acetylcysteamine
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Figure 3.1.3: 1H nmr spectra of Mosher's esters (162), (163) and (164).
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3.1.9: Synthesis of the N-acetylcysteamine thioester of (2E, 4S, 5S)-5-
hydroxy-4-methylhex-2-enoate (165k
By the same reasoning to that described in the previous synthesis, the
target molecule for this synthesis was the N-acetylcysteamine thioester of
[7-2H31 -(2E, 4S, 5S)-5-hydroxy-4-methylhex-2-enoate (165). The asymmetry
within the molecule was introduced as before such that the starting point




A linear approach to this was first investigated, as shown in scheme
3.1.31. Thus ethoxyethoxy protection of the hydroxy entity within (161)
preceeded reduction with Lithium aluminium hydride to produce (25,3S)-



















Scheme 3.1.31: Linear synthesis of the N-acetylcysteamine thioester
of (2E, 4R, 5R)-5-hydroxy-4-methylhex-2-enoate.
Swern oxidation53 of this produced the aldehyde (167) in 63% yield.
The use of DIBAL to affect the direct conversion of the ester (161) (in
protected form) to the aldehyde (167) was investigated, but proved to be
unyielding.
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A Wittig reaction was used to produce producing ethyl (2E, 4S, 5S)-5-
(1-ethoxy)ethoxy-4-methylhex-2-enoate (168) in 90% yield from the
aldehyde (161). The free acid was formed by saponification which also led
to deprotection upon acidification in 45% yield. This was followed by DCC
DMAP 46 coupling with N-acetylcysteamine (98) to produce the N-acetyl
cysteamine thioester (2E, 4S, 5S)-5-hydroxy-4-methylhex-2-enoate (165) in
59% yield from the acid
A synthetic route of increased convergency was developed in order to
reduce the amount of work required subsequent to putative label
introduction. This involved reacting the aldehyde (167) with the ylid (107)
as shown in scheme 3.1.32. Initial investigations were directed towards
forming the ylid in situ from the triphenylphosphonium salt (109) in the







Scheme 3.1.32: Convergent synthesis of the N-acetylcysteamirie thioester
of (2E, 4R, 5R)-5-hydroxy-4-methylhex-2-enoate.
However, use of the preformed ylid (107), as described in chapter 3,
was found to affect the required conversion. Deprotection of the hydroxy
function prior to purification led to recovery of the desired material (165)
in 61% yield. This synthetic scheme was the one used for the preparation
of the labelled material. The 1 H and 2H nmr spectra of unlabelled and
labelled materials are shown in figure 3.1.4.
3.1.10: Administration of putative biosynthetic precursors to
Pseudomonas fluorescens
The biomimetic forms of the three proposed intermediates on the
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Figure 3.1.4: 1H and 2H nmr spectra of unlabelled and labelled N-acetylcysteamine
thioester of(2E, 4S, 5S)-5-hydroxy-4-methylhex-2-enoate (165).
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form as described. These were then administered to the bacteria
simultaneously with tetradecyithiopropionic acid (89), the t3-oxidase
inhibitor. Cultures were worked up as usual and the isolated methyl
pseudomonate (58) analysed by nmr spectroscopic methods.
The 13C nmr spectrum produced from the isolated metabolite (12mg)
after adminstration of 207mg of the N-acetylcysteamine thioester of [2,3-
13C 21-acetoacetate (144) is shown in figure 3.1.5. There is no coupling
between the C-13 and C-12 resonances indicating no intact incorporation.
The resonance at 651.51 appears to be weaker than the other signals in the
spectrum. This is the peak due to the methyl ester introduced as part of the
purification procedure, and its relative weakness may be the result of
enhancement of all other signals via catabolism. Degradation of the
administered compound would be expected to lead to both [1-13C]- and [2-
13C]- acetates, so incorporation at all positions would be expected. The two
carbons derived from methionine also appear weaker than the rest,
though this is not so prominent as for the methyl signal.
The 2H nmr spectrum resulting from the metabolite isolated (13mg)
after administration of 243mg of [5- 2H 31 -(2S, 3S)-3-hydroxy-2-methyl
butanoate (159) is shown in figure 3.1.6. The absence of a signal at 60.95
indicates that intact incorporation did not take place. The signals observed
at 61.25, 62.6 and 63.7-4.3 indicate that catabolism has occurred. The signal
at 61.9 is probably due to the presence of D 20. During the work-up 12mg of
the administered compound was also isolated from the culture broths.
Figure 3.1.7 displays the 2H nmr spectrum of the methyl pseudo
monate that was isolated from the cultures to which 197mg of [7- 2H3]-
(2E,4S,5S)-5-hydroxy-4-methyl-hex-2-enoate (165) were administered.
There is no evidence for intact incorporation of label, although the weak
signals at 61.22 may be indicative of some incorporation of label via
catabolism.
3.2: THE ORTGIN OF C-15 OF MONIC ACID (84)
3.2.1: The cleavage of acetate
The derivation of C-15 from acetate as opposed to methionine 1
 in
monic acid (84) biosynthesis was the first discovery of such a process. As
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Figure 3.1.7: 2H nmr spectrum of pseudomonic acid (44) after administration
of [7 2II2] -(2E, 4S, 5S)-5-hydroxy-4-methylhex-2-enoate (163).
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The explanantion of this phenomenon by way of 13—hydroxy——methyl
glutarate (64) has since been invalidated.
Studies on virginiamycin (60) biosynthesis gave rise to the suggestion
that a similar pathway was being expressed. 55 This was rationalised by
invoking the aldol condensation of an acetyl CoA (9) unit onto a pre-
formed polyketide chain, followed by thioester hydrolysis, decarboxylative
dehydration and alkene isomerisation, as shown in scheme 3.2.1.
Evidence for this was presented from feeding studies utilising [3-13C]-
serine (169). This is converted into acetyl CoA (9)56, via pyruvate (11), and









Scheme 3.2.1: Mechanism for introduction of a cleaved
acetate unit onto a polyketide chain.
When fed to Streptomyces virgini [2- 13C]-acetate gave an equal
enrichment of all the carbons derived from this moiety in virginiamycin
(60) biosynthesis. However, when [3- 13C]-serine (169) was similarly used,
the signal due to C-33 (the branched methyl) was enhanced by ca2.2 times
that of the other enriched signals, figure 3.2.1., as was predicted by the
proposed pathway.
0




Figure 3.2.1: Enhanced enrichment of C-33 (*) by [3-13C]-serine (167),
compared to other positions labelled by [2-13C]-acetate (•)
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Interestingly no follow up to this work has been reported on either the
biogenesis of virginiamycin (60) or any of the other metabolites shown to
exhibit this behaviour. The possibility that such a pathway may be
operating in the biosynthesis of pseudomonic acid (44) was therefore
investigated.
3.2.2: The synthesis of labelled serine (i.9.).
The most obvious label source for this synthesis was recognised as
being [1- 13C] formaldehyde. A synthesis utilising this had already been
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Scheme3.2.2: Synthesis of serine (169)
Diethyl acetamidomalonate (170) was reacted with formaldehyde in
the presence of a catalytic amount of sodium hydroxide. The mixture was
subsequently treated with an excess of sodium hydroxide overnight,
acidified with glacial acetic acid, heated to induce decarboxylation and
treated with concentrated hydrochloric acid to remove the amine
protecting group. Isolation and recrystallisation gave serine (169) in 61%
yield.
3.2.3: The administration of serine to Pseudomonas flu orescens.
In order to quantify any differential enrichment at C-15 in the 13C nmr
spectrum of methyl pseudomonate (58), two experiments were run
simultaneously. To one set of cultures was administered 250 mg of
sodium [2- 13C]-acetate, whereas to a second set of cultures derived from the
same seed flask (and thus the same slope) was fed 250mg of [3-13C]-serine
(169).
Unfortunately, the cultures fed with acetate failed to complete the
growth phase after administration, despite commencement of production
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having been observed by HPLC. The bacteria to which labelled serine (169)
had been administered did complete the growth phase, but produced only
3mg of the metabolite which was not enough material to obtain an
adequate 13C nmr spectrum.
Therefore nothing can be ascertained from this work regarding the
biosynthetic origins of C-15 on pseudomonic acid (44).
3.3: THE ORIGNS OF C-16 AND C-17
3.3.1: Biosynthetic methylation
That C-16 and C-17 were derived from the 'C 1 -pool' via S-adenosyl
methionine (59) was demonstrated during the initial investigations into
pseudomonic acid (44) biosynthesis. 1 This is a well defined and general
pathway for the introduction of methyl groups. 58 However, the timing of
this process relative to other operations in biosynthetic pathways is not
known.
Some evidence for methylation subsequent to chain extension was
gained from investigations into the biosynthesis of 5-methylorsellinic acid
(171), whereby tetraacetic acid (172) was inferred to be the methylation
substrate,59 scheme 3.3.1. However it was also possible to rationalise this
process as occurring after release from the polyketide synthase, and thus
being separate from the chain elongation process.










Scheme 3.3.1: Methylation of tetraacetic acid (172) on the biosynthetic
pathway to 5-methylorsellinic acid (171)
Study of the biosynthesis of aurovertin B (173) , aurovertin D (174) and
asteltoxin (175) indicated a dual incorporation of propionate and acetate!
methionine moities into the C3 starter unit, 60 scheme 3.3.2. This result
indicates that the methylation of acetate prior to chain incorporation may
be a valid biosynthetic hypothesis.
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The processive polyketide hypothesis predicts that methylation occurs
contemporaneously to homologation, but not whether the process is prior
or subsequent to the chain elongation step. In the former case, the chain







Scheme 3.3.2: The biosynthesis of the aurovertins (173, 174) and
asteltoxin (175) from a C3 starter unit derived from both
propionate and acetate/methionine.
However if this is the case in pseudomonic acid (44) biosynthesis the
methylmalonate would necessarily have to be formed by methylation of














HO'( SEnz + _A SEnz




In order to attempt clarification of the involvement of methyl-
malonate in polyketide biosynthesis it was decided to investigate the
methylation processes in pseudomonic acid (44) biogenesis. For these
studies a labelled form of methylmalonate was required.
3.3.2: Synthesis of labelled methylmalonate
The synthesis of labelled malonates has already been described in
chapter two. Methylation of diethyl malonate (73) was possible via the use
of sodium ethoxide and trapping of the resultant enolate with
iodomethane, scheme 3.3.4. Any residual diethyl malonate was removed
by a sodium hydroxide wash. 61 Distillation of the residue yielded diethyl
methylmalonate in 81% yield. For administration purposes this was
quantitatively saponified to the disodium salt (176).
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(73)
Scheme 3.3.4: Synthesis of disodium methylmalonate (176)
3.3.3: Administration of labelled methylmalonate to Pseudomonas
flu orescens.
In an initial experiment 250mg of disodium [4-13C]-methylmalonate
(176) was administered, leading to the isolation of 22mg of metabolite The
nmr spectrum of this is shown in figure 3.3.1. No evidence for
enhancement of signals can be observed at either 12.76 (C-17) or 65.37 (C-
16).
For increased sensitivity, 250mg of [2,4- 13C 2]-methylmalonate (176),
were fed to the bacteria and 25mg of metabolite was isolated. In the 13C
nmr spectrum of this (diagram3.3.2) there were no 13C- 13C couplings
detected between either the C-16/C8 or the C-17/C-12 resonances as would
be expected had intact incorporation occurred. There was no evidence for
any significant label incorporation into the rest of the metabolite.
This last fact was rather surprising as the vitamin B 12 dependent
methylmalonyl CoA (177) rearrangement to succinyl CoA (178)62 shown in
scheme 3.3.5 might have been expected to 'leak' label into pseudomonic
















































































Scheme 3.3.5: The rearrangement of methylmalonyl CoA (177)
to succinyl CoA (178)
A sample of [2,4- 13C2] methylmalonate was supplied to O'Hagan and
co-workers for similar studies into the biosynthesis of tenellin (179) in
Beauvaria bassiana. Again, no specific incorporation of label into the
methyl positions was observed, nor was there any evidence for non-





This work seems to supply strong evidence that methylation occurs
after chain elongation onto a polyketide chain, in accordance with more
classical ideas. The nature of the relationship between the methylase and
the polyketide synthase remains unresolved, however. If pseudomonic
acid (44) biosynthesis is mediated by a Type I polyketide synthase then it
may be inferred that the methyltransferase activity will be found within
the multifunctional protein.
3.4: Conclusions and further work.
From these studies it has been shown that methylation via the 'Cl-
pool' in polyketide biosynthesis occurs directly onto the polyketide chain,
and not via pre-methylation of a chain extending unit. The question of
methylation via cleavage of acetate units remains unanswered. The
experiment using labelled serine needs to be repeated. The use of [2- 13C]-
malonate, and variation in the time of feeding to see if any differential
incorporation can be observed might also be useful for these studies. It is
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plausible that malonate, via decarboxylation, is the actual source of acetate
for the postulated aldol condensation reaction,
The results from feeding proposed chain elongation intermediates
suggested that catabolism had taken place. Repetition of these experiments
with increased amounts of inhibitor, or even the use of an alternative
inhibitor, may prove worthwhile. Increased pulse feeding may also prove
to be a beneficial approach.
However this problem appears to be endemic to studies of this kind
and it is probable that full realisation of the biochemical processes
underpinning polyketide biosynthesis will remain elusive until




The 2H nmr spectra were run on a Jeol 400X instrument, at 61.3 MHz,
in CHC13 solution with C2HC13 as an external reference. Optical rotations
were recorded on a Perkin-Elmer Z41MC polarimeter.
All other general experimental is as previously described.
Synthesis of ethyl acetoacetate (145)
To l5ml of freshly distilled anhydrous THF under a nitrogen
atmosphere at -78°C was added 3.39g (21.O7mmol) of HMDS. This was
followed by the addition of 8.l2ml (19.5mmol) of a 1.6M solution of butyl
lithium. After 30 minutes ethyl acetate (1.03g, 11.O7mmol) was added and
the mixture left a further 30 minutes. Acetyl chloride (0.87g, 11,2mmol)
was then added and the mixture left for 30 minutes. After being allowed to
warm to room temperature 15m1 of 2M HC1 was added to the reaction and
the layers separated. The aqueous layer was extracted with ethyl acetate (3
x) and the combined organic layers were dried over anhydrous
magnesium sulphate, filtered and concentrated in vacuo to yield an
orange oil. This was purified by bulb to bulb distillation (46°C, lOmbar) to
give ethyl acetoacetate (145) (1.0347g. 7.93mmol, 71%) as a colourless oil.
max(th film) 1721 cm; H 1.3 (3H, t, J=6.5Hz CH3), 2.3 (3H, s, CH3CO), 3.45
(2H, s, COCH 2CO), 4.15 (2H, q, J=6.5Hz, OCH2); m/z: 131 (M+1, 4.5%) 130
(nf, 3.7), 85 (15.4), 84 (16.1), 44 (100).
Xflihetic approaches to the N-acetylcysteamine thioester of acetoacetate
A) Via carbonyl activation (The method of Martin33)
a) Ethyl acetoacetate (145) (lOg, 77mmol) was dissolved in 5Oml of dry
toluene in a Dean-Stark apparatus under nitrogen. To this was added
20mg of PTSA and 10.79m1 (15.4mmol)) of ethylene glycol. The mixture
was heated under reflux overnight. After cooling the solution was washed
sequentially with 50m1 of 5% sodium bicarbonate and water (2 x 5OmD.
The organics were then dried, filtered and concentrated to yield ethyl (3,3-
ethyleneketal)butanoate (146) as a colourless oil (8.977g, 5.l96mmol, 67%).
H (60MHz) 1.2 (3H, t, J7Hz, CH3), 1.45 (3H, s, CH3), 2.65 (2H, s, CH2CO), 3.95
(4H, s, O(CH2)20), 4.15 (21-1, q, J=71-lz, OCH2)
b) To ig (5.75mmol) of ethyl (3,3-ethyleneketal)butanoate (146) was
added 3.15m1 of 2M sodium hydroxide solution. The mixture was left
stirring overnight. The water was removed in vacuo and the residue
freeze dried to yield sodium (3,3-ethyleneketal)butanoate (147) as a white
solid (0.86g, 5.75m1, 100%). öH (6OMHz, D20) 1.5 (3H. s CH3), 2.55 (21-1, s,
CH2CO), 4.0 (4H, s,O(CH2)20)
c) The sodium salt (147) (0.697g, 4.2mmol) was suspended in 5m1 of
freshly distilled anhydrous TI-IF. To this was added methyl chioroformate
(0.99g, 10.5 mmol) and 0.051g (0.42mmol) of DMAP. The mixture was left
vigorously stirring overnight before being filtered through celite. The
filtrate was washed with saturated ammonium chloride, dried over
anhydrous magnesium sulphate, filtered and concentrated in vacuo to
give the methyl formate-(3,3-ethylene ketal) butanoate mixed anhydride
(148) (0.525g, 2.574 mmol, 61%). H(6O MHz) 1.5 (3H, s, CH3), 2.6 (2H, s, CH)F
3.9 (3H, s, CH3)F 4..0 (4H, s, O(CH)20)
d) This mixed anhydride (148) (0.648g, 3.l8mmol) was dissolved in 8m1
of dry THF to which was added freshly prepared N-acetylcysteamine (1.02g,
6.4lmmol). After stirring overnight lOml of ethyl acetate was added and
the solution washed with 1M potassium hydroxide solution. The aqueous
layer was extracted with ethyl acetate (2Oml) and the combined organic
extracts were dried over anhydrous magnesium sulphate, filtered and
concentrated to give 0.625g (2.33mmol, 80%) of the N-acetylcysteamine
thioester of (3,3-ethylene ketol)butanoate. H(60 MHz) 1.4 (3H, s, CH3), 2.05
(3H, s, CH3), 2.95 (2H, s, CH 4CO), 3.05 (2H, t, J=6.2Hz, CH2S), 3.55 (21-1, m,
CH2N), 4.0 (4H, s, O(C1-1 2) 20), 6.15 (IH, br s, NH)
B Via Meidrum's acid (The method of Ley)
a) Meidrum's acid (153) (1.805g, 12.6mmol)-was added to 4Oml of
freshly distilled dichioromethane under a nitrogen atmosphere. To this
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was added 1.09m1 (15.12 mmol) of acetyl chloride and 1.18m1 (24.5mmol)
of pyridine. The resultant mixture was stirred for an hour at 0°C and then
for a further hour at room temperature. The mixture was then poured
into 60m1 of 2M HC1 at 0°C. The layers were separated and the aqueous
layer extracted with dichloromethane (2 x 50m1). The combined organics
were then dried over magnesium sulphate, filtered and concentrated in
vacuo to yield 2.179g (11.72 mmol, 93%) of acetyl Meidrum's acid (148) as
orange-brown crystals. H 1.83 (6H, s, 2 x CH3), 2.8 (3H, s, CH3), 15.05 (1H, br
s, OH)
b) The acetyl Meidrum's acid (148) (0.107g, 0.575mmo1) was dissolved
in 8m1 of chloroform under a dry nitrogen atmosphere. Freshly prepared
N-acetylcysteamine (0.680g. 5.75mmol) was added in 2m1 of chloroform.
The mixture was heated under reflux and monitored by TLC. After 16
hours no apparent change had been observed. An aliquot was
concentrated and analysed by 1H nmr spectroscopy, which revealed the
presence of starting materials only. Prolonged reaction times gave no
further change.
C) Via N,S-diacetylcysteamine (The method of Cane)
To 40m1 of freshly distilled anhydrous THF under a dry nitrogen
atmosphere at -78°C was added 0.72m1 (5.l26mmol) of diisopropylamine.
To this was added 3.21 ml of a 1.6M solution of n-butyl lithium
(5.l26mmol). After 20 minutes N,S-diacetylcysteamine (151) (0.413g.
2.563mmo1) was added as a solution in lOml of anhydrous THF. After a
further 20 minutes was added acetyl chloride (0.18m1, 2.563mmo1) in a
dropwise manner. After 5 minutes the mixture was allowed to warm to
room temperature and then washed with water (4Oml) and brine (3Oml).
The organics were dried over anhydrous magnesium sulphate, filtered
and concentrated in vacuo.
The crude product was shown by 1 H nmr to be returned N,S-diacetyl
cysteamine.
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D) Via acetoacetic acid
a) Preparation of acetoacetic acid (156)
To ethyl acetoacetate (145) (4.222g, 32.5 mmol) was added 25m1 of an
aqueous 2M solution of sodium hydroxide. This was stirred at 5-10°C for 7
hours before being cooled to 0°C. The pH was adjusted to 1.0 by the slow
addition of 6M HC1 and the resultant solution extracted with cold ethyl
acetate (10 x 30m1). The combined organics were dried over anhydrous
magnesium sulphate, filtered and concentrated in vacuo to give
acetoacetic acid (156) (3.095g, 30.34mmol, 93%) as a colourless oil that froze
to a white solid upon refrigeration. omax(thin film) 2930, 1712 cm 1; oH 2.3
(3H, s, CH3CO), 3.5 (2H, s, COCH2CO), 5.05 (s, enol CH), 10.05 (IH, br s, OH);
30.05 (Cl-I3), 49.09 (Cl-I2), 171.77 (CO), 201.77 (CO2H)
b) Attempted thioesterification mediated by phenyl dichlorophosphate
Acetoacetic acid (156) (0.25g, 2.4mmol) was dissolved in 5m1 of DME at
0°C. To this was added sequentially pyridine (0.4lml, 5mmol), N-
acetylcysteamine (98) (0.89g. 7.48mmol) and phenyl dichlorophosphate
(157) (0.56m1, 3.75mmol). The mixture was allowed to warm to room
temperature with stirring overnight. The resultant suspension was
filtered through celite and concentrated to leave a yellow oil.
The H nmr spectrum of this gave no evidence for formation of
product
c) Attempted thioesterification mediated by DCC/DMAP
To a stirred solution of acetoacetic acid (156) (0.338g, 3.32mmol) and N-
acetylcysteamine (98) (0.51g, 4.32mmol) in dichloromethane at 0°C under
nitrogen was added DCC (0.72g, 3.49mmol) and DMAP (0.043g, 0.349mmo1)
slowly in 5m1 of dichioromethane. The mixture was left overnight and
then filtered through celite. The filtrate was dried over anhydrous
magnesium sulphate, filtered and concentrated to leave a yellow oil.
The 1 H nmr spectrum of this showed no evidence for formation of
product.
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d) Thioesterification mediated by DCC/pyridine
To acetoacetic acid (156) (0.235g, 2.3 mmol) in lOml of dichioromethane
at -25°C under a nitrogen atmosphere was added freshly prepared N-acetyl
cysteamine (156) (O.356g, 2.99mmol) in 5m1 of dichioromethane. After five
minutes was added DCC(0.498, 2.42mmol) in dichioromethane containing
3 drops of pyridine. The system was allowed to warm to room temperature
overnight and the resultant suspension filtered through celite. The filtrate
was dried over anhydrous magnesium sulphate, filtered, concentrated.
Purification by preparative TLC using plates pre-treated with triethyl
amine (acetone/dichioromethane, 2:3) gave the N-acetylcysteamine
thioester of acetoacetate (156) as a colourless syrup (0.355g. 1.635nimol,
71%). max H03) 3390, 1719, 1694, 1668, 1651cm'; 6H 1.97 (3H, CH3CON),
2.28 (3H, s, CH3CO) F 3.09 (2H, t, J=6.7Hz, CH2S), 3.45 (2H, m, CH2N), 3.73 (2H,
s, COCH 2CO), 5.45, (s, enol CH), 6.37 (1H, br s, NH); 6, 23.14 (CH2N), 29.21
(CH2S), 30.45 (CH3CO), 39.15 (CH3CON), 58.03 (CH2), 170.55 (CON), 192.26
(CO), 199.95 (COS); m/z 203 (M, 0.6%), 119 (36.5), 118 (11.5), 85 (16.7), 60
(84), 43 (97.7), 30 (100).
Synthesis of the N-acetylcysteamine thioester of [2,3-13C2] acetoacetatefl44)
a) To l5ml of freshly distilled anhydrous THF under a nitrogen
atmosphere at -78°C was added 2.45g (15.l9mmol) of HMDS. This was
followed by the addition of 5.91m1 (14.77mmol) of a 1.6M solution of butyl
lithium. After 30 minutes ethyl [2- 13C2]-acetate (0.76g, 8.44mmol) was added
and the mixture left a further 30 minutes. [1-'3C1-acetyl chloride (0.826g,
10.l3mmol) was then added and the mixture left a further 30 minutes.
After being allowed to warm to room temperature 15m1 of 1M HC1 was
added to the reaction and the layers separated. The aqueous layer was
extracted with ethyl acetate (3 x 20m1) and the combined organic layers
were dried over anhydrous magnesium sulphate, filtered and
concentrated in vacuo to yield an orange oil. This was purified by bulb to
bulb distillation (46°C, 20 mmHg) to give ethyl [2,3-' 3C2]-acetoacetate (145)
(0.763g. 5.82mmol, 69%) as a colourless oil. max 1722 cm'; H 1.29 (3H, t,
J=7.1Hz, Cl-I3), 2.27 (3H, dd, JCH_6l-, 1CH3' CH313C0), 3.45 (2F1, dd,
JCH 130.2F'z, JCH 6.21, 13CH213C0), 4.17 (2H, q, J=7.lHz, CH2); m/z 133
(M^1, 5.8%), 132 (M 4, 5.0), 131 (3.1), 87 (14.3), 86 (18.9), 44 (100).
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b) To ethyl [2,3- 13C 2]-acetoacetate (145) (0.753g. 5.71 mmol) was added
5ml of an aqueous 2M solution of sodium hydroxide. This was stirred at 5-
10°C for 7 hours before being cooled to 0°C. The pH was adjusted to 1.0 by
the slow addition of 6M HC1 and the resultant solution extracted with cold
ethyl acetate (10 x lOmi). The combined organic layers were dried over
anhydrous magnesium sulphate, filtered and concentrated in vacuo to
give 12,3-13C2]-acetoacetic acid (156) (0.436g, 4.lmmol, 72%) as a colourless
oil that froze to a white solid upon refrigeration. umax(thin film) 2933, 1709
cm1; H (3H, d 2JcH=6.4Hz, CH313C0), 3.5 (2H, dd, 1J =130 .5Hz ,2J=6.4Hz,
13CH213C0)
c) To [2,3-13C 2]-acetoacetic acid (156) (0.428g, 4.04 mmol) in 5m1 of
dichioromethane at -25°C under a nitrogen atmosphere was added freshly
prepared N-acetylcysteamine (98) (O.626g, 15.24mmol) in 2m1 of dichioro
methane. After five minutes was added DCC (8.70, 4.24mmol) in 2m1 of
dichioromethane containing 3 drops of pyridine. The system was allowed
to warm to room temperature overnight and the resultant suspension
filtered through celite. The filtrate was dried over anhydrous magnesium
sulphate, filtered, concentrated. Purification by prep. TLC using plates pre.-
treated with triethyl amine (acetone/dichioromethane, 2:3) gave the N-
acetylcysteamine thioester of [2,3- 13C2]-acetoacetate (144) as a colourless
syrup (O.331g, 1.8Ommol, 45%). Dmax(CHC13) 3392, 1719, 1693, 1668, 1651 cm
H 1,97 (3H, s, CH3CON), 2.28 (3H, dd, J2cH =6 .3Hz JCH11' CH3CO), 3.09
(2H, t, J=6.6Hz, CH 2S), 3,35 (3H, m, CH2N and highfield resonance of 13CH2
doublet), 3.73 (2H, dd, 1J=130.7Hz 2J=6.3Hz, 13CH2), 5.94 (1H, br s, NH); &
58.3 (d, J-37.6 Hz, 13CH2), 199.95 (d, J=37.6 Hz, 13C0), m/z 205 (M, 0.8%), 119
(41,3), 118 (9.7), 87 (15.3), 44 (56.7), 43 (43.4), 30 (100).
Synthesis of the N-acetylcysteamine thioester of (2S, 3S)-3-hydroxy-2-
methyl butanoate (159)
a) To 40g of D-glucose (10) in a 500m1 conical flask was added 300ml of
water. After dissolution 20 g of dried baker's yeast (single strain,
Sacchoromyces cerevisi) was added and the mixture shaken at 26°C (250
rpm) for 30 minutes. At this point Ig of ethyl acetoacetate (145) was added.
A further Ig was added 12 hours later. After a further 36 hours the mixture
was centrifuged (10,000g. 4°C, 10 minutes) and the supernatant extracted
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with ethyl acetate (5 x 200ml). The combined organics were dried over
anhydrous magnesium sulphate, filtered and concentrated in vacuo and
the residue was purified by bulb to bulb distillation (51°C, 3mmHg) to give
ethyl (3S)-3-hydroxybutanoate (160) (1.138g, 8.62mmol, 56%) as a colourless
oil. [a]D=+33.64°, c=3.38, CHC13 (lit: [a]D=+37.2°, c=1.3, CHC1 3); Umax(thfl
film) 3456, 1739 cm1; H 1.22 (3H, d, J=6.4Hz, CH3CH), 1.28 (3H, t, J7.2Hz,
CH3CH2), 2.46 (2H, m, CH 2CO), 4.16 (2H, q, J=7.2 Hz, CH 2O), 4.19 (1H, in,
CH3CH);	 14.2, 22.3, 42.7, 60.8, 64.1, 172.9; m/z 132 (M, 0.7%), 131 (M-1,
8.3), 117 (39.9), 102 (84), 88 (52.5), 87(52.3)
b) To 20m1 of freshly distilled anhydrous THF under a dry nitrogen
atmosphere at -78°C was added 1.08m1 of diisopropylamine (14.75mmol)
followed by 9.22m1 of a 1.6M solution of butyl lithium in hexanes (14.75).
After 30 minutes Ig of ethyl (3S)-3-hydroxybutanoate (160) was added as a
solution in 2ml of THF. After 20 minutes the mixture was warmed to -
45°C for 30 minutes and then recooled to -78°C. lodomethane (1.12g,
14.85mmol) was added and the mixture left to warm to room temperature
overnight. To this was added 15m1 of saturated ammonium chloride
solution. The layers were separated and the aqueous layer extracted with
ether (5 x 20m1). The combined organics were dried over anhydrous
magnesium sulphate, filtered and concentrated in vacuo. The residue was
purified by bulb to bulb distillation (56°C, 4mmHg) to give ethyl (2S, 3S)-3-
hydroxy-2-methyl butanoate (161) as a colourless oil (0.764g, 5.24mmol,
71%). [a]D=+22.3°, c=1.7, CHC13
 (lit66: [a]D=+19.1°, c=1.3, CHC1 3); o(thin
film) 3347, 1715 cm1; H 1.15 (3H, t, 6.3Hz, CH 3CH2), 1.25 (3H, d, J=6.4Hz,
CH3CH), 1.30 (3H, d, J=6.4Hz, CH3CH), 2.45 (IH, dq, J=6.3 Hz, 6.4Hz, H-2),
3.85 (IH, m, H-3), 4.18 (2H, q, J=6.3Hz, OCH 2); c5, 13.68 (CH3), 14.21 (CH3),
20.57 (CH.3), 47.21 (CHCO), 60.53 (CO2CH2), 69.33 (CHOH), 175.83 (CO2); m/z
145 (M, 0.7%), 131 (7), 102 (84.2), 101 (36.5), 74 (100), 56 (48.3)
c): To 1.985g (13.6mmol) of ethyl (2S, 3S)-3-hydroxy-2-methylbutanoate
(161) was added 15m1 of 2M NaOH. The mixture was stirred overnight and
then extracted with ethyl acetate (lOmi). The pH of the aqueous layer was
adjusted to 1.0 and then re-extracted with ethyl acetate (5 x 15m1). The
combined organic extracts were dried over anhydrous magnesium
sulphate, filtered and concentrated in vacuo to leave 1.396g (11.83mmol,
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87%) of (2S, 3S)-3-hydroxy-2-methylbutanoic acid. u(thin film) 3393, 1717
cm1; H 1.25, d, J=6.5Hz, CH3), 1.29 (3H, d, J=6.5Hz, CH3), 2.51 (1H, m, H-2),
3.87 (IH, m, CHOH), 6.8 (2H, br s,2 x OH)
d) To 0.585g (4.94mmol) of (25, 3S)-3-hydroxy-2-methylbutanoic acid in
5ml of dichioromethane under a nitrogen atmosphere at 0°C was added
0.764g (6.4mmol) of freshly prepared N-acetylcysteamine (98) in 2m1
dichioromethane. To this was added DCC (1.067g. 5.l9mmol) and DMAP
(0.06g, 0.52mmol) in 5m1 of dichioromethane The reaction was left to
warm to room temperature overnight at which point the mixture was
filtered through celite. The filtrate was washed with saturated ammonium
chloride solution, dried over anhydrous magnesium sulphate, filtered and
concentrated. The residue was purified by flash column chromatography
(acetone/dichioromethane, 2:3 with 3 drops of triethylamine) to yield the
N-acetylcysteamine thioester of (2S, 3S)-3-hydroxy-2-methylbutanoate (159)
as a colourless syrup (0.841g, 3.85mmol, 78%). u(CHC13) 3299, 1686, 1657,
1562, 1557 6H 1.2 (3H, d, J=6.9Hz, CH3), 1.24 (3H, d, J=6.5Hz, CH3), 1.97
(3H, s, CH3CO), 2.7 (1H, m, CHCH3), 3.05 (2H, t, J=6.5Hz, CH 2S), 3.47 (2H, m,
CH2N), 3.96 (1H, m, CHOH), 5.8 (1H, br s, NH); & 21.06 (CH3), 22.41 (CH3),
23.19 (CH2N), 28.58 (CH2S), 39.39 (CH3CON), 55.7 (CHCO), 69.89 (CHOH),
170.5 (CON), 204.2 (COS); m/z: 220 (M+1, 0.9%), 119 (100), 101 (11.3), 60 (83)
Synthesis of the N-acetylcysteamine thioester of [5- 21131-(2S, 3S)-3-hydroxy-
2-methylbutanoate (159).
a) To 15m1 of freshly distilled anhydrous THF under a dry nitrogen
atmosphere at -78°C was added 1.04g of diisopropylamine (10.33mmol)
followed by 4.55ml of a 1.6M solution of butyllithium in hexanes
(11.36mmol). After 30 minutes 0.606g (43.S93mmol) of ethyl (3S)-3-
hydroxybutanoate (160) was added as a solution 2m1 of THF. After 20
minutes mixture was warmed to -45°C for 30 minutes and then recooled to
-78°C. To the mixture [ 2H3]-iodomethane (Ig, 6.89mmol) was added and the
mixture left to warm to room temperature overnight. To this was added
15m1 of saturated ammonium chloride solution. The layers were
separated and the aqueous layer extracted with ether (5 x 20m1). The
combined organics were dried over anhydrous magnesium sulphate,
filtered and concentrated in vacuo. The residue was purified by bulb to
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bulb distillation (56°C, 4mmHg) to give ethyl [5-2H3]-(2S, 3S)-3-hydroxy-2-
In ethylbutanoate (161) as a colourless oil (0.462g, 3.O82mmol, 67%).
°max(tM1 film) 3352, 1715 cm1; 6H 1.15 (3H, t, J=6Hz, CH2CH3) 1.30 (3H, d,
J=6.S Hz, CH 3), 2.45 (IH, br m, CHC 2H3), 3.85 (IH, m ,CHOH), 4.18 (2H, q,
J6Hz, OCH 2); m/z: 134 (M-15, 5.0%), 105 (79.7), 104 (45.0), 77 (100), 59
(51.7).
d) To 0.443g (2.953mmo1) of ethyl [5-2H3]-(2S, 3S)-3-hydroxy-2-methyl
butanoate (161) was added 3m1 of 2M NaOH. The mixture was stirred
overnight and then extracted with ethyl acetate (lOmi). The pH of the
aqueous layer was adjusted to 1.0 and then re-extracted with ethyl acetate
(5 x 15m1). The combined organic extracts were dried over anhydrous
magnesium sulphate, filtered and concentrated in vacuo to leave 0.285g
(2.36mmol, 80%) of [5- 2H 3]-(2S,3 S)-2-3hydroxy-2-methyl butanoic acid.
l)max(t	 film) 3389, 1719 cm1; 6H 1.29 (3H, d, J=6.5Hz, CH3), 2.51 (1H, br m,
CHC2H3), 3.87(1H, m, CHOH), 6.9 (2H, br s, 2 x OH')
c): To 0.276g (2.28mmol) of [5-2H3]-(2S, 3S)-3-hydroxy-2-methylbutanoic
acid in Sml of dichioromethane under a nitrogen atmosphere at 0°C was
added 0.353g (2.97mmol) of freshly prepared N-acetylcysteamine (98) in
2m1 dichioromethane. To this was added DCC (0.494g, 2.4Ommol) and
DMAP (0.03g, 0.24mmol) in 5m1 of dichloromethane The reaction was left
to warm to room temperature overnight at which point the mixture was
filtered through celite. The filtrate was washed with saturated ammonium
chloride solution, dried over anhydrous magnesium sulphate, filtered and
concentrated. The residue was purified by flash column chromatography
(acetone/dichioromethane, 2:3 with 3 drops of triethylamine) to yield the
N-acetylcysteamine thioester of E5-2H3]-(2S,3S)-3-hydroxy-2-methyl
butanoate (159) as a colourless syrup (0.299g, 1.35mmol, °"°). maxHQ3)
3303, 1687, 1656, 1562, 1558 cm 1 ; oH 1.24 (2H, d, J=7Hz, CH3), 1.97 (3H, s,
CH3CON), 2.70 (1H ,br m, CHC 2H3), 2.83 (1H, br s, OH), 3.05 (2H,t, J=6.5Hz,
CH 2S), 3.47 (2H, m, CH 2N), 3.96 (1H, m, CHOH), 6.42 (1H, br m, NH), &
21.19 (CH), 23.32 (CH2N), 28.74 (CH2S), 39.44 (CH3CON), 55.84 (CHCO), 70.04
(CHOH), 170.47 (CON), 204.17 (COS); OD 1.13 (br s); m/z 207 (Mt15, 3.6%),
190 (2.5), 119 (100), 86 (40), 60 (86)
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Mosher's ester of ethyl 3-hydroxybutanoate (164)
To 0.054g (0.4lmmol) of racemic ethyl 3-hydroxybutanoate (160) was
added 0.103g (0.4lmmol) of R-(+)-Mosher's acid chloride, 5 drops of carbon
tetrachioride followed by 5 drops of pyridine. The mixture was left to stand
overnight. After this time was added imi of water, and the resultant
mixture poured into 20 ml of ether. This was washed with 1M HC1
saturated sodium carbonate solution and water. The organic layer was
dried over anhydrous magnesium sulphate, filtered and concentrated.
Purification by preparative TLC (ethyl acetate/petroleum 40-60, 3:2) gave
the Mosher's ester of racemic ethyl 3-hydroxybutanoate (164) (0.021g.
0.l9mmol, 46%) as a colourless oil. 5H 1.17-1.25 (3H, m, CH3), 1.3-1.45 (3H,
dd, J=l8FIz, 7Hz, CH3), 2.47-2.8 (2H, m, H-2a, H-2j3), 3.45 (3H, s, OMe), 4.0-4.2
(2H, m, OCH2), 5.57 (IH, m, H-3), 7.40, 7.54 (5H, 2 x br s, Phenyl); m/z 303
(Mt45, 3%), 216 (2), 189 (100), 115 (24.3), 73 (34.3), 69 (34.8).
Mosher's ester of ethyl (3S)-3-hydroxybutanoate (162)
To 0.032g (0.24mmol) of ethyl (3S)-3-hydroxybutanoate (160) was added
0.061g (0.24mmol) of R-(+)-Mosher's acid chloride, 5 drops of carbon
tetrachloride followed by 5 drops of pyridine. The mixture was left to stand
overnight. After this time was added lml of water, and the resultant
mixture poured into 20 ml of ether. This was washed with 1M HC1
saturated sodium carbonate solution and water. The organic layer was
dried over anhydrous magnesium sulphate, filtered and concentrated.
Purification by preparative TLC (ethyl acetate/petroleum 40-60, 3:2) gave
the Mosher's ester of ethyl (3S)-3-hydroxybutanoate (162) (0.048g, ,
0.l3mmol, 54%) as a colourless oil. H 1.19 (3H, t, J=7.lHz, CH3), 1.43 (3H, d,
J=6.2Hz, CH3), 2.48-2.73 (2H, m, H-2cx, H-213), 3.55 (3H, s, OMe), 4.05 (2H, m,
OCH2), 5.57 (1H, m, H-3), 7.40,7.52 (5H, 2 x br s, phenyl); m/z 303 (M-45,
2.2%), 216 (4.4), 189 (100), 115 (19.3), 73 (30), 69 (28,1).
Mosher's ester of ethyl (2S, 3S)-3-hydroxy-2-methylbutanoate (164)
To 0.054g (0.37mmol) of ethyl (2S,3S)-3-hydroxy-2-methylbutanoate
(161) was added 0.093g (0.37mmol) of R-(+)-Mosher's acid chloride, 5 drops
of carbon tetrachloride followed by 5 drops of pyridine. The mixture was
left to stand overnight. After this time was added lml of water, and the
resultant mixture poured into 20 ml of ether. This was washed with 1M
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HC1 , saturated sodium carbonate solution and water. The organic layer
was dried over anhydrous magnesium sulphate, filtered and concentrated.
Purification by preparative TLC (ethyl acetate/petroleum 40-60, 3:2) gave
the Mosher's ester of ethyl (3S,2S)-3-hydroxy-2-methylbutanoate (163)
(0.062g, 0.l7mmol, 46%) as a colourless oil. 6H 1.12-1.2 (6H, m, 2 x CH3), 1.36
(3H, d, J=6.4Hz, CH3), 2.73 (1H, p, J=7.3Hz, H-2), 3.54 (3H, s, OMe), 3.99 (2H,
m, OCH2), 5.39, m, H-3), 7.41,7.51 (5H, 2 x br s, phenyl); m/z 317 (M-45,
2.1%), 216 (4.2), 189 (100), 115 (7.9), 73 (34.1).
Synthesis of the N-acetylcysteamine thioester of (5S, 4S, 2E)-5-hydroxy4-
methylhex-2-enoate (165).
a) To 4.72g (32.2mmol) of ethyl (2S, 3S)-3-hydroxy-2-methylbutanoate
(161) in lOmi of ethoxyethene was added 1 drop of TFA. The mixture was
left stirring overnight and the volatiles removed in vacuo to leave ethyl
(2S, 3S)-3-(1'-ethoxy)ethoxy-2-methyl butanoate as a colourless oil (7.03g,
32.lmmol, 99%). o(thin film) 1725 cm1; H 1.08-1.3 (15H, m, 5 x CH3), 2.44
(IH, m, CHCH3), 3.38-3.67 (2H, m, OCH 2CH3), 3.84 (1H, m, CHO), 4.15 (2H,
m, OCH2), 4.69 (IH, OCH(CH3)O), m/z 203 (M-15, 1.1%), 173 (3.5), 129 (23.6),
73 (100), 45 (40.7).
b) To 0.5299g (13.94mmol) of lithium aluminium hydride suspended
in lOmi of freshly distilled ether at 0°C under a nitrogen atmosphere was
added ethyl (2S, 3S)-3-(1 -ethoxy)ethoxy-2-methylbutanoate (3.039g, 13.94
mmol) dropwise as a solution in 5m1 of anhydrous ether. The mixture
was stirred at room temperature for one hour and then under reflux for
two hours. After cooling to 0°C, the mixture was slowly decomposed by the
dropwise addition of water. Upon completion ethyl acetate was added
(20m1) and the mixture filtered with ethyl acetate washing. The organics
were dried over anhydrous magnesium sulphate, filtered, concentrated
and the residue purified by bulb to bulb distillation (77°C, 5mmHg) to yield
(2S, 3S)-3-(1'-ethoxy)ethoxy-2-methylbutanol (166) (2.12g, 12.O5mmol, 87%)
as a colourless oil. Umax(thifl film) 3400, 1445, 1377cm1; H 0.94, (3H, d,
J=6.9Hz, CH3CH), 1.2-1.35 (9H, m, 3 x CH3), 3.4-3.8 (5H, m, 2 x CH2O and H-
3), 4.71 (1H, m, OCH(CH3)O); m/z 116 (M-15, 0.6%), 131 (4.4%), 69 (26.1),73
(100), 45 (94.1).
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c) To 25m1 of dichioromethane at -78°C under a nitrogen atmosphere
was added 1.20m1 (13.75mmol) of oxalyl chloride. To this was added 1.95m1
of dimethylsuiphoxide (27.5mmol). Two minutes later (2S, 3S)-3-(1-
ethoxy) ethoxy-2-methylbutanol (166) was added over two minutes as a
solution in 3m1 of dichioromethane. After a further 15 minutes
triethylamine (17.49m1, l25mmol) was added, and after five minutes the
mixture was allowed to warm to room temperature. Water (30m1) was
added and the layers separated. The aqueous layer was was extracted with
dichioromethane (2 x 30m1) and the combined organics dried over
anhydrous magnesium sulphate, filtered and concentrated in vacuo. The
residue was taken up in 15m1 of dichloromethane and washed
sequentially with water, 5% sodium bicarbonate solution, water, 1%
hydrochloric acid, and water. The solution was dried over anhydrous
magnesium sulphate, filtered and concentrated in vacuo to yield (2S, 3S)-
3-(1'-ethoxy)ethoxybutanal (167) (1.498g, 8.42mmol, 67%) as a pale straw oil
'Jrnax(thl film) 1719 cm1; 6H 1.0-1.4 (12H, m, 4 x CH3).), 2.5 (1H, m, H-2), 3.4
(2H, m, CH2CH3), 4.0 (IH, m, CI-IOH), 4.75 (IH, m, OCH(CFI3)O), 9.77 (1H, s,
CHO); m/z 175 (M-i-1, 2.1%), 174 (M, 0.5%), 159 ( 1.1), 73 (97), 45 (100), 43
(31).
A) linear approach
a) A chloroform solution of (3S,2S)-3-(1 '-ethoxy)ethoxy-2-methyl
butanal (0.503g. 2.86mmol) (167) and the ethyl ester of
triphenyiphosphorane acetate was heated under reflux for 24 hours. After
cooling the solvent was removed and the mixture purified by flash
column chromatography (ethyl acetate/petrol 40-60, 4:1) to yield ethyl (2E,
4S, 5S)-5-(1'-ethoxy) ethoxy-4-methylhex-2-enoate (168) as a colourless oil
(0.2719g. 1.11mmol, 39%). thin film) 1719, 1654 cm1; 6H 1.05-1.38 (15H,
m, 3xCH 3), 2.47 (1H, m, H-4), 3.43-3.7 (3H, m, OCH 2
 and H-5), 4.20 (2H, q,
J-6.7Hz, OCH 2), 4.72 (1H, m, OCH(CH3)O), 5.81 (1H, d, J-15.3Hz, H-2), 6.91
(IH, dd, J=15.3 Hz, J=3 Hz, H-3)
b) To ethyl (2E, 4S, 5S)-5-(1 '-ethoxy)ethoxy-4-methylhex-2-enoate (168)
(0.2?2g, 1.11mmol) was added 0.83ml of a 1.96M NaOH solution. This was
stirred at room temperature overnight and then acidified to pH 1.0 and left
stirring overnight. The mixture was extracted with ethyl acetate (5 x lOmi)
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and the combined organics were dried over anhydrous magnesium
sulphate, filtered and concentrated in vacuo to give (2E, 4S, 5S)-5-hydroxy-
4-methylhex-2-enoic acid (0.070g, 0.44mmol, 45%) as a white solid. 6H 1.1
(3H, d,J=6.9Hz, CH3), 1.23 (3H, d, J=6.3FIz, CH3), 2.41 (1H, m, H-4), 3.8 (IH, m
,H-5), 5.85 (1H, d, J=15.8 Hz, J=7.1 Hz, H-2), 7.13 (1H, dd, J=15.8 Hz, J=7.lHz,
H-3), 7.97 (21-1, br s, 2 x OH).
c) To (2E, 4S, 5S)-5-hydroxy-2-methylhex-2-enoic add (O.07g, 0.44mmol)
in 3m1 of dichloromethane under a nitrogen atmosphere was added O.065g
(0.54mmol) of freshly prepared N-acetylcysteamine (98) in lml of dichioro
methane. To this was added DCC (0.117g, 0.45mmol) and two crystals of
DMAP in 2m1 of dichioromethane. The mixture was left overnight and
then filtered through celite. After removal of the soJvent ii.i VDLWD the
residue was purified by preparative TLC (acetone fdIcMoromethane 2.:3 to
yield the N-acetyl cysteamine thioester of (2E, 4S, 5S)-5-hydroxy-4-
methylhex-2-enoate (165) (0.072g. 0.29mmol, 59%) as a colourless syrup.
Umax (CHC1 3) 3299, 1659, 1625, 1559, 1551 cm1; H 1.1 (3H, d, J=7.3 Hz, CH3),
1.21 (3H, d, J=6.4 Hz, CH3), 1.98 (3H, s, CH3CON), 2.37 (1H, m, H-4), 3.09 (21-1,
t, J=6.5Hz, CH 2S), 3.46 (2H, m, CH2N), 3.78 (IH, m, H-5), 6.07 (1H, br s, NH),
6.09 (IH, d, J=15.9 Hz, H-2), 1.92 (IH, dd, J=15.9 Hz, 6.9Hz, H-3); 14.16
(Cl-I3), 21.01 (Cl-I3), 23.29 (CH2N), 28.43 (CH2S), 39.77 (COCH3), 40.04 (CHC=C),
70.76 (CHOH), 128.93 (C-2), 148.00 (C-3), 170.64 (CON), 190.46 (COS); m/z 201
(M-44, 7.7%), 119 (41.3), 83 (91.3), 82 (63.5), 55 (100), 45 (65.2)
B) convergent approach
To (2S,3S)-3-(1'-ethoxy)ethoxy-2-methylbutanal (167) (0.2417g, 1.37
mmol) in lOmi of chloroform was added the N-acetylcysteamine thioester
of triphenyl phosphorane acetate (107) (0.578g, 1.37mmol). The mixture
was heated under reflux for 18 hours. The solvent was removed and the
residue taken up in lOmi of methanol. To this was added 1 drop of
trifluoroacetic acid and the mixture left stirring overnight. The volatiles
were removed and the residue purified by flash column chromatography
(acetone/dichioromethane, 2:3) to yield the N-acetylcysteamine thioester
of (2E, 4S, 5S)-5-hydroxy-4-methylhex-2-enoate (165) (0.197g, 0.814 mmol,
59%) as a colourless syrup. Spectroscopic data as above
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Synthesis of the N-acetylcysteamine thioester of [7-2113]-(5S, 45, 2E) -5
hydroxy-4-methylhex-2-enoate (165).
a) To 0.931g (6.2lmmol) of ethyl [5-2H3]-(2S, 3S)-3-hydroxy-2-methyl
butanoate (161) in 5m1 of ethoxyethene was added I drop of TFA. The
mixture was left stirring overnight and the volatiles removed in vacuo to
leave ethyl [5-2H3]-(2S, 3S)-3-(1'-ethoxy)ethoxy-2-methyl butanoate as a
colourless oil (1.263g. 6.2lmmol, 100%). t ma (th1fl film) 1725 cm 1; oH 1.08-
1.3 (12H, m, 4 x CH3), 2.44 (1H,br m, CHC2H3), 3.38-3.67 (2H, m, OCH2CH3),
3.84 (IH, m, CHO), 4.15 (2H, m, OCH2), 4.69 (1H, OCH(CH3)O), m/z 203 (M-
18, 0.6%), 202 (2.3), 149 (5.3), 84 (42.8), 73 (77.1), 45 (100).
b) To 0.196g (5.lmmol) of lithium aluminium hydride suspended in
lOmi of freshly distilled ether at 0°C under a nitrogen atmosphere was
added ethyl [5-2H3J-(2S, 3S)-3-( I -ethoxy)ethoxy-2-methylbutanoate (1 .045g,
5.lOmmol) as a solution in 5m1 of anhydrous ether. The mixture was
stirred at room temperature for one hour and then under reflux for two
hours. After cooling to 0°C, the mixture was slowly decomposed by the
dropwise addition of water. Upon completion ethyl acetate was added
(2Oml) and the mixture filtered with ethyl acetate washing. The organics
were dried over anhydrous magnesium sulphate, filtered, concentrated
and the residue purified by bulb to bulb distillation (77°C, 5mmHg) to
yield [5-2H3]-(2S, 3S)-3-(1'-ethoxy)ethoxy-2-methylbutanol (166) (0.685g,
4.23mmol, 83%) as a colourless oil. ax(tufim) 3394, 1445, 1375cm1, 3H
1.2-1.35 (9H, m, 3 x CH3), 1.64 (IH, br s, OH) 3.4-3.8 (5H, m, 2 x CH 2O and H-
3), 4.71 (1H, m, OCH(CH3)O); m/z 161 (M 4-18, 0.9%), 73 (100), 45 (89.4).
c) To l5ml of dichioromethane at -78°C under a nitrogen atmosphere
was added 0.59m1 (4.6mmol) of oxalyl chloride. To this was added 0.72g of
dimethylsulphoxide (9.l9mmol). Two minutes later [5- 2H31-(2S, 3S)-3-(1'-
ethoxy) ethoxy-2-methylbutanol (166) (0.678g, 4.l8mmol) was added over
two minutes as a solution in 3m! of dichioromethane. After a further 15
minutes triethylamine (4.22g, 41.8mmol) was added, and after five
minutes the mixture was allowed to warm to room temperature. Water
(20m1) was added and the layers separated. The aqueous layer was extracted
with dichioromethane (2 x 20m1) and the combined organics dried over
anhydrous magnesium sulphate, filtered and concentrated in vacuo. The
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residue was taken up in 15m1 of dichioromethane and washed
sequentially with water, 5% sodium bicarbonate solution, water, 1%
hydrochloric acid, and water. The solution was dried over anhydrous
magnesium sulphate, filtered and concentrated in vacuo to yield [5-2H 3]-
(2S, 3S)-3-(l'-ethoxy)ethoxybutanal (167) (0.439g, 2.67mmol, 64%) as a pale
straw oil. omax(thin film) 1721 cm 1; oH 1.0-1.4 (9H, m, 3 x CH3).), 2.5 (1H, m,
H-2), 3.4 (2H, In, CH2CH3), 4.0 (1H, m, CHOH), 4.75 (1H, m, OCH(CH3)O),
9.77 (IH, S, CHO); m/z 159 (M'-15, 1.1%), 73 (97), 45 (100), 43 (31).
d) To [5-2H3]-(2S, 3S)-3-(1'-ethoxy)ethoxy-2-methylbutanal (167) (O.2417g,
1.37mmol) in lOmi of chloroform was added the N-acetylcysteamine
thioester of triphenyl phosphorane acetate (107) (0.578g, 1.37mmol). The
mixture was heated under reflux for 18 hours. The solvent was removed
and the residue taken up in lOmi of methanol. To this was added 1 drop of
trifluoroacetic acid and the mixture left stirring overnight. The volatiles
were removed and the residue purified by flash column chromatography
(acetone/dichioromethane, 2:3) to yield the N-acetylcysteamine thioester
of 17-2H3]-(2E, 4S, 5S)-5-hydroxy-4-methylhex-2-enoate (165) (0. 197g, 0.814
mmol, 59%) as a colourless syrup. Omax(CHC13) 3301, 1659, 1624, 1560, 1459
cm1; 0H 1.21 (3H, d, J=6.4 Hz, CM 3), 1.98 (3H, s, CH3CON), 2.37 (1H, m, H-4),
3.09 (2H, t, J=6.5Hz, CH2S), 3.46 (2H, m, CH 2N), 3.78 (1H, m, H-5), 6.07 (1H,
br S, NH), 6.09 (1H, d, J15.9 HZ, H-2), 1.92 (1H, dd, J=15.9 Hz, 6.9Hz, H-3); k
21.05 (CH3), 23.27 (CH2N), 28.44 (CH2S), 39.73 (CH3CON), 40.04 (CHC=C),
70.76 (CHOH), 128.89 (C-2), 148.04 (C-3), 170.66 (CON), 190.48 (COS); 0D 1.05
(br s); m/z 204 (M-44, 12.2%), 119 (47.9), 58 (100), 43 (77).
Synthesis of disodium 2-methylmalonate (176)
a) To 0.2571g of sodium under a nitrogen atmosphere at 0°C was added
lOmi of absolute ethanol. Once dissolution was complete diethyl malonate
(73) (1.5g. 9.32mmol) was added and the mixture left 30 minutes.
lodomethane (l.998g, 13.98mmol) was added and the mixture left 30 more
minutes. Water (5ml) was added and the solvents removed in vacuo. The
residue was taken up in lOml of ether and washed for 1 minute with 30%
(w/v) sodium hydroxide solution. The ethereal solution was dried over
anhydrous magnesium sulphate, filtered and concentrated in vacuo. Bulb
to bulb distillation (72°C, 6mmHg) gave diethyl 2-methylmalonate (1.371g.
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7.57mmol,81%) as a colourless oil. Vmax(th jfl film) 2991, 1728 cm 1; oH 1.15
(3H, t, fr6.7 Hz, CH2CH3), 1.42 (3H, d, h7Hz, CH3CH), 3.42 (IH, q, J=71-Lz,
CHCH3), 4.2 (2H, q, J=67Hz, OCH2CH).
b) To O.873g (5.O2mmol) of diethyl 2-methylmalonate was added 5.25m1
of 1.96M NaOH solution. This was stirred overnight. The water was
removed in vacuo and the residue freeze dried to leave 0.811g
(5.Olmmol,100%) of disodium 2-methylmalonate (176) as a white solid.
1Jnax(fl11O1) 1551, 1449 cm 1; OH(2H20) 1.39 (3H, dq, J=7.lHz, CH3CH), 3.17 (1H,
q, J7.1Hz, CHCH3).
Synthesis of disodium [2,4- 13C2]-methylmalonate (176)
a) To 0.2571g of sodium under a nitrogen atmosphere at 0°C was added
lOmi of absolute ethanol. Once dissolution was complete diethyl [2- 13C]-
malonate (1.5g, 9.32mmol) was added and the mixture left 30 minutes.
[ 13C1-Iodomethane (1.998g, 13.98mmol) was added and the mixture left 30
more minutes. Water (5m1) was added and the solvents removed in
vacuo. The residue was taken up in 10m1 of ether and washed for 1
minute with 30% (w/v) sodium hydroxide solution. The ethereal solution
was dried over anhydrous magnesium sulphate, filtered and concentrated
in vacuo. Bulb to bulb distillation (72°C, 6mmHg) gave diethyl [2,4-13C 2]
-methylmalonate (1.371g. 7.57mmol,81%) as a colourless oil. Oma (thfl film)
2987, 1725 cm;OH 1.15 (6H, t, J=6.6Hz, CH 3CH2), 1.42 (3H, dm, 1J=132Hz,
CH3CH), 3.2 (1H, dm, 1JcH=132Hz, CHCH3), 4.2 (4H, q, J=6.6Hz, OCFL)
b) To 0.338g (1.925mmo1) of diethyl [2,4- 13C 2]methy1malonate was
added 2.Olml of 1.96M NaOH solution. This was stirred overnight. The
water was removed in vacuo and the residue freeze dried to leave 0.315g
(1.921, 99%) of disodium [2,4-' 3C2]-methylmalonate (176) as a white solid.
Dmax1J00 1550, 1450 cm, OH(2H20) 1.39 (3H, dm, 1JcH 134Hz, CH3CH), 3.17
(1H, dm, 'JCH=134Hz, CHCH3).
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Synthesis of serine (169)
To an aqueous suspension (imi) of diethyl acetamidomalonate (170)
(1.154g, 5.32mmol) was added 0.46m1 of 40% formaiin (5.85 mmol) and I
drop of 2M NaOH. The mixture was stirred for two hours by which time a
colourless solution had formed. To this was added 5.6ml of 2M NaOH
(11 .5mmol) and the reaction left stirring overnight. Acetic acid (3.3m1) was
added and the mixture concentrated over a steam cone. To the resultant
syrup was added 3m1 of concentrated HC1 and the mixture heated under
reflux for 1 hour. The water was removed in vacuo and the resultant solid
residue leached with boiling absolute ethanol. The ethanolic solution was
concentrated and the residual solid taken up im 3.5 ml of 2M NaOH. This
was left stirring overnight. Water was added and the pH adjusted to 7.0.
The mixture was treated with activated charcoal and filtered. The water
was removed in vacuo to leave a cream solid. This re-dissolved in 3m1 of
water and an excess of hot absolute ethanol was added. After cooling
overnight the white solid was freeze dried to leave O.395g (3.79mm1, 61%)
of serine (169). Umax ijofl 1655, 1635, 1577 cm 1; 3H(2H20) 3.83 (1H, ,m,
CHCH2), 3.94 (21-1, m, CH Cl-fl; 56.29 (Cl-fl, 60.07 (Cl-I2), 172.29 (CO2H).
Synthesis of 13-13C1-serine (169)
To an aqueous suspension (imi) of diethyl acetamidomalonate (170)
(1.154g. 5.32mmol) was added lml of 20% [ 13C]-formalin (5.85 mmol) and 1
drop of 2M NaOH. The mixture was stirred for two hours by which time a
colourless solution had formed. To this was added 5.6m1 of 2M NaOH
(11:5mmol) and the reaction left stirring overnight. Acetic acid (3.3m1) was
added and the mixture concentrated over a steam cone. To the resultant
syrup was added 3m1 of conc. HC1 and the mixture heated under reflux for
1 hour. The water was removed in vacuo and the resultant solid residue
leached with boiling absolute ethanol. The ethanolic solution was
concentrated and the residual solid taken up in 3.5 ml of 2M NaOH. This
was left stirring overnight. Water was added and the pH adjusted to 7.0.
The mixture was treated with activated charcoal and filtered. The water
was removed in vacuo to leave a cream solid. This re-dissolved in 3m1 of
water and an excess of hot absolute ethanol was added. After cooling
overnight the white solid was freeze dried to leave 0.395g (3.79mm1, 61%)
of [3-13C]-serine (169). Umax(flUjOl) 1654, 1635, 1576 cmTit; 6H(2H20) 3.83 (1H, m,
CHCH2), 3.94 (2H, dm, 1JcH 141l-Jz CH2CH).
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Incorporation studies
a) The N-acetylcysteamine thioester of [2,3- 13C21-acetoacetate (144) plus
tetradecyithiopropionic acid (89)
Primary and secondary media were inoculated as previously described.
A 1 Omi solution (DMSO) containing the N-acetylcysteamine thioester of
[2,3- 13C2 1 -acetoacetate (144) (207mg) plus tetradecyithiopropionic acid (87)
(30mg) was prepared. 5m1 of this was added to the secondary medium
(0.5m1 per flask) seventeen hours after inoculation. This was repeated after
a further three hours. The cells were harvested as usual, and 14mg of
methyl pseudomonate (58) were isolated. The 'H nmr spectrum was
identical to that of an authentic sample.
b) The N-acetylcysteamine thioester of [5-2H3]-(2S,3S)-3-hydroxy-2-
methyl buatanoate (159) plus tetradecyithiopropionic acid (89)
Primary and secondary media were inoculated as previously described.
A lOmi solution (DMSO) containing The N-acetylcysteamine thioester of
[5-2H3]-(2S,3S)-3-hydroxy-2-methylbuatanoate (159) (243mg) plus tetradecyl
thiopropionic acid (89) (30mg) was prepared. 5ml of this was added to the
secondary medium (0.5m1 per flask) seventeen hours after inoculation.
This was repeated after a further three hours. The cells were harvested as
usual, and 12mg of methyl pseudomonate (58) were isolated. Also isolated
was 11mg of the N-acetylcysteamine thioester of [5- 2H31-(2S,3S)-3-hydroxy-
2-methylbutanoate (159). The 1 H nmr spectrum was identical to that of an
authentic sample. öD 1.21, 2.57, 3.73.
c) The N-acetylcysteamine thioester of [7- 2H2]-(2E,4S,5S)-5-hydroxy-4-
methylhex-2-enoate (165) plus tetradecyithiopropionic acid (89)
Primary and secondary media were inoculated as previously described.
A lOmi solution (DMSO) containing The N-acetylcysteamine thioester of
[7- 2H2]-(2E,4S,5S)-5-hydroxy-4-methylhex-2-enoate (165) (197mg) plus
tetradecylthiopropionic acid (89) (30mg) was prepared. 5m1 of this was
added to the secondary medium (0.5ml per flask) seventeen hours after
inoculation. This was repeated after a further three hours. The cells were
harvested as usual, and 11mg of methyl pseudomonate (58) were




Primary and secondary media were inoculated as previously described.
A lOml solution (H20) containing [3-13C]-serine (169) (250mg) was prepared.
5ml of this was added to the secondary medium (0.5m1 per flask)
seventeen hours after inoculation. This was repeated after a further three
hours. The cells were harvested as usual, and 3mg of methyl
pseudomonate (58) were isolated.The 1 H nmr spectrum was identical to
that of an authentic sample.
e) Sodium [2-13C1-acetate
Primary and secondary media were inoculated as previously described.
A lOmi solution (H20) containing Sodium [2-13C]-acetate (250mg) was
prepared. 5m1 of this was added to the secondary medium (0.5m1 per flask)
seventeen hours after inoculation. This was repeated after a further three
hours. At the end of the growth period, the media pH was 4.75, indicating
that the growth cycle had not been completed. No methyl pseudomonate
was isolated.
f) Disodium [4-13C]-2-methylmalonate (176)
Primary and secondary media were inoculated as previously described.
A lOmi solution (H20) containing disodium [4-13C]-2-methylmalonate (176)
(250mg) was prepared. 5m1 of this was added to the secondary medium
(0.5m1 per flask) seventeen hours after inoculation. This was repeated after
a further three hours. The cells were harvested as usual, and 22mg of
methyl pseudomonate (58) were isolated.The 1 H and 13C nmr spectra were
identical to that of an authentic sample.
g) Disodium [2,4-13C2]-2-methylmalonate (176)
Primary and secondary media were inoculated as previously described.
A lOmi solution (H20) containing disodium [2,4-13C2]-2-methylmalonate
(176) (250mg) was prepared. 5m1 of this was added to the secondary
medium (0.5m1 per flask) seventeen hours after inoculation. This was
repeated after a further three hours. The cells were harvested as usual, and
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25mg of methyl pseudomonate (58) were isolated.The 1H and 13C nmr
spectra were identical to that of an authentic sample.
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